WO2004024697A1 - アミン化合物及びその用途 - Google Patents
アミン化合物及びその用途 Download PDFInfo
- Publication number
- WO2004024697A1 WO2004024697A1 PCT/JP2003/011381 JP0311381W WO2004024697A1 WO 2004024697 A1 WO2004024697 A1 WO 2004024697A1 JP 0311381 W JP0311381 W JP 0311381W WO 2004024697 A1 WO2004024697 A1 WO 2004024697A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- ylmethyl
- methyl
- imidazole
- amino
- compound
- Prior art date
Links
- -1 Amine compounds Chemical class 0.000 title claims abstract description 555
- 125000003118 aryl group Chemical group 0.000 claims abstract description 32
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 29
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims abstract description 28
- 125000003367 polycyclic group Chemical group 0.000 claims abstract description 20
- 125000002950 monocyclic group Chemical group 0.000 claims abstract description 19
- 125000000304 alkynyl group Chemical group 0.000 claims abstract description 18
- 125000003342 alkenyl group Chemical group 0.000 claims abstract description 15
- 125000002947 alkylene group Chemical group 0.000 claims abstract description 14
- 125000004122 cyclic group Chemical group 0.000 claims abstract description 12
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 7
- 201000011510 cancer Diseases 0.000 claims abstract description 7
- 229910052717 sulfur Inorganic materials 0.000 claims abstract description 4
- 150000001875 compounds Chemical class 0.000 claims description 973
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 289
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 254
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 222
- 125000004432 carbon atom Chemical group C* 0.000 claims description 196
- KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 claims description 175
- 239000000203 mixture Substances 0.000 claims description 144
- 239000002253 acid Substances 0.000 claims description 52
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N EtOH Substances CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 45
- RAXXELZNTBOGNW-UHFFFAOYSA-N 1H-imidazole Chemical compound C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 claims description 33
- 150000003839 salts Chemical class 0.000 claims description 26
- 239000003795 chemical substances by application Substances 0.000 claims description 23
- 125000006165 cyclic alkyl group Chemical group 0.000 claims description 22
- 239000000651 prodrug Substances 0.000 claims description 22
- 229940002612 prodrug Drugs 0.000 claims description 22
- 229920006395 saturated elastomer Polymers 0.000 claims description 19
- 229910052799 carbon Inorganic materials 0.000 claims description 17
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 16
- 239000003814 drug Substances 0.000 claims description 16
- 125000000623 heterocyclic group Chemical group 0.000 claims description 16
- 229910052757 nitrogen Inorganic materials 0.000 claims description 16
- WEHWNAOGRSTTBQ-UHFFFAOYSA-N dipropylamine Chemical compound CCCNCCC WEHWNAOGRSTTBQ-UHFFFAOYSA-N 0.000 claims description 15
- 150000001721 carbon Chemical group 0.000 claims description 14
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 13
- 229940079593 drug Drugs 0.000 claims description 13
- 102100031650 C-X-C chemokine receptor type 4 Human genes 0.000 claims description 12
- 101000922348 Homo sapiens C-X-C chemokine receptor type 4 Proteins 0.000 claims description 12
- 150000001412 amines Chemical class 0.000 claims description 11
- 125000000547 substituted alkyl group Chemical group 0.000 claims description 11
- 125000001072 heteroaryl group Chemical group 0.000 claims description 9
- 125000005017 substituted alkenyl group Chemical group 0.000 claims description 9
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 8
- 239000004480 active ingredient Substances 0.000 claims description 8
- 230000003042 antagnostic effect Effects 0.000 claims description 7
- 125000004450 alkenylene group Chemical group 0.000 claims description 5
- 125000005842 heteroatom Chemical group 0.000 claims description 5
- 125000003545 alkoxy group Chemical group 0.000 claims description 4
- 150000001408 amides Chemical class 0.000 claims description 4
- 125000003277 amino group Chemical group 0.000 claims description 4
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 4
- 239000002576 chemokine receptor CXCR4 antagonist Substances 0.000 claims description 4
- 229940121384 cxc chemokine receptor type 4 (cxcr4) antagonist Drugs 0.000 claims description 4
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 claims description 4
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 4
- KIDHWZJUCRJVML-UHFFFAOYSA-N putrescine Chemical compound NCCCCN KIDHWZJUCRJVML-UHFFFAOYSA-N 0.000 claims description 4
- 125000004426 substituted alkynyl group Chemical group 0.000 claims description 4
- KHBQMWCZKVMBLN-UHFFFAOYSA-N Benzenesulfonamide Chemical compound NS(=O)(=O)C1=CC=CC=C1 KHBQMWCZKVMBLN-UHFFFAOYSA-N 0.000 claims description 3
- ULTYEWBAAMDHAY-UHFFFAOYSA-N N-[4-[(dipropylamino)methyl]phenyl]benzamide Chemical compound C(C1=CC=CC=C1)(=O)NC1=CC=C(C=C1)CN(CCC)CCC ULTYEWBAAMDHAY-UHFFFAOYSA-N 0.000 claims description 3
- 208000025747 Rheumatic disease Diseases 0.000 claims description 3
- 239000013543 active substance Substances 0.000 claims description 3
- 125000003282 alkyl amino group Chemical group 0.000 claims description 3
- LNETULKMXZVUST-UHFFFAOYSA-N alpha-naphthoic acid Natural products C1=CC=C2C(C(=O)O)=CC=CC2=C1 LNETULKMXZVUST-UHFFFAOYSA-N 0.000 claims description 3
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 3
- GLDVKMPSACNWFV-UHFFFAOYSA-N n',n'-dipropylbutane-1,4-diamine Chemical compound CCCN(CCC)CCCCN GLDVKMPSACNWFV-UHFFFAOYSA-N 0.000 claims description 3
- 125000001424 substituent group Chemical group 0.000 claims description 3
- RWSKPSZMSSSBBL-UHFFFAOYSA-N 3-[5-[[1h-imidazol-2-ylmethyl-[(1-methylimidazol-2-yl)methyl]amino]methyl]-1h-inden-2-yl]-n,n-dipropylpropan-1-amine Chemical compound C=1C=C2CC(CCCN(CCC)CCC)=CC2=CC=1CN(CC=1N(C=CN=1)C)CC1=NC=CN1 RWSKPSZMSSSBBL-UHFFFAOYSA-N 0.000 claims description 2
- CGOMKVLOEDYDPW-UHFFFAOYSA-N 3-[5-[[1h-imidazol-2-ylmethyl-[(1-methylimidazol-2-yl)methyl]amino]methyl]-1h-indol-2-yl]-n,n-dipropylpropan-1-amine Chemical compound C=1C=C2NC(CCCN(CCC)CCC)=CC2=CC=1CN(CC=1N(C=CN=1)C)CC1=NC=CN1 CGOMKVLOEDYDPW-UHFFFAOYSA-N 0.000 claims description 2
- RDZPZEDGOMNVHE-UHFFFAOYSA-N 4-[5-[[1h-imidazol-2-ylmethyl-[(1-methylimidazol-2-yl)methyl]amino]methyl]-1-propylbenzimidazol-2-yl]-n,n-dipropylbutan-1-amine Chemical compound C=1C=C2N(CCC)C(CCCCN(CCC)CCC)=NC2=CC=1CN(CC=1N(C=CN=1)C)CC1=NC=CN1 RDZPZEDGOMNVHE-UHFFFAOYSA-N 0.000 claims description 2
- CKFGJDYWCAGBLC-UHFFFAOYSA-N 4-[6-[[1h-imidazol-2-ylmethyl-[(1-methylimidazol-2-yl)methyl]amino]methyl]-1,3-benzothiazol-2-yl]-n,n-dipropylbutan-1-amine Chemical compound C1=C2SC(CCCCN(CCC)CCC)=NC2=CC=C1CN(CC=1N(C=CN=1)C)CC1=NC=CN1 CKFGJDYWCAGBLC-UHFFFAOYSA-N 0.000 claims description 2
- RVPIPENVFUTNQT-UHFFFAOYSA-N 4-[[4-[[bis(1h-imidazol-2-ylmethyl)amino]methyl]phenyl]methoxy]-n,n-dipropylbutan-1-amine Chemical compound C1=CC(COCCCCN(CCC)CCC)=CC=C1CN(CC=1NC=CN=1)CC1=NC=CN1 RVPIPENVFUTNQT-UHFFFAOYSA-N 0.000 claims description 2
- MMUYFDXBZYEESL-UHFFFAOYSA-N 4-[[bis(1h-imidazol-2-ylmethyl)amino]methyl]-n-[4-(dipropylamino)butyl]-n-methylbenzamide Chemical compound C1=CC(C(=O)N(C)CCCCN(CCC)CCC)=CC=C1CN(CC=1NC=CN=1)CC1=NC=CN1 MMUYFDXBZYEESL-UHFFFAOYSA-N 0.000 claims description 2
- 125000004419 alkynylene group Chemical group 0.000 claims description 2
- 239000003443 antiviral agent Substances 0.000 claims description 2
- 125000004438 haloalkoxy group Chemical group 0.000 claims description 2
- 125000005113 hydroxyalkoxy group Chemical group 0.000 claims description 2
- YGQYUWYLEZZDIA-UHFFFAOYSA-N n-[2-[4-[[4-[[bis(1h-imidazol-2-ylmethyl)amino]methyl]phenyl]methoxy]phenyl]ethyl]-n-propylpropan-1-amine Chemical compound C1=CC(CCN(CCC)CCC)=CC=C1OCC(C=C1)=CC=C1CN(CC=1NC=CN=1)CC1=NC=CN1 YGQYUWYLEZZDIA-UHFFFAOYSA-N 0.000 claims description 2
- RMQHXDZLEQCLON-UHFFFAOYSA-N n-[4-[(dipropylamino)methyl]phenyl]-4-[[1h-imidazol-2-ylmethyl(1h-1,2,4-triazol-5-ylmethyl)amino]methyl]benzamide Chemical compound C1=CC(CN(CCC)CCC)=CC=C1NC(=O)C(C=C1)=CC=C1CN(CC=1NC=CN=1)CC1=NNC=N1 RMQHXDZLEQCLON-UHFFFAOYSA-N 0.000 claims description 2
- ASPMPJMVKSLAQC-UHFFFAOYSA-N n-[[4-[[4-[[bis(1h-imidazol-2-ylmethyl)amino]methyl]phenyl]methoxy]phenyl]methyl]-n-propylpropan-1-amine Chemical compound C1=CC(CN(CCC)CCC)=CC=C1OCC(C=C1)=CC=C1CN(CC=1NC=CN=1)CC1=NC=CN1 ASPMPJMVKSLAQC-UHFFFAOYSA-N 0.000 claims description 2
- IPEHBUMCGVEMRF-UHFFFAOYSA-N pyrazinecarboxamide Chemical compound NC(=O)C1=CN=CC=N1 IPEHBUMCGVEMRF-UHFFFAOYSA-N 0.000 claims description 2
- 125000005156 substituted alkylene group Chemical group 0.000 claims description 2
- 229940005605 valeric acid Drugs 0.000 claims description 2
- WQYVJKVFGCQDMJ-UHFFFAOYSA-N 2-(dipropylamino)-5-[[4-[[1h-imidazol-2-ylmethyl-[(1-methylimidazol-2-yl)methyl]amino]methyl]phenyl]methyl-methylamino]pentanoic acid Chemical compound C1=CC(CN(C)CCCC(N(CCC)CCC)C(O)=O)=CC=C1CN(CC=1N(C=CN=1)C)CC1=NC=CN1 WQYVJKVFGCQDMJ-UHFFFAOYSA-N 0.000 claims 1
- NLXJZJBYFYSTOP-UHFFFAOYSA-N 3-[6-[[1h-imidazol-2-ylmethyl-[(1-methylimidazol-2-yl)methyl]amino]methyl]quinolin-2-yl]-n,n-dipropylpropan-1-amine Chemical compound C1=CC2=NC(CCCN(CCC)CCC)=CC=C2C=C1CN(CC=1N(C=CN=1)C)CC1=NC=CN1 NLXJZJBYFYSTOP-UHFFFAOYSA-N 0.000 claims 1
- JMNVNZNGKYGDSM-UHFFFAOYSA-N 4-[5-[[1h-imidazol-2-ylmethyl-[(1-methylimidazol-2-yl)methyl]amino]methyl]-1,3-benzothiazol-2-yl]-n,n-dipropylbutan-1-amine Chemical compound C=1C=C2SC(CCCCN(CCC)CCC)=NC2=CC=1CN(CC=1N(C=CN=1)C)CC1=NC=CN1 JMNVNZNGKYGDSM-UHFFFAOYSA-N 0.000 claims 1
- ALVFNTFGMQCWTJ-UHFFFAOYSA-N 4-[5-[[1h-imidazol-2-ylmethyl-[(1-methylimidazol-2-yl)methyl]amino]methyl]-1,3-benzoxazol-2-yl]-n,n-dipropylbutan-1-amine Chemical compound C=1C=C2OC(CCCCN(CCC)CCC)=NC2=CC=1CN(CC=1N(C=CN=1)C)CC1=NC=CN1 ALVFNTFGMQCWTJ-UHFFFAOYSA-N 0.000 claims 1
- FLOVXFNNMNZMND-UHFFFAOYSA-N 4-[5-[[1h-imidazol-2-ylmethyl-[(1-methylimidazol-2-yl)methyl]amino]methyl]-1-benzofuran-2-yl]-n,n-dipropylbutan-1-amine Chemical compound C=1C=C2OC(CCCCN(CCC)CCC)=CC2=CC=1CN(CC=1N(C=CN=1)C)CC1=NC=CN1 FLOVXFNNMNZMND-UHFFFAOYSA-N 0.000 claims 1
- PLDILLYHQHEWIN-UHFFFAOYSA-N 4-[6-[[1H-imidazol-2-ylmethyl-[(1-methylimidazol-2-yl)methyl]amino]methyl]naphthalen-2-yl]-N,N-dipropylbutan-2-amine Chemical compound C1=CC2=CC(CCC(C)N(CCC)CCC)=CC=C2C=C1CN(CC=1N(C=CN=1)C)CC1=NC=CN1 PLDILLYHQHEWIN-UHFFFAOYSA-N 0.000 claims 1
- SDOFLLCBUOSZJC-UHFFFAOYSA-N 4-[6-[[1h-imidazol-2-ylmethyl-[(1-methylimidazol-2-yl)methyl]amino]methyl]-1-propylbenzimidazol-2-yl]-n,n-dipropylbutan-1-amine Chemical compound C1=C2N(CCC)C(CCCCN(CCC)CCC)=NC2=CC=C1CN(CC=1N(C=CN=1)C)CC1=NC=CN1 SDOFLLCBUOSZJC-UHFFFAOYSA-N 0.000 claims 1
- LAOZLYFXZWGVLP-UHFFFAOYSA-N 4-[7-[[1h-imidazol-2-ylmethyl-[(1-methylimidazol-2-yl)methyl]amino]methyl]-3,4-dihydro-2h-chromen-3-yl]-n,n-dipropylbutan-1-amine Chemical compound C=1C=C2CC(CCCCN(CCC)CCC)COC2=CC=1CN(CC=1N(C=CN=1)C)CC1=NC=CN1 LAOZLYFXZWGVLP-UHFFFAOYSA-N 0.000 claims 1
- LTBLVIKWGMEOPY-UHFFFAOYSA-N 4-[[1h-imidazol-2-ylmethyl-[(1-methylimidazol-2-yl)methyl]amino]methyl]-n-[4-[(3-methylpyridin-2-yl)methylamino]butyl]benzenesulfonamide Chemical compound CC1=CC=CN=C1CNCCCCNS(=O)(=O)C(C=C1)=CC=C1CN(CC=1N(C=CN=1)C)CC1=NC=CN1 LTBLVIKWGMEOPY-UHFFFAOYSA-N 0.000 claims 1
- SJJGVDLJSMTXGV-UHFFFAOYSA-N 5-[6-[[1h-imidazol-2-ylmethyl-[(1-methylimidazol-2-yl)methyl]amino]methyl]quinolin-2-yl]-n,n-dipropylpentan-1-amine Chemical compound C1=CC2=NC(CCCCCN(CCC)CCC)=CC=C2C=C1CN(CC=1N(C=CN=1)C)CC1=NC=CN1 SJJGVDLJSMTXGV-UHFFFAOYSA-N 0.000 claims 1
- 101100006941 Caenorhabditis elegans sex-1 gene Proteins 0.000 claims 1
- LBESEAOTJBFBRH-UHFFFAOYSA-N N-[[4-[(dipropylamino)methyl]-N-[2-(1H-imidazol-2-yl)-1-quinolin-3-ylethyl]anilino]methyl]benzamide Chemical compound C(C1=CC=CC=C1)(=O)NCN(C1=CC=C(C=C1)CN(CCC)CCC)C(C=1C=NC2=CC=CC=C2C=1)CC=1NC=CN=1 LBESEAOTJBFBRH-UHFFFAOYSA-N 0.000 claims 1
- QKIUAMUSENSFQQ-UHFFFAOYSA-N dimethylazanide Chemical compound C[N-]C QKIUAMUSENSFQQ-UHFFFAOYSA-N 0.000 claims 1
- 125000001188 haloalkyl group Chemical group 0.000 claims 1
- 125000005843 halogen group Chemical group 0.000 claims 1
- 206010061289 metastatic neoplasm Diseases 0.000 claims 1
- WSFSSNUMVMOOMR-BJUDXGSMSA-N methanone Chemical compound O=[11CH2] WSFSSNUMVMOOMR-BJUDXGSMSA-N 0.000 claims 1
- DMDXQHYISPCTGF-UHFFFAOYSA-N n',n'-dipropylethane-1,2-diamine Chemical compound CCCN(CCC)CCN DMDXQHYISPCTGF-UHFFFAOYSA-N 0.000 claims 1
- ANAGJFVEPFXSOJ-UHFFFAOYSA-N n-[4-(dipropylamino)butyl]-4-[[1h-imidazol-2-ylmethyl-[(1-methylimidazol-2-yl)methyl]amino]methyl]benzenesulfonamide Chemical compound C1=CC(S(=O)(=O)NCCCCN(CCC)CCC)=CC=C1CN(CC=1N(C=CN=1)C)CC1=NC=CN1 ANAGJFVEPFXSOJ-UHFFFAOYSA-N 0.000 claims 1
- YDNIHMQRHGGBOJ-UHFFFAOYSA-N n-[[4-[[1h-imidazol-2-ylmethyl(1h-1,2,4-triazol-5-ylmethyl)amino]methyl]phenyl]methyl]-n-methyl-n',n'-dipropylbutane-1,4-diamine Chemical compound C1=CC(CN(C)CCCCN(CCC)CCC)=CC=C1CN(CC=1NC=CN=1)CC1=NNC=N1 YDNIHMQRHGGBOJ-UHFFFAOYSA-N 0.000 claims 1
- WKVBYMKWCBNULU-UHFFFAOYSA-N n-[[4-[[4-[[bis(1h-imidazol-2-ylmethyl)amino]methyl]phenyl]methoxymethyl]phenyl]methyl]-n-propylpropan-1-amine Chemical compound C1=CC(CN(CCC)CCC)=CC=C1COCC(C=C1)=CC=C1CN(CC=1NC=CN=1)CC1=NC=CN1 WKVBYMKWCBNULU-UHFFFAOYSA-N 0.000 claims 1
- CYHYRMWTZVZWNU-UHFFFAOYSA-N n-cyclohexyl-n'-[[4-[[1h-imidazol-2-ylmethyl-[(1-methylimidazol-2-yl)methyl]amino]methyl]phenyl]methyl]-n'-methylbutane-1,4-diamine Chemical compound C=1C=C(CN(CC=2NC=CN=2)CC=2N(C=CN=2)C)C=CC=1CN(C)CCCCNC1CCCCC1 CYHYRMWTZVZWNU-UHFFFAOYSA-N 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 230000000144 pharmacologic effect Effects 0.000 claims 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract description 34
- 239000001257 hydrogen Substances 0.000 abstract description 17
- 241000725303 Human immunodeficiency virus Species 0.000 abstract description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 8
- 201000010099 disease Diseases 0.000 abstract description 7
- 206010027476 Metastases Diseases 0.000 abstract description 4
- 208000015181 infectious disease Diseases 0.000 abstract description 3
- 230000009401 metastasis Effects 0.000 abstract description 3
- 229910052760 oxygen Inorganic materials 0.000 abstract description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 849
- 239000002904 solvent Substances 0.000 description 428
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 274
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 234
- 238000000034 method Methods 0.000 description 190
- 238000006243 chemical reaction Methods 0.000 description 172
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 141
- 238000003786 synthesis reaction Methods 0.000 description 134
- 230000015572 biosynthetic process Effects 0.000 description 126
- 239000000243 solution Substances 0.000 description 112
- 239000003638 chemical reducing agent Substances 0.000 description 103
- PYOKUURKVVELLB-UHFFFAOYSA-N trimethyl orthoformate Chemical compound COC(OC)OC PYOKUURKVVELLB-UHFFFAOYSA-N 0.000 description 103
- 238000004519 manufacturing process Methods 0.000 description 97
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 78
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 76
- 239000007787 solid Substances 0.000 description 76
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 69
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 69
- BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 68
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 68
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 60
- 239000012279 sodium borohydride Substances 0.000 description 55
- 229910000033 sodium borohydride Inorganic materials 0.000 description 55
- 239000007864 aqueous solution Substances 0.000 description 45
- 238000010898 silica gel chromatography Methods 0.000 description 45
- 239000012044 organic layer Substances 0.000 description 43
- NBBJYMSMWIIQGU-UHFFFAOYSA-N Propionic aldehyde Chemical compound CCC=O NBBJYMSMWIIQGU-UHFFFAOYSA-N 0.000 description 42
- 239000012024 dehydrating agents Substances 0.000 description 42
- 238000005481 NMR spectroscopy Methods 0.000 description 41
- 238000003756 stirring Methods 0.000 description 37
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 31
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 30
- 150000001299 aldehydes Chemical class 0.000 description 29
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 28
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 27
- 239000000126 substance Substances 0.000 description 27
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 26
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 25
- 238000001914 filtration Methods 0.000 description 24
- 239000010410 layer Substances 0.000 description 24
- NUJOXMJBOLGQSY-UHFFFAOYSA-N manganese dioxide Chemical compound O=[Mn]=O NUJOXMJBOLGQSY-UHFFFAOYSA-N 0.000 description 24
- 239000007788 liquid Substances 0.000 description 23
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 22
- ZTQSAGDEMFDKMZ-UHFFFAOYSA-N butyric aldehyde Natural products CCCC=O ZTQSAGDEMFDKMZ-UHFFFAOYSA-N 0.000 description 21
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 21
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 21
- 239000000741 silica gel Substances 0.000 description 20
- 229910002027 silica gel Inorganic materials 0.000 description 20
- 238000001035 drying Methods 0.000 description 18
- IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine hydrate Chemical compound O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 description 18
- 239000007800 oxidant agent Substances 0.000 description 18
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 16
- 239000012280 lithium aluminium hydride Substances 0.000 description 15
- YLZOPXRUQYQQID-UHFFFAOYSA-N 3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)-1-[4-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]piperazin-1-yl]propan-1-one Chemical compound N1N=NC=2CN(CCC=21)CCC(=O)N1CCN(CC1)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F YLZOPXRUQYQQID-UHFFFAOYSA-N 0.000 description 14
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 14
- 235000017557 sodium bicarbonate Nutrition 0.000 description 14
- 239000003377 acid catalyst Substances 0.000 description 12
- 239000003054 catalyst Substances 0.000 description 12
- 238000010586 diagram Methods 0.000 description 12
- 238000000605 extraction Methods 0.000 description 12
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 12
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 12
- LDXJRKWFNNFDSA-UHFFFAOYSA-N 2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)-1-[4-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]piperazin-1-yl]ethanone Chemical compound C1CN(CC2=NNN=C21)CC(=O)N3CCN(CC3)C4=CN=C(N=C4)NCC5=CC(=CC=C5)OC(F)(F)F LDXJRKWFNNFDSA-UHFFFAOYSA-N 0.000 description 11
- 238000004440 column chromatography Methods 0.000 description 11
- 239000012298 atmosphere Substances 0.000 description 10
- JHIVVAPYMSGYDF-UHFFFAOYSA-N cyclohexanone Chemical compound O=C1CCCCC1 JHIVVAPYMSGYDF-UHFFFAOYSA-N 0.000 description 10
- 238000005227 gel permeation chromatography Methods 0.000 description 10
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 10
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical compound CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 9
- YAGCIXJCAUGCGI-UHFFFAOYSA-N butoxycarbonyl butyl carbonate Chemical compound CCCCOC(=O)OC(=O)OCCCC YAGCIXJCAUGCGI-UHFFFAOYSA-N 0.000 description 9
- 239000012153 distilled water Substances 0.000 description 9
- 239000000499 gel Substances 0.000 description 9
- 239000000047 product Substances 0.000 description 9
- 210000000689 upper leg Anatomy 0.000 description 9
- UEBFLTZXUXZPJO-UHFFFAOYSA-N 1-methylimidazole-2-carbaldehyde Chemical compound CN1C=CN=C1C=O UEBFLTZXUXZPJO-UHFFFAOYSA-N 0.000 description 8
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 8
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 8
- 238000001816 cooling Methods 0.000 description 8
- 238000001704 evaporation Methods 0.000 description 8
- UKVIEHSSVKSQBA-UHFFFAOYSA-N methane;palladium Chemical compound C.[Pd] UKVIEHSSVKSQBA-UHFFFAOYSA-N 0.000 description 8
- QAEDZJGFFMLHHQ-UHFFFAOYSA-N trifluoroacetic anhydride Chemical compound FC(F)(F)C(=O)OC(=O)C(F)(F)F QAEDZJGFFMLHHQ-UHFFFAOYSA-N 0.000 description 8
- XYHKNCXZYYTLRG-UHFFFAOYSA-N 1h-imidazole-2-carbaldehyde Chemical compound O=CC1=NC=CN1 XYHKNCXZYYTLRG-UHFFFAOYSA-N 0.000 description 7
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 7
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 7
- 239000012267 brine Substances 0.000 description 7
- 239000012299 nitrogen atmosphere Substances 0.000 description 7
- 239000003921 oil Substances 0.000 description 7
- 235000019198 oils Nutrition 0.000 description 7
- OZAIFHULBGXAKX-UHFFFAOYSA-N 2-(2-cyanopropan-2-yldiazenyl)-2-methylpropanenitrile Chemical compound N#CC(C)(C)N=NC(C)(C)C#N OZAIFHULBGXAKX-UHFFFAOYSA-N 0.000 description 6
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 6
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 6
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 6
- 238000005406 washing Methods 0.000 description 6
- VFYFMNCKPJDAPV-UHFFFAOYSA-N 2,2'-(5-oxo-1,3-dioxolan-4,4-diyl)diessigs Chemical compound C1N(C2)CN3CN1CN2C3.OC(=O)CC1(CC(O)=O)OCOC1=O VFYFMNCKPJDAPV-UHFFFAOYSA-N 0.000 description 5
- VZSRBBMJRBPUNF-UHFFFAOYSA-N 2-(2,3-dihydro-1H-inden-2-ylamino)-N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]pyrimidine-5-carboxamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C(=O)NCCC(N1CC2=C(CC1)NN=N2)=O VZSRBBMJRBPUNF-UHFFFAOYSA-N 0.000 description 5
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 5
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical group C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 5
- 239000000706 filtrate Substances 0.000 description 5
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 5
- 150000002430 hydrocarbons Chemical group 0.000 description 5
- 208000030507 AIDS Diseases 0.000 description 4
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 4
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 4
- MKYBYDHXWVHEJW-UHFFFAOYSA-N N-[1-oxo-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propan-2-yl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(C(C)NC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 MKYBYDHXWVHEJW-UHFFFAOYSA-N 0.000 description 4
- AFCARXCZXQIEQB-UHFFFAOYSA-N N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CCNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 AFCARXCZXQIEQB-UHFFFAOYSA-N 0.000 description 4
- PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- KKEYFWRCBNTPAC-UHFFFAOYSA-N Terephthalic acid Chemical compound OC(=O)C1=CC=C(C(O)=O)C=C1 KKEYFWRCBNTPAC-UHFFFAOYSA-N 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 239000006260 foam Substances 0.000 description 4
- 239000008098 formaldehyde solution Substances 0.000 description 4
- 150000002576 ketones Chemical class 0.000 description 4
- 229910052744 lithium Inorganic materials 0.000 description 4
- ZCSHNCUQKCANBX-UHFFFAOYSA-N lithium diisopropylamide Chemical compound [Li+].CC(C)[N-]C(C)C ZCSHNCUQKCANBX-UHFFFAOYSA-N 0.000 description 4
- WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 description 4
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 4
- 229910000029 sodium carbonate Inorganic materials 0.000 description 4
- FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 4
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 3
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical group C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 3
- NIPNSKYNPDTRPC-UHFFFAOYSA-N N-[2-oxo-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 NIPNSKYNPDTRPC-UHFFFAOYSA-N 0.000 description 3
- UFWIBTONFRDIAS-UHFFFAOYSA-N Naphthalene Chemical compound C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 description 3
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 125000004202 aminomethyl group Chemical group [H]N([H])C([H])([H])* 0.000 description 3
- 230000000798 anti-retroviral effect Effects 0.000 description 3
- IOJUPLGTWVMSFF-UHFFFAOYSA-N benzothiazole Chemical compound C1=CC=C2SC=NC2=C1 IOJUPLGTWVMSFF-UHFFFAOYSA-N 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 238000004587 chromatography analysis Methods 0.000 description 3
- 238000007872 degassing Methods 0.000 description 3
- 238000010511 deprotection reaction Methods 0.000 description 3
- 238000002414 normal-phase solid-phase extraction Methods 0.000 description 3
- 229910052763 palladium Inorganic materials 0.000 description 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 3
- 239000008213 purified water Substances 0.000 description 3
- 150000003254 radicals Chemical class 0.000 description 3
- 238000006722 reduction reaction Methods 0.000 description 3
- 238000010992 reflux Methods 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- TUPNSSNDXLGGBQ-UHFFFAOYSA-N 1,3-dioxoisoindole-2-carboxylic acid Chemical compound C1=CC=C2C(=O)N(C(=O)O)C(=O)C2=C1 TUPNSSNDXLGGBQ-UHFFFAOYSA-N 0.000 description 2
- HMUNWXXNJPVALC-UHFFFAOYSA-N 1-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)C(CN1CC2=C(CC1)NN=N2)=O HMUNWXXNJPVALC-UHFFFAOYSA-N 0.000 description 2
- IANQTJSKSUMEQM-UHFFFAOYSA-N 1-benzofuran Chemical group C1=CC=C2OC=CC2=C1 IANQTJSKSUMEQM-UHFFFAOYSA-N 0.000 description 2
- FCEHBMOGCRZNNI-UHFFFAOYSA-N 1-benzothiophene Chemical group C1=CC=C2SC=CC2=C1 FCEHBMOGCRZNNI-UHFFFAOYSA-N 0.000 description 2
- BAXOFTOLAUCFNW-UHFFFAOYSA-N 1H-indazole Chemical compound C1=CC=C2C=NNC2=C1 BAXOFTOLAUCFNW-UHFFFAOYSA-N 0.000 description 2
- ICFGFAUMBISMLR-UHFFFAOYSA-N 1h-pyrazole-5-carbaldehyde Chemical compound O=CC=1C=CNN=1 ICFGFAUMBISMLR-UHFFFAOYSA-N 0.000 description 2
- PKZJLOCLABXVMC-UHFFFAOYSA-N 2-Methoxybenzaldehyde Chemical compound COC1=CC=CC=C1C=O PKZJLOCLABXVMC-UHFFFAOYSA-N 0.000 description 2
- SXAMGRAIZSSWIH-UHFFFAOYSA-N 2-[3-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]-1,2,4-oxadiazol-5-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C1=NOC(=N1)CC(=O)N1CC2=C(CC1)NN=N2 SXAMGRAIZSSWIH-UHFFFAOYSA-N 0.000 description 2
- LBLYYCQCTBFVLH-UHFFFAOYSA-M 2-methylbenzenesulfonate Chemical compound CC1=CC=CC=C1S([O-])(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-M 0.000 description 2
- YNJSNEKCXVFDKW-UHFFFAOYSA-N 3-(5-amino-1h-indol-3-yl)-2-azaniumylpropanoate Chemical compound C1=C(N)C=C2C(CC(N)C(O)=O)=CNC2=C1 YNJSNEKCXVFDKW-UHFFFAOYSA-N 0.000 description 2
- OAKURXIZZOAYBC-UHFFFAOYSA-M 3-oxopropanoate Chemical compound [O-]C(=O)CC=O OAKURXIZZOAYBC-UHFFFAOYSA-M 0.000 description 2
- WITBGLGAUOJYMJ-UHFFFAOYSA-N 4-[(dipropylamino)methyl]aniline Chemical compound CCCN(CCC)CC1=CC=C(N)C=C1 WITBGLGAUOJYMJ-UHFFFAOYSA-N 0.000 description 2
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 2
- HCFAJYNVAYBARA-UHFFFAOYSA-N 4-heptanone Chemical compound CCCC(=O)CCC HCFAJYNVAYBARA-UHFFFAOYSA-N 0.000 description 2
- RGHHSNMVTDWUBI-UHFFFAOYSA-N 4-hydroxybenzaldehyde Chemical compound OC1=CC=C(C=O)C=C1 RGHHSNMVTDWUBI-UHFFFAOYSA-N 0.000 description 2
- 101001053401 Arabidopsis thaliana Acid beta-fructofuranosidase 3, vacuolar Proteins 0.000 description 2
- 101001053395 Arabidopsis thaliana Acid beta-fructofuranosidase 4, vacuolar Proteins 0.000 description 2
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 2
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 2
- 108050006947 CXC Chemokine Proteins 0.000 description 2
- 102000019388 CXC chemokine Human genes 0.000 description 2
- 102000019034 Chemokines Human genes 0.000 description 2
- 108010012236 Chemokines Proteins 0.000 description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 235000003332 Ilex aquifolium Nutrition 0.000 description 2
- 241000209027 Ilex aquifolium Species 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 2
- OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 2
- 239000012359 Methanesulfonyl chloride Substances 0.000 description 2
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 2
- LFTLOKWAGJYHHR-UHFFFAOYSA-N N-methylmorpholine N-oxide Chemical compound CN1(=O)CCOCC1 LFTLOKWAGJYHHR-UHFFFAOYSA-N 0.000 description 2
- 229910002651 NO3 Inorganic materials 0.000 description 2
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 2
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 2
- 239000005700 Putrescine Substances 0.000 description 2
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 2
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical group C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 2
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical group C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 2
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical compound [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- 235000019270 ammonium chloride Nutrition 0.000 description 2
- 230000008485 antagonism Effects 0.000 description 2
- 230000036436 anti-hiv Effects 0.000 description 2
- 230000000840 anti-viral effect Effects 0.000 description 2
- 125000004429 atom Chemical group 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- HSDAJNMJOMSNEV-UHFFFAOYSA-N benzyl chloroformate Chemical compound ClC(=O)OCC1=CC=CC=C1 HSDAJNMJOMSNEV-UHFFFAOYSA-N 0.000 description 2
- WGQKYBSKWIADBV-UHFFFAOYSA-N benzylamine Chemical compound NCC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-N 0.000 description 2
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 2
- WPJAWKJPJWLNJG-UHFFFAOYSA-N bis(methoxycarbonyl)azaniumylideneazanide Chemical compound COC(=O)[N+](=[N-])C(=O)OC WPJAWKJPJWLNJG-UHFFFAOYSA-N 0.000 description 2
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 235000008504 concentrate Nutrition 0.000 description 2
- 125000000753 cycloalkyl group Chemical group 0.000 description 2
- 239000012351 deprotecting agent Substances 0.000 description 2
- NKLCNNUWBJBICK-UHFFFAOYSA-N dess–martin periodinane Chemical compound C1=CC=C2I(OC(=O)C)(OC(C)=O)(OC(C)=O)OC(=O)C2=C1 NKLCNNUWBJBICK-UHFFFAOYSA-N 0.000 description 2
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 2
- WVDDGKGOMKODPV-UHFFFAOYSA-N hydroxymethyl benzene Natural products OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 2
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 description 2
- 125000001041 indolyl group Chemical group 0.000 description 2
- NQXWGWZJXJUMQB-UHFFFAOYSA-K iron trichloride hexahydrate Chemical compound O.O.O.O.O.O.[Cl-].Cl[Fe+]Cl NQXWGWZJXJUMQB-UHFFFAOYSA-K 0.000 description 2
- BYXYCUABYHCYLY-UHFFFAOYSA-N isoindole-1,3-dione;potassium Chemical compound [K].C1=CC=C2C(=O)NC(=O)C2=C1 BYXYCUABYHCYLY-UHFFFAOYSA-N 0.000 description 2
- AWJUIBRHMBBTKR-UHFFFAOYSA-N isoquinoline Chemical compound C1=NC=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 239000012046 mixed solvent Substances 0.000 description 2
- JMANVNJQNLATNU-UHFFFAOYSA-N oxalonitrile Chemical compound N#CC#N JMANVNJQNLATNU-UHFFFAOYSA-N 0.000 description 2
- 125000002971 oxazolyl group Chemical group 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 2
- UHZYTMXLRWXGPK-UHFFFAOYSA-N phosphorus pentachloride Chemical compound ClP(Cl)(Cl)(Cl)Cl UHZYTMXLRWXGPK-UHFFFAOYSA-N 0.000 description 2
- XKJCHHZQLQNZHY-UHFFFAOYSA-N phthalimide Chemical compound C1=CC=C2C(=O)NC(=O)C2=C1 XKJCHHZQLQNZHY-UHFFFAOYSA-N 0.000 description 2
- 125000003386 piperidinyl group Chemical group 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 229960003975 potassium Drugs 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 229910000027 potassium carbonate Inorganic materials 0.000 description 2
- 235000011181 potassium carbonates Nutrition 0.000 description 2
- FYRHIOVKTDQVFC-UHFFFAOYSA-M potassium phthalimide Chemical compound [K+].C1=CC=C2C(=O)[N-]C(=O)C2=C1 FYRHIOVKTDQVFC-UHFFFAOYSA-M 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 125000003373 pyrazinyl group Chemical group 0.000 description 2
- PBMFSQRYOILNGV-UHFFFAOYSA-N pyridazine Chemical group C1=CC=NN=C1 PBMFSQRYOILNGV-UHFFFAOYSA-N 0.000 description 2
- 125000000714 pyrimidinyl group Chemical group 0.000 description 2
- 125000000168 pyrrolyl group Chemical group 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000012312 sodium hydride Substances 0.000 description 2
- 229910000104 sodium hydride Inorganic materials 0.000 description 2
- 125000004434 sulfur atom Chemical group 0.000 description 2
- XTHPWXDJESJLNJ-UHFFFAOYSA-N sulfurochloridic acid Chemical compound OS(Cl)(=O)=O XTHPWXDJESJLNJ-UHFFFAOYSA-N 0.000 description 2
- 239000013076 target substance Substances 0.000 description 2
- 229940095064 tartrate Drugs 0.000 description 2
- DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 2
- 125000003039 tetrahydroisoquinolinyl group Chemical group C1(NCCC2=CC=CC=C12)* 0.000 description 2
- OSBSFAARYOCBHB-UHFFFAOYSA-N tetrapropylammonium Chemical compound CCC[N+](CCC)(CCC)CCC OSBSFAARYOCBHB-UHFFFAOYSA-N 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- URAYPUMNDPQOKB-UHFFFAOYSA-N triacetin Chemical compound CC(=O)OCC(OC(C)=O)COC(C)=O URAYPUMNDPQOKB-UHFFFAOYSA-N 0.000 description 2
- 229960005486 vaccine Drugs 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- 239000003643 water by type Substances 0.000 description 2
- TXUICONDJPYNPY-UHFFFAOYSA-N (1,10,13-trimethyl-3-oxo-4,5,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-17-yl) heptanoate Chemical compound C1CC2CC(=O)C=C(C)C2(C)C2C1C1CCC(OC(=O)CCCCCC)C1(C)CC2 TXUICONDJPYNPY-UHFFFAOYSA-N 0.000 description 1
- LGLVVVCSQBZONM-HCCLCSBVSA-N (2r)-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-acetamido-5-(diaminomethylideneamino)pentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-5-(diaminomethylideneamino)pentano Chemical compound NC(N)=NCCC[C@@H](NC(=O)C)C(=O)N[C@H](CCCN=C(N)N)C(=O)N[C@H](CCCN=C(N)N)C(=O)N[C@H](CCCN=C(N)N)C(=O)N[C@H](CCCN=C(N)N)C(=O)N[C@H](CCCN=C(N)N)C(=O)N[C@H](CCCN=C(N)N)C(=O)N[C@H](CCCN=C(N)N)C(=O)N[C@H](CCCN=C(N)N)C(N)=O LGLVVVCSQBZONM-HCCLCSBVSA-N 0.000 description 1
- DLZXLCHQWOZGSE-UHFFFAOYSA-N (3-nitrophenyl)methylazanium;chloride Chemical compound Cl.NCC1=CC=CC([N+]([O-])=O)=C1 DLZXLCHQWOZGSE-UHFFFAOYSA-N 0.000 description 1
- SCYULBFZEHDVBN-UHFFFAOYSA-N 1,1-Dichloroethane Chemical compound CC(Cl)Cl SCYULBFZEHDVBN-UHFFFAOYSA-N 0.000 description 1
- UGUHFDPGDQDVGX-UHFFFAOYSA-N 1,2,3-thiadiazole Chemical group C1=CSN=N1 UGUHFDPGDQDVGX-UHFFFAOYSA-N 0.000 description 1
- KEIFWROAQVVDBN-UHFFFAOYSA-N 1,2-dihydronaphthalene Chemical group C1=CC=C2C=CCCC2=C1 KEIFWROAQVVDBN-UHFFFAOYSA-N 0.000 description 1
- 125000000355 1,3-benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 1
- ZGTFNNUASMWGTM-UHFFFAOYSA-N 1,3-thiazole-2-carbaldehyde Chemical compound O=CC1=NC=CS1 ZGTFNNUASMWGTM-UHFFFAOYSA-N 0.000 description 1
- WORJRXHJTUTINR-UHFFFAOYSA-N 1,4-dioxane;hydron;chloride Chemical compound Cl.C1COCCO1 WORJRXHJTUTINR-UHFFFAOYSA-N 0.000 description 1
- VXNZUUAINFGPBY-UHFFFAOYSA-N 1-Butene Chemical compound CCC=C VXNZUUAINFGPBY-UHFFFAOYSA-N 0.000 description 1
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 1
- YUBDLZGUSSWQSS-UHFFFAOYSA-N 1-benzylpiperidin-4-amine Chemical compound C1CC(N)CCN1CC1=CC=CC=C1 YUBDLZGUSSWQSS-UHFFFAOYSA-N 0.000 description 1
- 125000004973 1-butenyl group Chemical group C(=CCC)* 0.000 description 1
- QWENRTYMTSOGBR-UHFFFAOYSA-N 1H-1,2,3-Triazole Chemical group C=1C=NNN=1 QWENRTYMTSOGBR-UHFFFAOYSA-N 0.000 description 1
- HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical compound C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 description 1
- BWFCRMDFKOIFHA-UHFFFAOYSA-N 2,2-dimethyl-n',n'-dipropylpropane-1,3-diamine Chemical compound CCCN(CCC)CC(C)(C)CN BWFCRMDFKOIFHA-UHFFFAOYSA-N 0.000 description 1
- 125000004816 2,2-dimethylethylene group Chemical group [H]C([H])([H])C([*:2])(C([H])([H])[H])C([H])([H])[*:1] 0.000 description 1
- DDHUNHGZUHZNKB-UHFFFAOYSA-N 2,2-dimethylpropane-1,3-diamine Chemical compound NCC(C)(C)CN DDHUNHGZUHZNKB-UHFFFAOYSA-N 0.000 description 1
- FRUWMYWEARDNTC-UHFFFAOYSA-N 2,3,3a,4-tetrahydro-1h-indole Chemical group C1C=CC=C2NCCC21 FRUWMYWEARDNTC-UHFFFAOYSA-N 0.000 description 1
- AHDSRXYHVZECER-UHFFFAOYSA-N 2,4,6-tris[(dimethylamino)methyl]phenol Chemical compound CN(C)CC1=CC(CN(C)C)=C(O)C(CN(C)C)=C1 AHDSRXYHVZECER-UHFFFAOYSA-N 0.000 description 1
- SURCGQGDUADKBL-UHFFFAOYSA-N 2-(2-hydroxyethylamino)-5-nitrobenzo[de]isoquinoline-1,3-dione Chemical compound [O-][N+](=O)C1=CC(C(N(NCCO)C2=O)=O)=C3C2=CC=CC3=C1 SURCGQGDUADKBL-UHFFFAOYSA-N 0.000 description 1
- CPHXLFKIUVVIOQ-UHFFFAOYSA-N 2-(trifluoromethoxy)benzaldehyde Chemical compound FC(F)(F)OC1=CC=CC=C1C=O CPHXLFKIUVVIOQ-UHFFFAOYSA-N 0.000 description 1
- ZDVRPKUWYQVVDX-UHFFFAOYSA-N 2-(trifluoromethyl)benzaldehyde Chemical compound FC(F)(F)C1=CC=CC=C1C=O ZDVRPKUWYQVVDX-UHFFFAOYSA-N 0.000 description 1
- XXZCIYUJYUESMD-UHFFFAOYSA-N 2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]-3-(morpholin-4-ylmethyl)pyrazol-1-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C=1C(=NN(C=1)CC(=O)N1CC2=C(CC1)NN=N2)CN1CCOCC1 XXZCIYUJYUESMD-UHFFFAOYSA-N 0.000 description 1
- WWSJZGAPAVMETJ-UHFFFAOYSA-N 2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]-3-ethoxypyrazol-1-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C=1C(=NN(C=1)CC(=O)N1CC2=C(CC1)NN=N2)OCC WWSJZGAPAVMETJ-UHFFFAOYSA-N 0.000 description 1
- FYELSNVLZVIGTI-UHFFFAOYSA-N 2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]-5-ethylpyrazol-1-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C=1C=NN(C=1CC)CC(=O)N1CC2=C(CC1)NN=N2 FYELSNVLZVIGTI-UHFFFAOYSA-N 0.000 description 1
- WZFUQSJFWNHZHM-UHFFFAOYSA-N 2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)CC(=O)N1CC2=C(CC1)NN=N2 WZFUQSJFWNHZHM-UHFFFAOYSA-N 0.000 description 1
- ZRPAUEVGEGEPFQ-UHFFFAOYSA-N 2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]pyrazol-1-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C=1C=NN(C=1)CC(=O)N1CC2=C(CC1)NN=N2 ZRPAUEVGEGEPFQ-UHFFFAOYSA-N 0.000 description 1
- YJLUBHOZZTYQIP-UHFFFAOYSA-N 2-[5-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]-1,3,4-oxadiazol-2-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C1=NN=C(O1)CC(=O)N1CC2=C(CC1)NN=N2 YJLUBHOZZTYQIP-UHFFFAOYSA-N 0.000 description 1
- XUYYZZZIGRNCLM-UHFFFAOYSA-N 2-[[4-[[4-[(dipropylamino)methyl]anilino]methyl]phenyl]methyl]isoindole-1,3-dione Chemical compound C1=CC(CN(CCC)CCC)=CC=C1NCC(C=C1)=CC=C1CN1C(=O)C2=CC=CC=C2C1=O XUYYZZZIGRNCLM-UHFFFAOYSA-N 0.000 description 1
- CSDSSGBPEUDDEE-UHFFFAOYSA-N 2-formylpyridine Chemical compound O=CC1=CC=CC=N1 CSDSSGBPEUDDEE-UHFFFAOYSA-N 0.000 description 1
- 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 description 1
- GWYFCOCPABKNJV-UHFFFAOYSA-M 3-Methylbutanoic acid Natural products CC(C)CC([O-])=O GWYFCOCPABKNJV-UHFFFAOYSA-M 0.000 description 1
- USXJXXKTQADSPA-UHFFFAOYSA-N 3-[(dipropylamino)methyl]aniline Chemical compound CCCN(CCC)CC1=CC=CC(N)=C1 USXJXXKTQADSPA-UHFFFAOYSA-N 0.000 description 1
- SOJDQCMXYVRUJX-UHFFFAOYSA-N 3-[5-[[1h-imidazol-2-ylmethyl-[(1-methylimidazol-2-yl)methyl]amino]methyl]-1-benzofuran-2-yl]-n,n-dipropylpropan-1-amine Chemical compound C=1C=C2OC(CCCN(CCC)CCC)=CC2=CC=1CN(CC=1N(C=CN=1)C)CC1=NC=CN1 SOJDQCMXYVRUJX-UHFFFAOYSA-N 0.000 description 1
- LOWYEOHECBZADB-UHFFFAOYSA-N 3-amino-2-[4-(dipropylamino)butyl]-5-[[1h-imidazol-2-ylmethyl-[(1-methylimidazol-2-yl)methyl]amino]methyl]inden-1-one Chemical compound C=1C=C2C(=O)C(CCCCN(CCC)CCC)=C(N)C2=CC=1CN(CC=1N(C=CN=1)C)CC1=NC=CN1 LOWYEOHECBZADB-UHFFFAOYSA-N 0.000 description 1
- NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 1
- BWCDLEQTELFBAW-UHFFFAOYSA-N 3h-dioxazole Chemical group N1OOC=C1 BWCDLEQTELFBAW-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- PWSHUCWQUXJJHK-UHFFFAOYSA-N 4-[(1,3-dioxoisoindol-2-yl)methyl]benzaldehyde Chemical compound C1=CC(C=O)=CC=C1CN1C(=O)C2=CC=CC=C2C1=O PWSHUCWQUXJJHK-UHFFFAOYSA-N 0.000 description 1
- AYCQCBGYYQFRHK-UHFFFAOYSA-N 4-[(dipropylamino)methyl]phenol Chemical compound CCCN(CCC)CC1=CC=C(O)C=C1 AYCQCBGYYQFRHK-UHFFFAOYSA-N 0.000 description 1
- SHBLJBHMPCOVGU-UHFFFAOYSA-N 4-[5-[[1h-imidazol-2-ylmethyl-[(1-methylimidazol-2-yl)methyl]amino]methyl]-1-methoxy-2,3-dihydro-1h-inden-2-yl]-n,n-dipropylbutan-1-amine Chemical compound C=1C=C2C(OC)C(CCCCN(CCC)CCC)CC2=CC=1CN(CC=1N(C=CN=1)C)CC1=NC=CN1 SHBLJBHMPCOVGU-UHFFFAOYSA-N 0.000 description 1
- RYMHHQXDRUUVMT-UHFFFAOYSA-N 4-[5-[[1h-imidazol-2-ylmethyl-[(1-methylimidazol-2-yl)methyl]amino]methyl]-1-methylindol-2-yl]-n,n-dipropylbutan-1-amine Chemical compound C=1C=C2N(C)C(CCCCN(CCC)CCC)=CC2=CC=1CN(CC=1N(C=CN=1)C)CC1=NC=CN1 RYMHHQXDRUUVMT-UHFFFAOYSA-N 0.000 description 1
- WOFOOGPRMMLOCN-UHFFFAOYSA-N 4-[5-[[1h-imidazol-2-ylmethyl-[(1-methylimidazol-2-yl)methyl]amino]methyl]-1h-indol-2-yl]-n,n-dipropylbutan-1-amine Chemical compound C=1C=C2NC(CCCCN(CCC)CCC)=CC2=CC=1CN(CC=1N(C=CN=1)C)CC1=NC=CN1 WOFOOGPRMMLOCN-UHFFFAOYSA-N 0.000 description 1
- PKOZJRIXNVSKNN-UHFFFAOYSA-N 4-[6-[[1h-imidazol-2-ylmethyl-[(1-methylimidazol-2-yl)methyl]amino]methyl]-1h-benzimidazol-2-yl]-n,n-dipropylbutan-1-amine Chemical compound C1=C2NC(CCCCN(CCC)CCC)=NC2=CC=C1CN(CC=1N(C=CN=1)C)CC1=NC=CN1 PKOZJRIXNVSKNN-UHFFFAOYSA-N 0.000 description 1
- YSZLJWANPZTIPE-UHFFFAOYSA-N 4-[6-[[1h-imidazol-2-ylmethyl-[(1-methylimidazol-2-yl)methyl]amino]methyl]-3,4-dihydro-2h-chromen-2-yl]-n,n-dipropylbutan-1-amine Chemical compound C=1C=C2OC(CCCCN(CCC)CCC)CCC2=CC=1CN(CC=1N(C=CN=1)C)CC1=NC=CN1 YSZLJWANPZTIPE-UHFFFAOYSA-N 0.000 description 1
- UPQFDMVJSOIUOY-UHFFFAOYSA-N 4-[[bis(1h-imidazol-2-ylmethyl)amino]methyl]-n-[4-[cyclohexyl(methyl)amino]butyl]benzamide Chemical compound C1CCCCC1N(C)CCCCNC(=O)C(C=C1)=CC=C1CN(CC=1NC=CN=1)CC1=NC=CN1 UPQFDMVJSOIUOY-UHFFFAOYSA-N 0.000 description 1
- YLOJTDCTLRUWCV-UHFFFAOYSA-N 4-[[bis(1h-imidazol-2-ylmethyl)amino]methyl]benzoic acid Chemical compound C1=CC(C(=O)O)=CC=C1CN(CC=1NC=CN=1)CC1=NC=CN1 YLOJTDCTLRUWCV-UHFFFAOYSA-N 0.000 description 1
- YFXHTFAYYVYVTC-UHFFFAOYSA-N 4-[[bis[(1-methylimidazol-2-yl)methyl]amino]methyl]benzoic acid Chemical compound CN1C=CN=C1CN(CC=1C=CC(=CC=1)C(O)=O)CC1=NC=CN1C YFXHTFAYYVYVTC-UHFFFAOYSA-N 0.000 description 1
- VUTBELPREDJDDH-UHFFFAOYSA-N 4-amino-5-hydroxymethyl-2-methylpyrimidine Chemical compound CC1=NC=C(CO)C(N)=N1 VUTBELPREDJDDH-UHFFFAOYSA-N 0.000 description 1
- 125000004042 4-aminobutyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])N([H])[H] 0.000 description 1
- CQPGDDAKTTWVDD-UHFFFAOYSA-N 4-bromobutanenitrile Chemical compound BrCCCC#N CQPGDDAKTTWVDD-UHFFFAOYSA-N 0.000 description 1
- MBVFRSJFKMJRHA-UHFFFAOYSA-N 4-fluoro-1-benzofuran-7-carbaldehyde Chemical compound FC1=CC=C(C=O)C2=C1C=CO2 MBVFRSJFKMJRHA-UHFFFAOYSA-N 0.000 description 1
- PIMQQGJMDMAZGT-UHFFFAOYSA-N 4-methylthiobenzaldehyde Chemical compound CC1=CC=C(C=S)C=C1 PIMQQGJMDMAZGT-UHFFFAOYSA-N 0.000 description 1
- GFMRZAMDGJIWRB-UHFFFAOYSA-N 5-[(2-methylpropan-2-yl)oxycarbonylamino]pentanoic acid Chemical compound CC(C)(C)OC(=O)NCCCCC(O)=O GFMRZAMDGJIWRB-UHFFFAOYSA-N 0.000 description 1
- CONKBQPVFMXDOV-QHCPKHFHSA-N 6-[(5S)-5-[[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]methyl]-2-oxo-1,3-oxazolidin-3-yl]-3H-1,3-benzoxazol-2-one Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)C[C@H]1CN(C(O1)=O)C1=CC2=C(NC(O2)=O)C=C1 CONKBQPVFMXDOV-QHCPKHFHSA-N 0.000 description 1
- AHISYUZBWDSPQL-UHFFFAOYSA-N 6-methylpyridine-2-carbaldehyde Chemical compound CC1=CC=CC(C=O)=N1 AHISYUZBWDSPQL-UHFFFAOYSA-N 0.000 description 1
- 208000012124 AIDS-related disease Diseases 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 101100132433 Arabidopsis thaliana VIII-1 gene Proteins 0.000 description 1
- 101100459319 Arabidopsis thaliana VIII-2 gene Proteins 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
- 108050005711 C Chemokine Proteins 0.000 description 1
- 102000017483 C chemokine Human genes 0.000 description 1
- 102000001902 CC Chemokines Human genes 0.000 description 1
- 108010040471 CC Chemokines Proteins 0.000 description 1
- FTWFDZDKTPWDJA-UHFFFAOYSA-N CC(C)(C)[SiH](C1=CC=CC=C1)C1=CC=CC=C1.Cl Chemical compound CC(C)(C)[SiH](C1=CC=CC=C1)C1=CC=CC=C1.Cl FTWFDZDKTPWDJA-UHFFFAOYSA-N 0.000 description 1
- MAJLTTBFDJJFCO-UHFFFAOYSA-N CC1=C(C(=O)N(C)C2=CC=C(C=C2)CN(CCC)CCC)C=CC=C1 Chemical compound CC1=C(C(=O)N(C)C2=CC=C(C=C2)CN(CCC)CCC)C=CC=C1 MAJLTTBFDJJFCO-UHFFFAOYSA-N 0.000 description 1
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 102000009410 Chemokine receptor Human genes 0.000 description 1
- 108050000299 Chemokine receptor Proteins 0.000 description 1
- XJUZRXYOEPSWMB-UHFFFAOYSA-N Chloromethyl methyl ether Chemical compound COCCl XJUZRXYOEPSWMB-UHFFFAOYSA-N 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 101710091045 Envelope protein Proteins 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 208000031886 HIV Infections Diseases 0.000 description 1
- 208000037357 HIV infectious disease Diseases 0.000 description 1
- 102100034349 Integrase Human genes 0.000 description 1
- VQTUBCCKSQIDNK-UHFFFAOYSA-N Isobutene Chemical group CC(C)=C VQTUBCCKSQIDNK-UHFFFAOYSA-N 0.000 description 1
- AMIMRNSIRUDHCM-UHFFFAOYSA-N Isopropylaldehyde Chemical compound CC(C)C=O AMIMRNSIRUDHCM-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- 241000428198 Lutrinae Species 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- QPJVMBTYPHYUOC-UHFFFAOYSA-N Methyl benzoate Natural products COC(=O)C1=CC=CC=C1 QPJVMBTYPHYUOC-UHFFFAOYSA-N 0.000 description 1
- WITXFYCLPDFRNM-UHFFFAOYSA-N N-Benzylphthalimide Chemical compound O=C1C2=CC=CC=C2C(=O)N1CC1=CC=CC=C1 WITXFYCLPDFRNM-UHFFFAOYSA-N 0.000 description 1
- 108010056642 N-alpha-acetyl-nona-D-arginine amide acetate Proteins 0.000 description 1
- XCQHXRZZCHZBBD-UHFFFAOYSA-N N1(CCNCC1)C(=O)NC1=CC=C(C=C1)CN(CC=1NC=CN1)CC=1NC=CN1 Chemical compound N1(CCNCC1)C(=O)NC1=CC=C(C=C1)CN(CC=1NC=CN1)CC=1NC=CN1 XCQHXRZZCHZBBD-UHFFFAOYSA-N 0.000 description 1
- 102100037591 Neuroserpin Human genes 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- 241000233855 Orchidaceae Species 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 101710188315 Protein X Proteins 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 102100021669 Stromal cell-derived factor 1 Human genes 0.000 description 1
- 101710088580 Stromal cell-derived factor 1 Proteins 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 229910021626 Tin(II) chloride Inorganic materials 0.000 description 1
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N Valeric acid Natural products CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- JLCHNBRGUPQWKF-UHFFFAOYSA-J [OH-].[C+4].[OH-].[OH-].[OH-] Chemical compound [OH-].[C+4].[OH-].[OH-].[OH-] JLCHNBRGUPQWKF-UHFFFAOYSA-J 0.000 description 1
- 125000000738 acetamido group Chemical group [H]C([H])([H])C(=O)N([H])[*] 0.000 description 1
- ORWKVZNEPHTCQE-UHFFFAOYSA-N acetic formic anhydride Chemical compound CC(=O)OC=O ORWKVZNEPHTCQE-UHFFFAOYSA-N 0.000 description 1
- 150000008065 acid anhydrides Chemical class 0.000 description 1
- 125000004442 acylamino group Chemical group 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- IAJILQKETJEXLJ-QTBDOELSSA-N aldehydo-D-glucuronic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-QTBDOELSSA-N 0.000 description 1
- 125000004183 alkoxy alkyl group Chemical group 0.000 description 1
- 125000004466 alkoxycarbonylamino group Chemical group 0.000 description 1
- 125000004414 alkyl thio group Chemical group 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 125000003368 amide group Chemical group 0.000 description 1
- 125000004103 aminoalkyl group Chemical group 0.000 description 1
- QCTBMLYLENLHLA-UHFFFAOYSA-N aminomethylbenzoic acid Chemical compound NCC1=CC=C(C(O)=O)C=C1 QCTBMLYLENLHLA-UHFFFAOYSA-N 0.000 description 1
- 229960003375 aminomethylbenzoic acid Drugs 0.000 description 1
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 125000005577 anthracene group Chemical group 0.000 description 1
- 238000010533 azeotropic distillation Methods 0.000 description 1
- ZSIQJIWKELUFRJ-UHFFFAOYSA-N azepane Chemical group C1CCCNCC1 ZSIQJIWKELUFRJ-UHFFFAOYSA-N 0.000 description 1
- QXNDZONIWRINJR-UHFFFAOYSA-N azocane Chemical group C1CCCNCCC1 QXNDZONIWRINJR-UHFFFAOYSA-N 0.000 description 1
- 125000005604 azodicarboxylate group Chemical group 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- 125000005605 benzo group Chemical group 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- FFBHFFJDDLITSX-UHFFFAOYSA-N benzyl N-[2-hydroxy-4-(3-oxomorpholin-4-yl)phenyl]carbamate Chemical compound OC1=C(NC(=O)OCC2=CC=CC=C2)C=CC(=C1)N1CCOCC1=O FFBHFFJDDLITSX-UHFFFAOYSA-N 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- IZGKHHFFYLRBPL-UHFFFAOYSA-N benzyl n-(4-aminobutyl)carbamate Chemical compound NCCCCNC(=O)OCC1=CC=CC=C1 IZGKHHFFYLRBPL-UHFFFAOYSA-N 0.000 description 1
- 125000000440 benzylamino group Chemical group [H]N(*)C([H])([H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 description 1
- MOOAHMCRPCTRLV-UHFFFAOYSA-N boron sodium Chemical compound [B].[Na] MOOAHMCRPCTRLV-UHFFFAOYSA-N 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 125000005622 butynylene group Chemical group 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- KXDHJXZQYSOELW-UHFFFAOYSA-N carbonic acid monoamide Natural products NC(O)=O KXDHJXZQYSOELW-UHFFFAOYSA-N 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000007810 chemical reaction solvent Substances 0.000 description 1
- 230000035605 chemotaxis Effects 0.000 description 1
- WORJEOGGNQDSOE-UHFFFAOYSA-N chloroform;methanol Chemical compound OC.ClC(Cl)Cl WORJEOGGNQDSOE-UHFFFAOYSA-N 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 125000004093 cyano group Chemical group *C#N 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- CGZZMOTZOONQIA-UHFFFAOYSA-N cycloheptanone Chemical compound O=C1CCCCCC1 CGZZMOTZOONQIA-UHFFFAOYSA-N 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 1
- 125000004956 cyclohexylene group Chemical group 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000004979 cyclopentylene group Chemical group 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 125000004980 cyclopropylene group Chemical group 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
- 238000010908 decantation Methods 0.000 description 1
- 125000004472 dialkylaminosulfonyl group Chemical group 0.000 description 1
- ZFTFAPZRGNKQPU-UHFFFAOYSA-N dicarbonic acid Chemical compound OC(=O)OC(O)=O ZFTFAPZRGNKQPU-UHFFFAOYSA-N 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- BJXYHBKEQFQVES-NWDGAFQWSA-N enpatoran Chemical compound N[C@H]1CN(C[C@H](C1)C(F)(F)F)C1=C2C=CC=NC2=C(C=C1)C#N BJXYHBKEQFQVES-NWDGAFQWSA-N 0.000 description 1
- 125000004185 ester group Chemical group 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- VRHAQNTWKSVEEC-UHFFFAOYSA-N ethyl 1,3-dioxoisoindole-2-carboxylate Chemical compound C1=CC=C2C(=O)N(C(=O)OCC)C(=O)C2=C1 VRHAQNTWKSVEEC-UHFFFAOYSA-N 0.000 description 1
- URZKCMPZWPHMAF-UHFFFAOYSA-N ethyl 1,3-dioxoisoindole-4-carboxylate Chemical compound CCOC(=O)C1=CC=CC2=C1C(=O)NC2=O URZKCMPZWPHMAF-UHFFFAOYSA-N 0.000 description 1
- QHGVNPJOYZAWMB-UHFFFAOYSA-N ethyl 2-[[[4-[[4-[(dipropylamino)methyl]phenyl]carbamoyl]phenyl]methyl-[(1-methylimidazol-2-yl)methyl]amino]methyl]imidazole-1-carboxylate Chemical compound C1=CC(CN(CCC)CCC)=CC=C1NC(=O)C(C=C1)=CC=C1CN(CC=1N(C=CN=1)C(=O)OCC)CC1=NC=CN1C QHGVNPJOYZAWMB-UHFFFAOYSA-N 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 125000000816 ethylene group Chemical group [H]C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- REHUGJYJIZPQAV-UHFFFAOYSA-N formaldehyde;methanol Chemical compound OC.O=C REHUGJYJIZPQAV-UHFFFAOYSA-N 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- WBJINCZRORDGAQ-UHFFFAOYSA-N formic acid ethyl ester Natural products CCOC=O WBJINCZRORDGAQ-UHFFFAOYSA-N 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229940097043 glucuronic acid Drugs 0.000 description 1
- 235000013773 glyceryl triacetate Nutrition 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 1
- 150000004678 hydrides Chemical class 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- XOYMAJLARWXZBA-UHFFFAOYSA-N isoquinoline-3-carbaldehyde Chemical compound C1=CC=C2C=NC(C=O)=CC2=C1 XOYMAJLARWXZBA-UHFFFAOYSA-N 0.000 description 1
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 1
- ZLTPDFXIESTBQG-UHFFFAOYSA-N isothiazole Chemical compound C=1C=NSC=1 ZLTPDFXIESTBQG-UHFFFAOYSA-N 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 235000012204 lemonade/lime carbonate Nutrition 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- YNESATAKKCNGOF-UHFFFAOYSA-N lithium bis(trimethylsilyl)amide Chemical compound [Li+].C[Si](C)(C)[N-][Si](C)(C)C YNESATAKKCNGOF-UHFFFAOYSA-N 0.000 description 1
- 229910000103 lithium hydride Inorganic materials 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 229940057948 magnesium stearate Drugs 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- GBMDVOWEEQVZKZ-UHFFFAOYSA-N methanol;hydrate Chemical compound O.OC GBMDVOWEEQVZKZ-UHFFFAOYSA-N 0.000 description 1
- SJFNDMHZXCUXSA-UHFFFAOYSA-M methoxymethyl(triphenyl)phosphanium;chloride Chemical compound [Cl-].C=1C=CC=CC=1[P+](C=1C=CC=CC=1)(COC)C1=CC=CC=C1 SJFNDMHZXCUXSA-UHFFFAOYSA-M 0.000 description 1
- RBTRYPAYLTVGDV-UHFFFAOYSA-N methyl 2-(aminomethyl)benzoate Chemical compound COC(=O)C1=CC=CC=C1CN RBTRYPAYLTVGDV-UHFFFAOYSA-N 0.000 description 1
- QKASDIPENBEWBU-UHFFFAOYSA-N methyl 2-(bromomethyl)benzoate Chemical compound COC(=O)C1=CC=CC=C1CBr QKASDIPENBEWBU-UHFFFAOYSA-N 0.000 description 1
- ZBCGBIZQNMVMPC-UHFFFAOYSA-N methyl isoquinoline-3-carboxylate Chemical compound C1=CC=C2C=NC(C(=O)OC)=CC2=C1 ZBCGBIZQNMVMPC-UHFFFAOYSA-N 0.000 description 1
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- XONPDZSGENTBNJ-UHFFFAOYSA-N molecular hydrogen;sodium Chemical compound [Na].[H][H] XONPDZSGENTBNJ-UHFFFAOYSA-N 0.000 description 1
- 239000002324 mouth wash Substances 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- GZUCMODGDIGMBI-UHFFFAOYSA-N n',n'-dipropylpropane-1,3-diamine Chemical compound CCCN(CCC)CCCN GZUCMODGDIGMBI-UHFFFAOYSA-N 0.000 description 1
- SZQCTDJMFAHMEJ-UHFFFAOYSA-N n,n-dipropylpiperidin-1-amine Chemical compound CCCN(CCC)N1CCCCC1 SZQCTDJMFAHMEJ-UHFFFAOYSA-N 0.000 description 1
- UZZSSTXYFRORNI-UHFFFAOYSA-N n-[2-(aminomethyl)phenyl]benzamide Chemical compound NCC1=CC=CC=C1NC(=O)C1=CC=CC=C1 UZZSSTXYFRORNI-UHFFFAOYSA-N 0.000 description 1
- SVUDXIPZNRDCOG-UHFFFAOYSA-N n-[2-(dipropylamino)ethyl]-6-[[1h-imidazol-2-ylmethyl-[(1-methylimidazol-2-yl)methyl]amino]methyl]-4-oxo-1h-quinazoline-2-carboxamide Chemical compound C1=C2C(=O)NC(C(=O)NCCN(CCC)CCC)=NC2=CC=C1CN(CC=1N(C=CN=1)C)CC1=NC=CN1 SVUDXIPZNRDCOG-UHFFFAOYSA-N 0.000 description 1
- DFNVHINGMBHTKC-UHFFFAOYSA-N n-[4-(dimethylamino)butyl]benzamide Chemical compound CN(C)CCCCNC(=O)C1=CC=CC=C1 DFNVHINGMBHTKC-UHFFFAOYSA-N 0.000 description 1
- HBXZSRUDMQWOPM-UHFFFAOYSA-N n-[4-[(dipropylamino)methyl]phenyl]-4-[[(5-ethylpyridin-2-yl)methyl-(1h-imidazol-2-ylmethyl)amino]methyl]benzamide Chemical compound C1=CC(CN(CCC)CCC)=CC=C1NC(=O)C(C=C1)=CC=C1CN(CC=1N=CC(CC)=CC=1)CC1=NC=CN1 HBXZSRUDMQWOPM-UHFFFAOYSA-N 0.000 description 1
- BAVUTVHIDHDBFW-UHFFFAOYSA-N n-[4-[bis(2-methylpropyl)amino]butyl]-4-[[1h-imidazol-2-ylmethyl-[(1-methylimidazol-2-yl)methyl]amino]methyl]benzenesulfonamide Chemical compound C1=CC(S(=O)(=O)NCCCCN(CC(C)C)CC(C)C)=CC=C1CN(CC=1N(C=CN=1)C)CC1=NC=CN1 BAVUTVHIDHDBFW-UHFFFAOYSA-N 0.000 description 1
- ZPMNQEPYFFZVMR-UHFFFAOYSA-N n-[4-[cyclohexyl(methyl)amino]butyl]-4-[[1h-imidazol-2-ylmethyl-[(1-methylimidazol-2-yl)methyl]amino]methyl]benzenesulfonamide Chemical compound C1CCCCC1N(C)CCCCNS(=O)(=O)C(C=C1)=CC=C1CN(CC=1N(C=CN=1)C)CC1=NC=CN1 ZPMNQEPYFFZVMR-UHFFFAOYSA-N 0.000 description 1
- GCQQNSBJEQSGQQ-UHFFFAOYSA-N n-[[4-(aminomethyl)phenyl]methyl]-4-[(dipropylamino)methyl]aniline Chemical compound C1=CC(CN(CCC)CCC)=CC=C1NCC1=CC=C(CN)C=C1 GCQQNSBJEQSGQQ-UHFFFAOYSA-N 0.000 description 1
- ZLFCRXLEGRDETK-UHFFFAOYSA-N n-[[4-[(dipropylamino)methyl]phenyl]methyl]-n'-(1h-imidazol-2-ylmethyl)-n'-[(1-methylimidazol-2-yl)methyl]butane-1,4-diamine Chemical compound C1=CC(CN(CCC)CCC)=CC=C1CNCCCCN(CC=1N(C=CN=1)C)CC1=NC=CN1 ZLFCRXLEGRDETK-UHFFFAOYSA-N 0.000 description 1
- CKFUSMBQRFKUOU-UHFFFAOYSA-N n-[[4-[[1h-imidazol-2-ylmethyl-[(1-methylimidazol-2-yl)methyl]amino]methyl]-1,3-thiazol-2-yl]methyl]-n-methyl-n',n'-dipropylbutane-1,4-diamine Chemical compound S1C(CN(C)CCCCN(CCC)CCC)=NC(CN(CC=2NC=CN=2)CC=2N(C=CN=2)C)=C1 CKFUSMBQRFKUOU-UHFFFAOYSA-N 0.000 description 1
- LCZGFMWGMAIWRZ-UHFFFAOYSA-N n-[[4-[[bis(1h-imidazol-2-ylmethyl)amino]methyl]phenyl]methyl]-n-methyl-n',n'-dipropylbutane-1,4-diamine Chemical compound C1=CC(CN(C)CCCCN(CCC)CCC)=CC=C1CN(CC=1NC=CN=1)CC1=NC=CN1 LCZGFMWGMAIWRZ-UHFFFAOYSA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- PVWOIHVRPOBWPI-UHFFFAOYSA-N n-propyl iodide Chemical compound CCCI PVWOIHVRPOBWPI-UHFFFAOYSA-N 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 125000004957 naphthylene group Chemical group 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 108010080874 neuroserpin Proteins 0.000 description 1
- 150000002825 nitriles Chemical class 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- NXJCBFBQEVOTOW-UHFFFAOYSA-L palladium(2+);dihydroxide Chemical compound O[Pd]O NXJCBFBQEVOTOW-UHFFFAOYSA-L 0.000 description 1
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 125000000843 phenylene group Chemical group C1(=C(C=CC=C1)*)* 0.000 description 1
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- IVXQBCUBSIPQGU-UHFFFAOYSA-N piperazine-1-carboxamide Chemical compound NC(=O)N1CCNCC1 IVXQBCUBSIPQGU-UHFFFAOYSA-N 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 235000015497 potassium bicarbonate Nutrition 0.000 description 1
- 229910000028 potassium bicarbonate Inorganic materials 0.000 description 1
- 239000011736 potassium bicarbonate Substances 0.000 description 1
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 1
- 229940086066 potassium hydrogencarbonate Drugs 0.000 description 1
- LJCNRYVRMXRIQR-OLXYHTOASA-L potassium sodium L-tartrate Chemical compound [Na+].[K+].[O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O LJCNRYVRMXRIQR-OLXYHTOASA-L 0.000 description 1
- 229940114930 potassium stearate Drugs 0.000 description 1
- ANBFRLKBEIFNQU-UHFFFAOYSA-M potassium;octadecanoate Chemical compound [K+].CCCCCCCCCCCCCCCCCC([O-])=O ANBFRLKBEIFNQU-UHFFFAOYSA-M 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000012746 preparative thin layer chromatography Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 125000002568 propynyl group Chemical group [*]C#CC([H])([H])[H] 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000003419 rna directed dna polymerase inhibitor Substances 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 238000009938 salting Methods 0.000 description 1
- 229930195734 saturated hydrocarbon Natural products 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- PFUVRDFDKPNGAV-UHFFFAOYSA-N sodium peroxide Chemical compound [Na+].[Na+].[O-][O-] PFUVRDFDKPNGAV-UHFFFAOYSA-N 0.000 description 1
- 239000001476 sodium potassium tartrate Substances 0.000 description 1
- 235000011006 sodium potassium tartrate Nutrition 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 239000012321 sodium triacetoxyborohydride Substances 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000001119 stannous chloride Substances 0.000 description 1
- 235000011150 stannous chloride Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 229940032147 starch Drugs 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 125000006488 t-butyl benzyl group Chemical group 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 229940033134 talc Drugs 0.000 description 1
- YDBPZCVWPFMBDH-MRVPVSSYSA-N tert-butyl (2r)-2-formylpyrrolidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC[C@@H]1C=O YDBPZCVWPFMBDH-MRVPVSSYSA-N 0.000 description 1
- YDBPZCVWPFMBDH-QMMMGPOBSA-N tert-butyl (2s)-2-formylpyrrolidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC[C@H]1C=O YDBPZCVWPFMBDH-QMMMGPOBSA-N 0.000 description 1
- AOCSUUGBCMTKJH-UHFFFAOYSA-N tert-butyl n-(2-aminoethyl)carbamate Chemical compound CC(C)(C)OC(=O)NCCN AOCSUUGBCMTKJH-UHFFFAOYSA-N 0.000 description 1
- QLPCQDZWRXWROH-UHFFFAOYSA-N tert-butyl n-(3-amino-2,2-dimethylpropyl)carbamate Chemical compound CC(C)(C)OC(=O)NCC(C)(C)CN QLPCQDZWRXWROH-UHFFFAOYSA-N 0.000 description 1
- POHWAQLZBIMPRN-UHFFFAOYSA-N tert-butyl n-(3-aminopropyl)carbamate Chemical compound CC(C)(C)OC(=O)NCCCN POHWAQLZBIMPRN-UHFFFAOYSA-N 0.000 description 1
- WIVYTYZCVWHWSH-UHFFFAOYSA-N tert-butyl n-(4-aminophenyl)carbamate Chemical compound CC(C)(C)OC(=O)NC1=CC=C(N)C=C1 WIVYTYZCVWHWSH-UHFFFAOYSA-N 0.000 description 1
- CDAXAXAZXADXQU-UHFFFAOYSA-N tert-butyl n-[4-(dipropylamino)phenyl]carbamate Chemical compound CCCN(CCC)C1=CC=C(NC(=O)OC(C)(C)C)C=C1 CDAXAXAZXADXQU-UHFFFAOYSA-N 0.000 description 1
- CWXPZXBSDSIRCS-UHFFFAOYSA-N tert-butyl piperazine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCNCC1 CWXPZXBSDSIRCS-UHFFFAOYSA-N 0.000 description 1
- BCNZYOJHNLTNEZ-UHFFFAOYSA-N tert-butyldimethylsilyl chloride Chemical compound CC(C)(C)[Si](C)(C)Cl BCNZYOJHNLTNEZ-UHFFFAOYSA-N 0.000 description 1
- IWXDXDCALKLIKB-UHFFFAOYSA-N tert-butylperoxycarbonyl (2-methylpropan-2-yl)oxy carbonate Chemical compound CC(C)(C)OOC(=O)OC(=O)OOC(C)(C)C IWXDXDCALKLIKB-UHFFFAOYSA-N 0.000 description 1
- 125000000147 tetrahydroquinolinyl group Chemical group N1(CCCC2=CC=CC=C12)* 0.000 description 1
- 125000005329 tetralinyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 description 1
- 125000005756 tetralinylene group Chemical group 0.000 description 1
- 125000000383 tetramethylene group Chemical group [H]C([H])([*:1])C([H])([H])C([H])([H])C([H])([H])[*:2] 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- BRNULMACUQOKMR-UHFFFAOYSA-N thiomorpholine Chemical compound C1CSCCN1 BRNULMACUQOKMR-UHFFFAOYSA-N 0.000 description 1
- KJAMZCVTJDTESW-UHFFFAOYSA-N tiracizine Chemical compound C1CC2=CC=CC=C2N(C(=O)CN(C)C)C2=CC(NC(=O)OCC)=CC=C21 KJAMZCVTJDTESW-UHFFFAOYSA-N 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 229960002622 triacetin Drugs 0.000 description 1
- 150000003852 triazoles Chemical group 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
- GTLDTDOJJJZVBW-UHFFFAOYSA-N zinc cyanide Chemical compound [Zn+2].N#[C-].N#[C-] GTLDTDOJJJZVBW-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Definitions
- the present invention relates to an amine compound or a pharmacologically acceptable salt thereof or a prodrug thereof, and more particularly to an amine compound having an antiviral activity based on an antagonistic effect on a chemokine receptor CXCR4.
- the present effort relates to the use of these compounds as active ingredients, and in particular, to drugs for related diseases such as rheumatic diseases and cancer metastasis diseases, which are based on antagonism to the chemokine receptor CXCR4.
- Therapeutic agents for acquired immunodeficiency syndrome (AIDS) caused by human immunodeficiency virus (HIV) infection include reverse transcriptase inhibitors and protease inhibitors, but the emergence of drug-resistant HIV mutants loses therapeutic effects (See, for example, Shinseigaku, Vol. 53, No. 9, page 2031 (1998)).
- the combination therapy with these combinations also has many conditions to be taken when taking it, is complicated, has a large number to be taken, and has various side effects (for example, Nikkei Science, October, p. 29). (1998)).
- chemokines those that show chemotaxis to leukocytes are chemokines, and secreted proteins.
- Cys N-terminal cysteine sequence
- CXC-chemokines, CC-chemokines, C-chemokines, CX3C Classified as chemokines, the number of which is said to be about 30.
- CXCR4 which uses CXC-chemokine SDF-1 as a ligand
- CXCR4 which uses CXC-chemokine SDF-1 as a ligand
- HIV enters via the binding of the envelope protein gpl20 to CXCR4 on the host cell surface. That is, a drug having an antagonistic effect on CXCR4 is expected as an anti-HIV drug based on a novel mechanism of invasion inhibition, three compounds as low-molecular-weight drugs, and 3100 leaks (for example, Journal of Veterinary Medicine (See J. Exp.
- CXCR4 has been clearly linked to various diseases other than HIV infection.
- rheumatic diseases see, for example, WO 00/06086
- cancer metastases see, for example, Nature, 410, 50 (2001)
- An object of the present invention have excellent anti-retroviral activity, also have an excellent CXCR4 antagonizing SDF 1 alpha, mosquitoes ⁇ Tsu high safety, prodrugs of drugs ⁇ Piso with novel chemical structure
- the present inventors have conducted extensive research to develop a compound having an excellent antiretroviral activity and a novel chemical structure useful as an excellent CXCR4 antagonist for SDF-la. Exhibiting protective properties in cells inoculated with E. coli, and therefore have potential for the treatment of AIDS and AIDS-related complications, etc., and also exhibit potent CXCR4 antagonistic activity; and Therefore, we have discovered a group of amine compounds that have been shown to have potential for the treatment of rheumatism and cancer metastasis.
- an object of the present invention is to provide a compound represented by the following general formula (I), which has an antiviral activity mainly against HIV and has a CXCR4 antagonistic activity.
- the present invention provides a drug for the treatment of a patient infected with a virus, which comprises the compound of the above, and for the treatment of a patient such as rheumatism, cancer, and the like. That is, the present invention relates to a compound represented by the following general formula (1), a pharmacologically acceptable salt thereof, or a prodrug thereof.
- n 1N n 2 is an integer of 0 to 3.
- R 2 , R 3 , R 4 , R 5 each independently represent a hydrogen atom, optionally substituted carbon number 1 to 15, preferably 1 to 10 carbon atoms, more preferably 1 to 7 carbon atoms
- a 2 are each independently an optionally substituted monocyclic or polycyclic heteroaromatic ring, an optionally substituted partially saturated polycyclic heteroaromatic ring, And monocyclic or polycyclic aromatic rings, substituted and partially saturated A polycyclic aromatic ring, an optionally substituted heterocyclic ring, or a group represented by the following formula (2).
- R 7 , R 8 are each independently a hydrogen atom, an optionally substituted alkyl group having 1 to 15 carbon atoms, preferably 1 to 10 carbon atoms, more preferably an alkyl group having 1 to 7 carbon atoms, -15, preferably 2-10 carbon atoms, more preferably an alkenyl group having 2-7 carbon atoms, optionally substituted 2-15 carbon atoms, preferably 2-10 carbon atoms More preferably represents an alkynyl group having 2 to 7 carbon atoms, or an optionally substituted cyclic alkyl group having 3 to 15 carbon atoms, preferably 3 to 10 carbon atoms, more preferably 3 to 7 carbon atoms. . . '
- W is an optionally substituted carbon number of 1 to 15, preferably 1 to 10 carbon atoms, more preferably an alkylene group of 1 to 7 carbon atoms, and optionally substituted carbon atoms of 2 to 15 Alkenylene group having preferably 2 to 10 carbon atoms, more preferably 2 to 7 carbon atoms, 2 to 15 carbon atoms which may be substituted, preferably 2 to 10 carbon atoms, more preferably Is an alkylene group having 2 to 7 carbon atoms, an optionally substituted 3 to 15 carbon atoms, preferably 3 to 10 carbon atoms, more preferably a cyclic alkylene group having 3 to 7 carbon atoms, Monocyclic or polycyclic heteroaromatic ring, optionally substituted, partially saturated polycyclic heteroaromatic ring, optionally substituted A ring or a polycyclic aromatic ring, a partially substituted polycyclic aromatic ring which may be partially substituted, or a heterocyclic ring which may be substituted.
- X represents 0, CH 2 , U or a group represented by the following formula (3).
- R u is a hydrogen atom, an optionally substituted carbon number of 1 to 15, preferably 1 to 10 carbon atoms, more preferably an alkyl group of 1 to 7 carbon atoms, and an optionally substituted carbon number.
- 2-15 preferably an alkenyl group having 2 to 10 carbon atoms, more preferably 2 to 7 carbon atoms, 2 to 15 carbon atoms which may be substituted, preferably 2 to 10 carbon atoms, more preferably
- 13 ⁇ 4 represents an integer of 1 or 2.
- D represents a group represented by the following formula (4) or the following formula (6).
- R 13 is a hydrogen atom, an optionally substituted alkyl group having 1 to 15 carbon atoms, preferably an alkyl group having 1 to 10 carbon atoms, more preferably an alkyl group having 1 to 7 carbon atoms, 15, preferably 2 to 10 carbon atoms, more preferably an alkenyl group having 2 to 7 carbon atoms, 2 to 15 carbon atoms which may be substituted, preferably 2 to 10 carbon atoms, more preferably Is an alkynyl group having 2 to 7 carbon atoms, or an optionally substituted 3 to 15 carbon atoms, preferably 3 to 10 carbon atoms, more preferably a cyclic alkyl group having 3 to 7 carbon atoms, or the following formula:
- the group represented by (5) is shown.
- R 14 , R 15 , R 16 , and R 17 are each independently a hydrogen atom, an optionally substituted carbon number of 1 to 15, preferably 1 to 10 carbon atoms, more preferably an alkyl of 1 to 7 carbon atoms.
- a alkenyl group having 2 to 15 carbon atoms, preferably 2 to 10 carbon atoms, more preferably 2 to 7 carbon atoms, and 2 to 15 carbon atoms which may be substituted Alkynyl group having preferably 2 to 10 carbon atoms, more preferably 2 to 7 carbon atoms, or 3 to 15 carbon atoms which may be substituted, preferably 3 to 10 carbon atoms, more preferably It represents a cyclic alkyl group having 3 to 7 carbon atoms.
- Q is a single bond in the case the above-mentioned X is 0, X is a single bond in the case of NR U, or a group represented by the formula (3), X is CH 2, or by the formula (3) When represented, it represents a single bond, a group represented by S, 0, or 12 .
- R 12 is a hydrogen atom, substituted carbon atoms and optionally 1 to 1 5, preferably 1 to carbon atoms 1 0, more preferably an alkyl group having 1 to 7 carbon atoms, substituted carbon atoms and optionally 2 - 15, preferably 2 to 10 carbon atoms, more preferably an alkenyl group having 2 to 7 carbon atoms, 2 to 15 carbon atoms which may be substituted, preferably 2 to 10 carbon atoms, more preferably Represents an alkynyl group having 2 to 7 carbon atoms or an optionally substituted cyclic alkyl group having 3 to 15 carbon atoms, preferably 3 to 10 carbon atoms, and more preferably 3 to 7 carbon atoms.
- Y represents a group represented by the following formula (7).
- ⁇ % represents an integer of 0 to 6.
- R 18 and R 19 each independently represent a hydrogen atom, an optionally substituted carbon atom of 1 to 15, preferably 1 to 10 carbon atoms, more preferably an alkyl group of 1 to 7 carbon atoms, Alkenyl group having 2 to 15 carbon atoms, preferably 2 to 10 carbon atoms, more preferably 2 to 7 carbon atoms, and 2 to 15 carbon atoms which may be substituted, preferably 2 carbon atoms ⁇ 10, more preferably an alkyl group having 2 to 7 carbon atoms, an optionally substituted 3 to 15 carbon atoms, preferably 3 to 10 carbon atoms, more preferably a cyclic ring having 3 to 7 carbon atoms. It represents an alkyl group or an aromatic ring which may be substituted, and at this time, R 12 and R 18 may form a ring.
- n 4 and m 5 each represent an integer of 0 to 2.
- R 20 , R 21 , R 22 , and R 23 each independently represent a hydrogen atom, an optionally substituted carbon number of 1 to 15, preferably 1 to 10 carbon atoms, more preferably alkyl of 1 to 7 carbon atoms.
- z is a substituted or unsubstituted cyclic alkylene group having 3 to 15 carbon atoms, preferably 3 to 10 carbon atoms, more preferably 3 to 7 carbon atoms, or an optionally substituted monocyclic or polycyclic alkylene group.
- Heteroaromatic ring, optionally substituted polycyclic heteroaromatic ring, partially substituted monocyclic or polycyclic aromatic ring, optionally substituted V represents a partially saturated polycyclic aromatic ring, or an optionally substituted heterocyclic ring.
- B represents a group represented by the following formula (8). 2 or N (8)
- Q 2 represents an S, 0, R 27.
- R 24 and R 27 each independently represent a hydrogen atom, an optionally substituted carbon number of 1 to 15, preferably Preferably, it is an alkyl group having 1 to 10 carbon atoms, more preferably, an alkyl group having 1 to 7 carbon atoms, 2 to 15 carbon atoms which may be substituted, preferably 2 to 10 carbon atoms, more preferably carbon f. : An alkenyl group having 2 to 7 carbon atoms, which may be substituted, having 2 to 15 carbon atoms, preferably having 2 to 10 carbon atoms, more preferably an alkynyl group having 2 to 7 carbon atoms, and optionally having 2 to 7 carbon atoms.
- R 24 and R 27 are It may form a ring.
- R 25 and .R 26 are each independently a hydrogen atom when X is C3 ⁇ 4, optionally having 1 to 15 carbon atoms, preferably 1 to 10 carbon atoms, and more preferably 1 carbon atom.
- Alkyl group having 7 to 7 carbon atoms which may be substituted, 3 to 15 carbon atoms, preferably 3 to 10 carbon atoms, more preferably 3 to 7 carbon atoms, and 1 to 3 double bonds.
- Optionally substituted alkenyl group having 2 to 15 carbon atoms, preferably 2 to 10 carbon atoms, more preferably 2 to 7 carbon atoms, or 1 to 3 triple bonds and optionally substituted carbon atoms It represents an alkynyl group having 2 to 15, preferably 2 to 10 carbon atoms, more preferably 2 to 7 carbon atoms, and R 25 and R 26 may form a ring. May be linked via a heteroatom, a cyclic alkyl group, an aromatic ring, a heteroaromatic ring, or a heterocyclic ring to form a ring
- R 25 and R 26 each independently represent a hydrogen atom when X is not CH 2 , a substituent represented by the following formula (9), an optionally substituted carbon number of 1 to 15, preferably carbon
- the 1-3 include substituted optionally may carbons 2 to 5 also, preferably having 2 to 0 atoms, more preferably an alkynyl group of 2-7 carbon atoms, also, R 25 and R 26 are ring May be formed at that time, optionally via a heteroatom, a cyclic alkyl group, an aromatic ring, a heteroaromatic ring, or a heterocyclic ring. It may form a ring engaged. (9) Equation (9)
- G is an optionally substituted alkylene group having 1 to 15 carbon atoms, preferably 1 to 10 carbon atoms, more preferably 1 to 7 carbon atoms, and 2 to 15 carbon atoms which may be substituted.
- R 28 is an alkyl group having 1 to 15 carbon atoms, preferably 1 to 10 carbon atoms, more preferably 1 to 7 carbon atoms, which is substituted at any position other than the nitrogen atom which may be present on the ring.
- An alkenyl group having 2 to 15 carbon atoms which may be substituted, preferably 2 to 10 carbon atoms, more preferably 2 to 7 carbon atoms, and optionally having 2 to 15 carbon atoms which may be substituted Is an alkynyl group having 2 to 10 carbon atoms, more preferably an alkynyl group, an alkoxy group, a noloalkyl group, a haloalkoxy group, a hydroxyalkoxy group, a norogen atom, an amino group, an alkylamino group, a carboxyl group, Represents an alkoxycarbonyl group, a carbamoyl group, an alkylcanolebamoyl group, a saturated heterocyclic ring, or
- R 29 represents a hydrogen atom or the same group as R 24, and may combine with G to form a ring.
- one or two or more asymmetric carbons that may be present in the compound represented by the general formula (1), in the case of one, a pure optically active substance represented by the absolute configuration R or S, Mixtures of any proportion, racemates and, if more than one, optically pure di Astereomers, racemic forms thereof, or combinations thereof in any ratio exist, but any of them may be used.
- the terms used in the present specification are defined as follows, and are used alone or in combination.
- An alkyl group is a saturated hydrocarbon group which may be linear, branched or cyclic, such as methyl, ethyl, n-propyl, isopropyl, n-butyl, isoptyl, pentyl, And a neopentyl group.
- An alkenyl group is a hydrocarbon group having a double bond in either a straight chain, a branched chain, or a ring, such as an aryl group, a 1-butenyl group, a 2-butyl group, an isobutenyl group, and a cyclohexenyl group. And the like.
- the alkynole group is a hydrocarbon group having a triple bond in any of a straight chain, a branched chain and a ring, and examples thereof include a propynyl group and a 1-buturyl group.
- the cyclic alkyl group represents a cyclic hydrocarbon group, for example, a cyclopropyl group, a cyclobutyl group, a cyclopentyl group, a cyclohexyl group, a cycloheptyl group and the like.
- the aromatic ring means an aromatic ring composed of a hydrocarbon, and when it is a monocyclic ring, a benzene ring, and when it is a polycyclic ring, for example, a naphthalene ring, an anthracene ring, and the like.
- the partially saturated polycyclic aromatic ring includes, for example, a dihydronaphthalene ring, a tetralin ring, an indane ring and the like.
- Heteroaromatic ring means an aromatic ring in which one or more of nitrogen, oxygen and sulfur atoms are contained in the ring, and when it is a single ring, for example, a pyrrole ring, Furan ring, thiophene ring, pyridin ring, pyrimidine ring, pyridazine ring, pyrazine ring, imidazole ring, pyrazole ring, oxazole ring, thiazole ring, thiadiazole ring, oxaziazole ring, triazol ring and the like.
- quinoline, isoquinoline, benzimidazole, indazole, benzothiazole, benzo examples include a dioxazole ring, an indole ring, a benzfuran ring, and a benzthiophen ring.
- the partially saturated polycyclic heteroaromatic ring examples include a tetrahydroisoquinoline ring and a tetrahydroquinoline ring.
- Heterocycle means a saturated ring in which one or more of nitrogen, oxygen and sulfur atoms are contained in the ring, such as pyrrolidine, piperidine, piperazine, morpholine and thiomorpholine. And the like.
- An alkylene group is a hydrocarbon group that connects two groups to terminals, and examples thereof include an ethylene group, a propylene group, an isopropylene group, a butylene group, an isobutylene group, and a 2,2-dimethylethylene group.
- the alkenylene group is a group having a double bond in the alkylene, and includes, for example, a prodylene group, a 2-butenylene group, and a 1,3-ptagenylene group.
- the alkynylene group is a group having a triple bond in the alkylene group, and examples thereof include a propynylene group and a butynylene group.
- the cyclic alkylene group represented by W is a cyclic hydrocarbon group connecting two groups at arbitrary positions, and examples thereof include a cyclopropylene group, a cyclopentylene group, a cyclohexylene group, and a tetralinylene group.
- a ring refers to an aromatic ring connecting two groups at any position, for example, a phenylene group, a naphthalenylene group, and the like.
- a heteroaromatic ring connects two groups at any position.
- R 25 (R 26 ) N— R 25 and R 26 may form a ring, and R 25 and R 26 are directly bonded to form a nitrogen atom to which they are bonded
- the ring represents, for example, a piperidine ring, a piperidine ring, a hexamethyleneimine ring, a heptamethyleneimine ring, or the like, and R 25 and R 26 are bonded via a heteroatom to form a bond.
- they When they form a ring together with a nitrogen atom, they represent, for example, a morpholine ring, a piperazine ring, etc., and when they form a ring via an aromatic ring, they represent, for example, a tetrahydroisoquinoline ring, And a tetrahydroindole ring.
- R 25 and / or R 26 is a group represented by the formula (8), and 9 and G form a ring
- R 25 and R 26 are, for example, a tetralyl group, It represents an indanyl group, a tetrahydroquinolyl group, a tetrahydroisoquinolyl group, or the like.
- each substituent refers to a hydroxyl group, a thiol group, a formyl group, a carboxyl group, a sulfonyl group, an amino group, an amide group, a carbamoyl group, a cyano group, or an alkoxy group , Alkoxycarbonyl group, alkylamino group, acylamino group, alkoxycarbonylamino group, alkylthio group, aminosulfonyl group, dialkylaminosulfonyl group, methanesulfonyl group, p-toluenesulfonyl group, phenyl group and the like.
- a prodrug is a precursor substance that becomes an effective drug by undergoing biochemical metabolism after being administered to a living body, and includes N in a ring such as a heterocycle contained in the compound represented by the general formula (1).
- a compound in which at least one group which is metabolized and desorbed from N in a chain or a suitable group in the living body, such as an alkoxy group, a carbonyl group, a dialkylaminosulfone group, or the like, is represented by the general formula (1) It represents a compound in which one or more ester groups or the like utilizing alcohols or carboxylic acids which may be contained in the compound are bonded.
- compositions include, for example, trifluoroacetate, hydrochloride, acetate, sulfate, nitrate, lactate, maleate, methanesulfonate, toluenesulfonate, tartrate , Citrate, oxalate, malonate, succinate, fumarate, propionate, butyrate, dalcuronic acid, terephthalic acid, phosphoric acid and the like.
- FIGS. 1 to 24 show production process diagrams of some of the production methods of the compound of the present invention described below. That is, FIGS. 1 to 24 show reaction process diagrams of Production Methods 1 to 24, respectively.
- the compounds of the present invention can be produced by commonly used organic chemical reactions.
- the method for producing the compound of the present invention will be described below with reference to the accompanying drawings 1 to 24.
- the synthesis of the compound of the present invention is not limited to these. Manufacturing method example 1
- Compound (I-2) is reacted with commercially available di-butyl dicarbonate with a suitable base, for example, triethylamine, in a suitable solvent, for example, in the form of porcine to obtain compound (1-3).
- a suitable base for example, triethylamine
- the compound (I-3) is reacted with a suitable base, for example, an aqueous sodium hydroxide solution in a suitable solvent, for example, methanol to obtain a compound (1-4).
- a suitable base for example, an aqueous sodium hydroxide solution in a suitable solvent, for example, methanol
- a readily available compound (I-5) can be obtained by adding commercially available propionaldehyde, a suitable dehydrating agent such as trimethyl orthoformate, a suitable reducing agent such as sodium cyanoborohydride, and a suitable solvent such as methanol.
- a suitable base for example, an aqueous sodium hydroxide solution in a suitable solvent, for example, methanol
- a suitable solvent for example, methanol
- the compound (I-6) is deprotected by reacting with a suitable acid, for example, a salted hydrogen / dioxane solution in a suitable solvent, for example, methanol.
- a suitable acid for example, a salted hydrogen / dioxane solution in a suitable solvent, for example, methanol.
- a condensing agent for example, commercially available N-ethyl-N- (3-dimethylaminopropyl) carbodiimide (hereinafter, WSCD / 1-hydroxybenzotriazole (hereinafter, HOBt)) is reacted with a suitable solvent, for example, chloroform, to obtain a compound ( Obtain 1-7).
- the compound (1-7) is deprotected by reacting with a suitable acid such as a solution of hydrogen chloride / dioxane in a suitable solvent such as methanol to obtain a compound (1-8).
- a suitable acid such as a solution of hydrogen chloride / dioxane in a suitable solvent such as methanol
- a commercially available compound (1-10) is reacted with a commercially available propionaldehyde and a suitable reducing agent, for example, sodium cyanoborohydride, in a suitable solvent, for example, methanol to obtain a compound (1-11).
- a suitable reducing agent for example, sodium cyanoborohydride
- the compound (1-11) is reacted with a suitable reducing agent, for example, hydrazine monohydrate in a suitable solvent, for example, methanol / tetrahydrofuran (hereinafter THF) to obtain a compound (I-12).
- a suitable reducing agent for example, hydrazine monohydrate in a suitable solvent, for example, methanol / tetrahydrofuran (hereinafter THF) to obtain a compound (I-12).
- a commercially available compound (I-10) is reacted with a commercially available cyclohexanone, a suitable dehydrating agent such as trimethyl orthoformate, and a suitable reducing agent such as sodium cyanoborohydride in a suitable solvent such as methanol. To give compound (1-15).
- Compound (1-15) is reacted with a commercially available benzyloxycarbonyl chloride, with a suitable base, for example, an aqueous sodium hydroxide solution in a suitable solvent, for example, dioxane, and reacted with benzyloxycarbonyl (hereinafter Cbz). ) After obtaining the protected form, the compound (1-16) is obtained by reacting with an appropriate reducing agent, for example, hydrazine monohydrate in an appropriate solvent, for example, methanol / THF.
- a suitable base for example, an aqueous sodium hydroxide solution in a suitable solvent, for example, dioxane
- aldehyde A 2 - CHO (A 2 are as described above) of the compound (1-17), suitable those reducing agents, for example, a Shiano sodium borohydride in a suitable solvent, for example, the reaction in methanol After that, the compound is reacted with a suitable reducing agent, for example, 10% palladium-carbon, in a hydrogen atmosphere, in a suitable solvent, for example, ethanol, and deprotected to give a compound of the formula (1) (1-18). ).
- suitable reducing agent for example, 10% palladium-carbon
- the compound (I-4) is deprotected and esterified by reacting the compound (I-4) with a suitable acid such as hydrochloric acid in a suitable solvent such as methanol to obtain a compound (I-2).
- a suitable acid such as hydrochloric acid
- a suitable solvent such as methanol
- compound (II-1) After reacting compound (1-2) with commercially available 2-imidazole carboxyaldehyde, a suitable reducing agent, for example, sodium borohydride, and a suitable solvent, for example, methanol, a suitable base, for example,
- a suitable reducing agent for example, sodium borohydride
- a suitable solvent for example, methanol
- a suitable base for example, a suitable base
- the compound (II-3) is obtained by reacting the readily available compound (II-2) with a commercially available isobutyl aldehyde, a suitable reducing agent such as sodium cyanoborohydride in a suitable solvent such as methanol. .
- Compound (II-3) is reacted with an appropriate reducing agent, for example, 10% palladium-carbon, in a hydrogen atmosphere, in an appropriate solvent, for example, ethanol, and deprotected.
- an appropriate reducing agent for example, 10% palladium-carbon
- an appropriate solvent for example, ethanol
- a condensing agent for example, commercially available dicyclohexyl carpoimide (hereinafter referred to as DCC) ZHOBt
- DCC dicyclohexyl carpoimide
- DMF dicyclohexyl carpoimide
- a compound (II-6) is obtained by reacting a readily available compound (II-5) with a commercially available propionaldehyde and a suitable reducing agent such as sodium cyanoborohydride in a suitable solvent such as methanol. .
- the compound (II-6) is deprotected by reacting with a suitable acid such as hydrochloric acid in a suitable solvent such as methanol, and then deprotecting the compound (II-1) with a suitable condensing agent such as DCCZHOBt.
- a suitable acid such as hydrochloric acid
- a suitable solvent such as methanol
- DCCZHOBt a suitable condensing agent
- the reaction is carried out in a suitable solvent, for example, DMF to obtain a compound ( ⁇ -7) which is a compound of the formula (1).
- the compound (I-12) is reacted with formic acid in a suitable solvent such as acetic anhydride ZTHF, and then reacted with a suitable reducing agent such as lithium aluminum hydride in a suitable solvent such as THF to give a compound (I-12). II-8 is obtained.
- a suitable solvent such as acetic anhydride ZTHF
- a suitable reducing agent such as lithium aluminum hydride in a suitable solvent such as THF
- compound (II-10) can be obtained by adding commercially available propionaldehyde, a suitable dehydrating agent, for example, trimethyl orthoformate, a suitable reducing agent, for example, sodium cyanoborohydride, and a suitable solvent, for example, methanol. The reaction is performed to obtain compound (II-11).
- a suitable dehydrating agent for example, trimethyl orthoformate
- a suitable reducing agent for example, sodium cyanoborohydride
- a suitable solvent for example, methanol
- Compound (11-11) is deprotected by reacting with an appropriate reducing agent, for example, 10% palladium-carbon in a hydrogen atmosphere, in an appropriate solvent, for example, ethanol, and then deprotecting the compound (II-1). Reaction with a suitable condensing agent, for example, DCC / HOBt, in a suitable solvent, for example, DMF, gives a compound of the general formula (1) ( ⁇ -12). Manufacturing method example 3
- the compound (IV-1) is reacted with a commercially available N-potassium lipoethoxyphthalimid with a suitable base, for example, sodium carbonate, in a suitable solvent, for example, THFZ water to obtain a compound (IV-2).
- a suitable base for example, sodium carbonate
- a suitable solvent for example, THFZ water
- the compound (IV-2) is reacted with a suitable oxidizing agent such as manganese dioxide in a suitable solvent such as chloroform to obtain a compound (IV-3).
- Compound (1-12) is reacted with compound (IV-3) and a suitable reducing agent, for example, sodium cyanoborohydride, in a suitable solvent, for example, methanol, and then commercially available di-t-butyl.
- Dicarbonate is reacted with a suitable base, for example, triethylamine, in a suitable solvent, for example, DMF to form 1: -butoxycarbonyl (hereinafter, Boc), and a suitable base,
- the compound (IV-4) is obtained by reacting with an aqueous methylamine solution in a suitable solvent, for example, methanol.
- Compound (IV-6) obtained by deprotecting compound (1-6) with an acid is converted to compound (IV-3), a suitable reducing agent such as sodium cyanoborohydride, and a suitable solvent such as methanol.
- a suitable reducing agent such as sodium cyanoborohydride
- a suitable solvent such as methanol.
- the mixture is converted to Boc to form a suitable base, for example,
- the compound (IV-7) is obtained by reacting an aqueous methylamine solution with an appropriate solvent such as methanol.
- a commercially available compound (IV-9) is reacted with a commercially available N-carbethoxyphthalimide with a suitable base such as sodium carbonate in a suitable solvent such as water to obtain a compound (IV-10).
- a suitable base such as sodium carbonate
- a suitable solvent such as water
- the compound (IV-10) is reacted with sulfonic acid chloride in a suitable solvent, for example, in a stoichiometric form to obtain a compound (IV-11).
- the compound (IV-12) is reacted with the compound (IV-6) and a suitable base such as triethylamine in a suitable solvent such as chloroform and then a suitable reducing agent such as an aqueous solution of methylamine.
- a suitable solvent such as methanol.
- the compound (V-1) is obtained by reacting with a suitable reducing agent such as aluminum hydride in a suitable solvent such as THF.
- the compound (V-2) is reacted with a commercially available methanesulfonyl chloride, a suitable base, for example, diisopropylethylamine, in a suitable solvent, for example, dichloromethane to give the compound (V-2). obtain.
- a suitable base for example, diisopropylethylamine
- Compound (V-4) is reacted with compound (V-1) and a suitable Mitsunobu reagent, for example, triphenylinolephosphine / getyl azodicarboxylate, in a suitable solvent, for example, THF, and the compound (V- Get 5).
- a suitable Mitsunobu reagent for example, triphenylinolephosphine / getyl azodicarboxylate
- a commercially available compound (V-7) obtained by esterification of 4-aminomethylbenzoic acid and reduction by condensed condensation with pionaldehyde is converted to a suitable reducing agent, for example, aluminum dimethyl lithium and a suitable solvent.
- a suitable reducing agent for example, aluminum dimethyl lithium and a suitable solvent.
- a suitable solvent for example, aluminum dimethyl lithium and a suitable solvent.
- Compound (V-8) is reacted with compound (V-2) and a suitable base such as potassium carbonate in a suitable solvent such as DMF, and then a suitable acid such as hydrochloric acid and a suitable solvent.
- a suitable base such as potassium carbonate
- a suitable acid such as hydrochloric acid and a suitable solvent.
- deprotection by reacting in methanol, and then using an easily available aldehyde A 2 —CH 0 (A 2 is as described above) and a suitable reducing agent such as sodium cyanoborohydride
- the compound (V-9) which is a conjugate of the general formula (1), is obtained by reacting in a suitable solvent such as methanol.
- the compound (V-11) is obtained by reacting a commercially available compound (V-10) with a commercially available propionaldehyde and a suitable reducing agent such as sodium cyanoborohydride in a suitable solvent such as methanol.
- a 2 -CH 0 (A 2 is as described above) and a suitable reducing agent such as sodium borohydride are reacted with a suitable solvent such as methanol to obtain a compound of the general formula (1) Compound (V-12) is obtained.
- the compound (V-14) is obtained by reacting a commercially available compound (V-13) with a commercially available propionaldehyde and a suitable reducing agent such as sodium cyanoborohydride in a suitable solvent such as methanol.
- Compound (V-14) is reacted with compound (V-2) and a suitable base such as potassium hydrogen carbonate in a suitable solvent such as dichloromethane and then a suitable acid such as hydrochloric acid and a suitable solvent , for example by reacting in methanol and deprotected, then easily aldehyde a 2 kills with availability - and CHO (a 2 are as defined above), a suitable reducing agent, for example a Shiano sodium borohydride in an appropriate solvent
- the compound is reacted in methanol to obtain a compound (V-15) which is a compound of the general formula (1). Manufacturing method example 6
- a commercially available compound (VI-3) is reacted with a commercially available propionaldehyde, a suitable dehydrating agent, for example, trimethinol orthoformate, and a suitable reducing agent, for example, sodium cyanoborohydride in a suitable solvent, for example, methanol. To give the compound (VI-4).
- a suitable dehydrating agent for example, trimethinol orthoformate
- a suitable reducing agent for example, sodium cyanoborohydride
- a commercially available compound (VII-1) is reacted with a suitable oxidizing agent, for example, m-chloroperbenzoic acid, in a suitable solvent, for example, dichloromethane to obtain a compound (VII-2).
- a suitable oxidizing agent for example, m-chloroperbenzoic acid
- a suitable solvent for example, dichloromethane
- the compound (VII-2) is reacted with trifluoroacetic anhydride in a suitable solvent such as dichloromethane to obtain a compound (VII-3).
- the compound (VII-3) is reacted with a suitable base such as sodium methoxide in a suitable solvent such as methanol to obtain a compound (VII-4).
- FIG. 8 shows a reaction process chart of Production Method Example 8.
- Compound (VIII-1) is reacted with a prodrug-forming reagent, for example, ethyl ethyl formate, and a suitable base, for example, triethylamine, in a suitable solvent, for example, formal form, to give a compound of the general formula (1).
- a prodrug-forming reagent for example, ethyl ethyl formate
- a suitable base for example, triethylamine
- FIG. 9 shows a reaction process chart of Production Method Example 9.
- FIG. 10 shows a reaction process diagram of Production Method Example 10.
- the compound (X-2) is obtained by reacting a commercially available compound (1-5) with a commercially available cyclohexanone, a suitable reducing agent such as sodium borohydride in a suitable solvent such as methanol. obtain.
- the compound (X-2) is reacted with a commercially available aqueous solution of formaldehyde, a suitable reducing agent, for example, sodium cyanoborohydride, and a suitable solvent, for example, methanol.
- a suitable reducing agent for example, sodium cyanoborohydride
- a suitable solvent for example, methanol
- the compound (X_3) is deprotected by reacting with a suitable acid, for example, a hydrogen chloride / dioxane solution in a suitable solvent, for example, methanol, and then deprotecting the compound ( ⁇ -1) with a suitable condensing agent, for example, WSCI /
- a suitable acid for example, a hydrogen chloride / dioxane solution in a suitable solvent, for example, methanol
- a suitable condensing agent for example, WSCI /
- the compound (X-4) is obtained by reacting HOBt with an appropriate solvent such as DMF.
- the compound (X-3) is deprotected by reacting with a suitable acid, for example, a hydrogen chloride Z dioxane solution in a suitable solvent, for example, methanol, and then deprotecting the compound (1-4) with a suitable condensing agent, for example, WSCI
- a suitable acid for example, a hydrogen chloride Z dioxane solution in a suitable solvent, for example, methanol
- a suitable condensing agent for example, WSCI
- the compound (X-5) is obtained by reacting / HOBt with an appropriate solvent, for example, chloroform.
- the compound (X-5) is reacted with a suitable acid, for example, a solution of hydrogen chloride / dioxane in a suitable solvent, for example, methanol to obtain a compound (X-6).
- a suitable acid for example, a solution of hydrogen chloride / dioxane in a suitable solvent, for example, methanol
- FIG. 11 shows a reaction process chart of Production Method Example 11.
- a 2 is readily available in case the same - the CH0, aldehyde A ⁇ CH0 and A 2 -CH0 readily available in case A 2 are not identical (, A 2 is the above-mentioned And compound (XI-1) and an appropriate reducing agent, for example, cyanoborohydride The compound is reacted with sodium in a suitable solvent, for example, methanol to obtain a compound (XI-2) which is a compound of the general formula (1).
- a suitable solvent for example, methanol
- the compound (XI-5) is reacted with a suitable reducing agent, for example, lithium aluminum hydride, in a suitable solvent, for example, THF to obtain a compound (XI-6).
- a suitable reducing agent for example, lithium aluminum hydride
- Compound (XI-6) is reacted with compound (W-12) and a suitable base such as triethylamine in a suitable solvent such as chloroform, and then a suitable reducing agent such as an aqueous methylamine solution.
- a suitable solvent such as methanol.
- a 2 is an aldehyde A ⁇ CH0 readily available in case the same, A had A 2 aldehyde are readily available if not identical A ⁇ CH0 and A 2 - CH0 (, A 2 is above the passing Is separately and sequentially reacted with a compound ( ⁇ -7), a suitable reducing agent, for example, sodium cyanoborohydride, and a suitable solvent, for example, methanol to obtain a compound (I) of the formula (1) XI-8) is obtained.
- a suitable reducing agent for example, sodium cyanoborohydride
- a suitable solvent for example, methanol
- FIG. 12 shows a reaction process chart of Production Method Example 12.
- the compound (II-1) is obtained by reacting the readily available compound (I-1) with a commercially available di-1-butyl dicarbonate and a suitable base such as triethylamine in a suitable solvent such as porcine. Get.
- the compound (XII-2) is reacted with a suitable reducing agent, for example, lithium aluminum hydride, in a suitable solvent, for example, to obtain a compound (XII-2).
- a suitable reducing agent for example, lithium aluminum hydride
- the compound (II-2) is reacted with a suitable oxidizing agent, for example, manganese dioxide, in a suitable solvent, for example, chloroform, to obtain a compound (XII-3).
- a suitable oxidizing agent for example, manganese dioxide
- a suitable solvent for example, chloroform
- Compound (XII-3) is reacted with compound ( ⁇ -2), a suitable dehydrating agent, for example, trimethinol orthoformate, and a suitable reducing agent, for example, sodium borohydride, in a suitable solvent, for example, methanol.
- a suitable dehydrating agent for example, trimethinol orthoformate
- a suitable reducing agent for example, sodium borohydride
- the compound (XII-4) is reacted with an aqueous formaldehyde solution, a suitable reducing agent such as sodium cyanoborohydride in a suitable solvent such as methanol to obtain a compound (XII-5).
- a suitable reducing agent such as sodium cyanoborohydride in a suitable solvent such as methanol
- the compound (XII-5) is reacted with a suitable acid such as a solution of hydrogen chloride in Z dioxane in a suitable solvent such as methanol to obtain a compound (XII-6).
- a suitable acid such as a solution of hydrogen chloride in Z dioxane in a suitable solvent such as methanol
- Aldehyde A ⁇ CH0 A 2 is readily available in case the same, an aldehyde A ⁇ CH0 and A 2 -CH0 readily available in case A 2 are not identical (, A 2 is Ri through the aforementioned ) Is reacted separately with compound (XII-6) and an appropriate reducing agent, for example, sodium cyanoborohydride, in an appropriate solvent, for example, methanol to give a compound of general formula (1) Compound (XII-7) is obtained.
- an appropriate reducing agent for example, sodium cyanoborohydride
- the compound (XII-7), which is a compound of the general formula (1), is reacted with a suitable reducing agent, for example, 10% palladium-carbon in a hydrogen atmosphere in a suitable solvent, for example, ethanol to obtain a compound of the general formula ( Compound (XII-8) which is the compound of 1) is obtained.
- a suitable reducing agent for example, 10% palladium-carbon in a hydrogen atmosphere in a suitable solvent, for example, ethanol
- Compound (II-6) is reacted with compound (I_4) and a suitable condensing agent, for example, WSCI / HOBt, in a suitable solvent, for example, chloroform to obtain compound (XII-110).
- a suitable condensing agent for example, WSCI / HOBt
- a suitable solvent for example, chloroform
- the compound (X-10) is reacted with a suitable acid, for example, a salt solution of hydrogen chloride in dioxane in a suitable solvent, for example, methanol to obtain a compound (XII-11).
- a suitable acid for example, a salt solution of hydrogen chloride in dioxane in a suitable solvent, for example, methanol
- FIG. 13 shows a reaction process diagram of Production Method Example 13.
- the compound (vi-1) is reacted with a suitable oxidizing agent, for example, manganese dioxide, in a suitable solvent, for example, dichloromethane to obtain a compound (III-1).
- a suitable oxidizing agent for example, manganese dioxide
- a suitable solvent for example, dichloromethane
- Compound (1-5) can be prepared using commercially available 2-imidazole carboxyaldehyde, a suitable dehydrating agent such as trimethyl orthoformate, and a suitable reducing agent such as sodium borohydride.
- the compound (II-2) is obtained by reacting with lithium in a suitable solvent, for example, methanol.
- Compound ( ⁇ -2) can be obtained by combining commercially available 1-methyl-2-imidazolecarboxaldehyde with a suitable acid such as acetic acid, a suitable reducing agent such as sodium cyanoborohydride and a suitable solvent such as methanol. Reaction is carried out to obtain compound (xm-3).
- a suitable acid such as acetic acid
- a suitable reducing agent such as sodium cyanoborohydride
- a suitable solvent such as methanol
- the compound (xm-4) is obtained by reacting the compound (III-3) with a suitable acid such as hydrochloric acid in a suitable solvent such as methanol.
- the compound ( ⁇ -4) is compound (Xffl-1), a suitable dehydrating agent such as trimethyl orthoformate, a suitable reducing agent such as sodium borohydride and a suitable solvent such as methanol. To give the compound ( ⁇ -5).
- the compound (xm 5) is reacted with a commercially available aqueous formaldehyde solution, a suitable dehydrating agent, for example, trimethyl orthoformate, and a suitable reducing agent, for example, sodium borohydride, in a suitable solvent, for example, methanol to give a compound of the general formula (
- the compound ( ⁇ -6) which is the compound of 1) is obtained.
- FIG. 14 shows a reaction process chart of Production Method Example 1.
- Compound (IV-6) obtained by deprotecting compound (1-6) with an acid is converted to compound (3-3), a suitable dehydrating agent such as trimethyl orthoformate, and a suitable reducing agent such as borohydride
- a suitable dehydrating agent such as trimethyl orthoformate
- a suitable reducing agent such as borohydride
- the compound (XIV-1) is obtained by reacting sodium with an appropriate solvent such as methanol.
- Process 14-2 Compound (XIV-l) is reacted with an aqueous formaldehyde solution and a suitable reducing agent such as sodium cyanoborohydride in a suitable solvent such as methanol to give a compound
- FIG. 15 shows a reaction process chart of Production Method Example 15.
- the compound (XV-1) is obtained by reacting a commercially available compound (VI-3) with di-t-butyl-dicarbonate and a suitable base such as an aqueous solution of sodium hydroxide in a suitable solvent such as dioxane.
- a commercially available compound (XVI-1) is reacted with a suitable oxidizing agent, for example, methac-oral perbenzoic acid, in a suitable solvent, for example, dichloromethane to obtain a compound (XVI-2).
- a suitable oxidizing agent for example, methac-oral perbenzoic acid
- a suitable solvent for example, dichloromethane
- the compound (XVI-2) is reacted with trifluoroacetic anhydride in a suitable solvent such as dichloromethane to obtain a compound (XVI-3).
- the compound (XVI-3) is reacted with a suitable base, for example, sodium methoxide, in a suitable solvent, for example, methanol to obtain a compound (XVI-4).
- a suitable base for example, sodium methoxide
- a suitable solvent for example, methanol
- the compound (XVI-5) is a compound (XVI-5) which is obtained by reacting the compound (XVI-4) with an appropriate oxidizing agent, for example, manganese dioxide, in an appropriate solvent, for example, in the form of a stoichiometric compound, and the starting aldehyde AfCHiKAi is as described above. Get.
- an appropriate oxidizing agent for example, manganese dioxide
- a commercially available compound (XVI-6) is reacted with a suitable oxidizing agent, for example, methac-oral perbenzoic acid, in a suitable solvent, for example, dichloromethane to obtain a compound (XVI-7).
- a suitable oxidizing agent for example, methac-oral perbenzoic acid
- a suitable solvent for example, dichloromethane
- the compound (XVI-8) is reacted with trifluoroacetic anhydride in a suitable solvent such as dichloromethane to obtain a compound (XVI-8).
- the compound (XVI-9) is reacted with a suitable base such as sodium methoxide in a suitable solvent such as methanol to obtain a compound (XVI-9).
- FIG. 17 shows a reaction process chart of Production Method Example 17.
- the compound (XVII-2) is reacted with a suitable solvent such as methanol in the presence of a suitable acid such as hydrochloric acid, followed by propionaldehyde and a suitable reducing agent such as sodium cyanoborohydride and
- a suitable solvent such as methanol
- a suitable acid such as hydrochloric acid
- propionaldehyde and a suitable reducing agent such as sodium cyanoborohydride
- the compound (XVII-3) is obtained by reacting with a dehydrating agent such as trimethyl orthoformate in a suitable solvent such as methanol.
- the compound (XVII-3) is reacted with a suitable reducing agent, for example, lithium aluminum hydride, in a suitable solvent, for example, THF, followed by salting with P-toluenesulfonic acid and a suitable base, for example, triethylamine in a suitable solvent.
- a suitable reducing agent for example, lithium aluminum hydride
- P-toluenesulfonic acid and a suitable base for example, triethylamine in a suitable solvent.
- a suitable base for example, triethylamine
- the compound (XVII-4) is reacted with phthalimide potassium in a suitable solvent such as DMF, and then reacted with a suitable base such as methylamine in a suitable solvent such as methanol to give the compound (XVII-5). ).
- the compound (XVII-5) is reacted with commercially available 2-imidazole carboxyaldehyde together with a suitable reducing agent such as sodium borohydride and a suitable dehydrating agent such as trimethyl orthoformate in a suitable solvent such as methanol. Then, with commercially available trimethyl-2-imidazole carboxyaldehyde and a suitable reducing agent such as sodium borohydride and a suitable dehydrating agent such as trimethyl orthoformate or a suitable acid catalyst such as acetic acid. The reaction is carried out in a solvent such as methanol to obtain a compound (XVII-6) which is a compound of the general formula (1).
- FIG. 18 shows a reaction process diagram of Production Method Example 18.
- the commercially available compound (XVIII-1) is reacted with N-promosuccinimide and a suitable radical generator such as azobisisobutyronitrile in a suitable solvent such as carbon tetrachloride to give the compound (XVIII-I). Get 2).
- the compound (XVIII-3) is reacted with a suitable oxidizing agent, for example, metachloroperoxybenzene, in a suitable solvent, for example, in a stoichiometric form to obtain a compound (XVIII-4).
- a suitable oxidizing agent for example, metachloroperoxybenzene
- the compound (XVIII-4) is reacted with a suitable acid anhydride, for example, trifluoroacetic anhydride, in a suitable solvent, for example, dichloromethane, followed by a suitable base, for example, sodium hydrogen carbonate and a suitable solvent, for example, methanol. React and compound
- the compound (XVIII-5) is reacted with a suitable oxidizing agent such as manganese dioxide in a suitable solvent such as chloroform to obtain a compound (XVIII-6).
- the compound (XVIII-7) is reacted with triphenylphosphonylideneacetonitrile in a suitable solvent, for example, THF to obtain a compound (XVIII-7).
- the compound (XVIII-8) is reacted with a suitable base such as methylamine in a suitable solvent such as methanol, followed by di-t-butyl dicarbonate and a suitable salt
- a suitable base such as methylamine
- a suitable solvent such as methanol
- the compound (XVIII-9) is obtained by reacting with a group such as triethylamine.
- the compound (XVIII-9) is reacted with a suitable reducing agent, such as lithium aluminum hydride, in a suitable solvent, such as THF, followed by propionaldehyde and a suitable reducing agent, such as sodium cyanoborohydride and Reaction with a suitable dehydrating agent such as trimethyl orthoformate in a suitable solvent such as methanol gives the compound (XVII 1-10).
- a suitable reducing agent such as lithium aluminum hydride
- a suitable solvent such as THF
- a suitable reducing agent such as sodium cyanoborohydride
- Reaction with a suitable dehydrating agent such as trimethyl orthoformate in a suitable solvent such as methanol gives the compound (XVII 1-10).
- the compound (XVIII-10) is reacted with a suitable solvent such as methanol in the presence of a suitable acid such as hydrochloric acid, followed by a commercially available 2-imidazole carboxyaldehyde and a suitable reducing agent such as hydrogen Reaction with sodium borohydride and a suitable dehydrating agent, for example trimethyl orthoformate, in a suitable solvent, for example methanol, followed by a commercially available 1-methyl-2-imidazolecarboxaldehyde and a suitable reducing agent, for example hydrogen Reaction with sodium borohydride and a suitable dehydrating agent and a suitable acid catalyst such as acetic acid in a suitable solvent such as methanol gives compound (XVIII-11) which is a compound of the general formula (1).
- a suitable solvent such as methanol
- a suitable acid such as hydrochloric acid
- a suitable reducing agent such as hydrogen Reaction with sodium borohydride and a suitable dehydrating agent, for example trimethyl orthoformate
- the compound (XVIII-12) is obtained by reacting the commercially available compound 4-bromobutyronitrile with triphenylphosphine in a suitable solvent, for example, toluene.
- the compound (XVIII-13) is reacted with the compound (XVIII-6) and the compound (XVIII-12) together with a suitable base such as lithium diisopropylamide in a suitable solvent such as THF to obtain the compound (XVIII-13).
- the compound (XVIII-13) is reacted with a suitable base, for example, methylamine, in a suitable solvent, for example, methanol, followed by reaction with di-1-butyldipropionate and a suitable base, for example, triethylamine, followed by Suitable under hydrogen atmosphere Reaction with a suitable catalyst, for example, palladium hydroxide, in a suitable solvent, for example, ethanol, gives the compound (XVIII-14).
- a suitable base for example, methylamine
- a suitable solvent for example, methanol
- a suitable base for example, triethylamine
- a suitable catalyst for example, palladium hydroxide
- the compound (XVIII-15) is reacted with a suitable solvent, for example, methanol in the presence of a suitable acid, for example, hydrochloric acid, followed by a commercially available 2-imidazole carboxyaldehyde and a suitable reducing agent, for example, hydrogen Reaction with sodium borohydride and a suitable dehydrating agent such as trimethyl orthoformate in a suitable solvent such as methanol, followed by a commercially available 1-methyl-2-imidazolecarboxaldehyde and a suitable reducing agent such as hydrogen Reaction with sodium borohydride and a suitable dehydrating agent, a suitable acid catalyst, for example, acetic acid, in a suitable solvent, for example, methanol, gives a compound (XVIII-16) which is a compound of the general formula (1).
- FIG. 19 shows a reaction process chart of Production Method Example 19.
- the compound (XIX-2) is reacted with a suitable base, for example, methylamine, in a suitable solvent, for example, methanol, followed by reaction with di-1-butyl dicarbonate and a suitable base, for example, triethylamine, and then Reducing agent, for example Reaction with lithium aluminum hydride in a suitable solvent such as THF gives the compound (XIX-3).
- a suitable base for example, methylamine
- a suitable solvent for example, methanol
- a suitable base for example, triethylamine
- Reducing agent for example Reaction with lithium aluminum hydride in a suitable solvent such as THF gives the compound (XIX-3).
- the compound (XIX-4) is reacted with a suitable catalyst, for example, palladium-carbon, in a suitable solvent, for example, a mixed solvent of formaldehyde and methanol in a hydrogen atmosphere, and then a suitable reducing agent, for example, aluminum hydride Reaction with lithium in a suitable solvent such as THF gives compound (XIX-5).
- a suitable catalyst for example, palladium-carbon
- a suitable solvent for example, a mixed solvent of formaldehyde and methanol in a hydrogen atmosphere
- a suitable reducing agent for example, aluminum hydride Reaction with lithium in a suitable solvent such as THF gives compound (XIX-5).
- the compound (XIX-5) is reacted with a suitable oxidizing agent, for example Dess-Martin periodinane, in a suitable solvent, for example dichloromethane, followed by dipropylamine and a suitable reducing agent, for example sodium cyanoborohydride and a suitable Reaction with a dehydrating agent such as trimethyl orthoformate in a suitable solvent such as methanol gives the compound (XIX-6).
- a suitable oxidizing agent for example Dess-Martin periodinane
- a suitable solvent for example dichloromethane
- a suitable reducing agent for example sodium cyanoborohydride
- a suitable Reaction with a dehydrating agent such as trimethyl orthoformate in a suitable solvent such as methanol gives the compound (XIX-6).
- the compound (XIX-6) is reacted with a suitable acid catalyst such as hydrochloric acid in a suitable solvent such as dioxane, followed by a commercially available 2-imidazolecarboxaldehyde and a suitable reducing agent such as sodium borohydride And reacting with a suitable dehydrating agent, for example, trimethyl orthoformate in a suitable solvent, for example, methanol to obtain compound (XIX-7).
- a suitable acid catalyst such as hydrochloric acid in a suitable solvent such as dioxane
- a suitable reducing agent such as sodium borohydride
- a suitable dehydrating agent for example, trimethyl orthoformate in a suitable solvent, for example, methanol
- Compound (XIX-7) is converted to a suitable solvent such as methanol with commercially available tomethyl-2-imidazole carboxaldehyde and a suitable reducing agent such as sodium borohydride and a suitable dehydrating agent such as acetic acid.
- a suitable solvent such as methanol
- a suitable reducing agent such as sodium borohydride
- a suitable dehydrating agent such as acetic acid.
- FIG. 20 shows a reaction process chart of Production Method Example 20.
- the compound (XX-3) is reacted with a suitable oxidizing agent, for example, manganese dioxide, in a suitable solvent, for example, in a stoichiometric form to obtain a compound (XX-4).
- a suitable oxidizing agent for example, manganese dioxide
- the compound (XX-5) is reacted with a suitable catalyst such as palladium black in a suitable solvent such as benzene under a hydrogen atmosphere to obtain a compound (XX-6).
- Compound (XX-7) is reacted with a suitable oxidizing agent, for example, desmartin penolenoginane, in a suitable solvent, for example, dichloromethane to obtain compound (XX-8).
- a suitable oxidizing agent for example, desmartin penolenoginane
- a suitable solvent for example, dichloromethane
- Compound (XX-9) is obtained by reacting compound (XX-8) with dipropylamine and a suitable reducing agent such as sodium borohydride and a suitable dehydrating agent such as trimethyl orthoformate in a suitable solvent such as methanol. .
- Process 20-9 The compound (XX-9) is reacted with a suitable deprotecting agent, for example, tetrabutylammonium fluoride (hereinafter, TBAF) in a suitable solvent, for example, THF to obtain a compound (XX-10).
- a suitable deprotecting agent for example, tetrabutylammonium fluoride (hereinafter, TBAF)
- THF tetrabutylammonium fluoride
- the compound (XX-10) is reacted with phthalimide and a suitable dehydrating agent such as triphenylphosphine and dimethyl diazodicarboxylate in a suitable solvent to obtain a compound (XX-11).
- the compound (XX-11) is reacted with a suitable base such as methylamine in a suitable solvent such as methanol to obtain a compound (XX-12).
- Methoxymethyltriphenylphosphonium chloride is reacted with a suitable base, for example, lithium diisopropylamide, in a suitable solvent, for example, THF, and the compound (XX-8) described above is added thereto, and the reaction is carried out.
- a suitable base for example, lithium diisopropylamide
- THF a suitable solvent
- XX-8 the compound described above is added thereto, and the reaction is carried out.
- the compound (XX-14) is reacted with a suitable acid catalyst, such as acetic acid, in a suitable solvent, such as methanol, followed by dipropylamine and a suitable reducing agent, such as sodium cyanoborohydride and a suitable dehydrating agent. Reaction with, for example, trimethyl orthoformate in a suitable solvent, for example, methanol gives compound (XX-15).
- a suitable acid catalyst such as acetic acid
- a suitable solvent such as methanol
- Process 20-15 The compound (XX-15) is reacted with phthalimide and a suitable dehydrating agent, for example, triphenylphosphine and dimethyl diazodicarboxylate in a suitable solvent to obtain a compound (XX-16).
- a suitable dehydrating agent for example, triphenylphosphine and dimethyl diazodicarboxylate
- the compound (XX-16) is reacted with a suitable base such as methylamine in a suitable solvent such as methanol to obtain a compound (XX-17).
- the compound (X-17) is reacted with commercially available 2-imidazolecarboxaldehyde with a suitable reducing agent such as sodium borohydride and a suitable dehydrating agent such as trimethyl orthoformate in a suitable solvent such as methanol.
- a suitable reducing agent such as sodium borohydride and a suitable dehydrating agent such as trimethyl orthoformate
- suitable solvent such as methanol.
- 1-methyl-2-imidazolecarboxaldehyde and a suitable reducing agent such as sodium borohydride and a suitable dehydrating agent such as trimethyl orthoformate or a suitable acid catalyst such as acetic acid and a suitable solvent such as methanol
- a compound (XX-18) which is a compound of the general formula (1). Manufacturing method example 21
- FIG. 21 shows a reaction process chart of Production Method Example 21.
- the compound (XXI-1) is reacted with the aforementioned compound (XVII-1) in a suitable solvent such as DMF in the presence of a suitable base such as lime carbonate to obtain a compound (XXI-1).
- the compound (XXI-2) is reacted with a suitable solvent such as methanol in the presence of a suitable acid such as hydrochloric acid, followed by propionaldehyde and a suitable reducing agent such as sodium cyanoborohydride and optionally A suitable dehydrating agent, for example orthogi Reaction with trimethyl acid in a suitable solvent such as methanol
- the compound (XXI-3) is reacted with a suitable reducing agent such as lithium aluminum hydride in a suitable solvent such as THF to obtain a compound (XXI-4).
- the compound (XXI-5) is reacted with a suitable base such as methylamine in a suitable solvent such as methanol to obtain a compound (XXI-6).
- the compound (XXI-6) is reacted with commercially available 2-imidazole carboxyaldehyde with a suitable reducing agent such as sodium borohydride and a suitable dehydrating agent such as trimethyl orthoformate in a suitable solvent such as methanol.
- a suitable reducing agent such as sodium borohydride and a suitable dehydrating agent such as trimethyl orthoformate
- suitable solvent such as methanol.
- 1-methyl-2-imidazolecarboxaldehyde and a suitable reducing agent such as sodium borohydride and a suitable dehydrating agent such as trimethyl orthoformate or a suitable acid catalyst such as acetic acid and a suitable solvent
- the reaction is performed in methanol to obtain a compound (XXI-8) which is a compound of the general formula (1).
- Manufacturing method example 22 is reacted with commercially available 2-imidazole carboxyaldehyde with a suitable reducing agent such as sodium borohydride and a suitable dehydrating agent such as tri
- FIG. 22 shows a reaction process chart of Production Method Example 22.
- Process 22-1 The compound (II-2) is obtained by reacting a commercially available compound (XXII-1) with t-butyldiphenylsilane chloride and a suitable base such as imidazole in a suitable solvent such as DMF.
- Compound (XXII-2) is reacted with a suitable oxidizing agent, for example, N-methylmorpholine-N-oxide, and tetrapropylammonium palpartate in a suitable solvent, for example, dimethyl methane.
- a suitable oxidizing agent for example, N-methylmorpholine-N-oxide
- tetrapropylammonium palpartate in a suitable solvent, for example, dimethyl methane.
- the compound (XXII-3) and the compound (XXII-4) are reacted with a suitable base, for example, lithium bistrimethylsilylamide, in a suitable solvent, for example, THF, and then with methanesulfonyl chloride and a suitable base, for example, triethylamine.
- a suitable base for example, lithium bistrimethylsilylamide
- THF a suitable solvent
- methanesulfonyl chloride and a suitable base for example, triethylamine.
- the compound (XXII-5) is obtained by reacting in a suitable solvent, for example, DMF, followed by a suitable strong base, for example, DBU.
- the compound (XXII-5) is reacted with a suitable reducing agent, for example, K-selectride @ , in a suitable solvent, for example, THF to obtain a compound (XXII-6).
- a suitable reducing agent for example, K-selectride @
- the compound ( ⁇ -6) is reacted with a suitable reducing agent, for example, sodium borohydride in a suitable solvent, for example, methanol to obtain a compound (XXII-7).
- a suitable reducing agent for example, sodium borohydride
- a suitable solvent for example, methanol
- the compound (XXII-8) is reacted with a suitable deprotecting agent such as TBAF in a suitable solvent such as THF, followed by a suitable oxidizing agent such as N-methylmorpholine-N-oxide and tetrapropylammonium
- a suitable deprotecting agent such as TBAF
- a suitable oxidizing agent such as N-methylmorpholine-N-oxide and tetrapropylammonium
- the compound (XXII-9) is obtained by reacting with pearltenate in a suitable solvent such as dichloromethane.
- Process 22-8 Compound (XXII-9) is reacted with dipropylamine and a suitable reduction such as sodium triacetoxyborohydride in a suitable solvent such as dichloroethane to obtain compound (XXII-10).
- the compound (XXII-10) is reacted with a suitable cyanogen agent, for example, zinc cyanide and a suitable catalyst, for example, tetrakistriphenylphosphine palladium, in a suitable solvent, for example, DMF to obtain a compound (XXII-11).
- a suitable cyanogen agent for example, zinc cyanide and a suitable catalyst, for example, tetrakistriphenylphosphine palladium
- the compound (II-11) is reacted with an appropriate reducing agent, for example, lithium aluminum hydride in an appropriate solvent, for example, THF to obtain a compound (II-12).
- an appropriate reducing agent for example, lithium aluminum hydride in an appropriate solvent, for example, THF
- the compound (XXII-12) is reacted with carbethoxyphthalimide and a suitable base such as carbonated carbonate in a suitable solvent such as DMF to obtain a compound (XXII-13).
- the compound (XXII-13) is reacted with a suitable acid catalyst such as hydrochloric acid in a suitable solvent such as a mixed solvent of methanol and dioxane to obtain a compound (XXII-14).
- a suitable acid catalyst such as hydrochloric acid
- a suitable solvent such as a mixed solvent of methanol and dioxane
- the compound ( ⁇ -14) is reacted with a suitable base such as hydrazine monohydrate in a suitable solvent such as methanol to obtain a compound (XXII-15).
- Compound ( ⁇ -16) can be obtained by combining commercially available 1-methyl-2-imidazolecarboxaldehyde with a suitable reducing agent such as sodium borohydride and a suitable dehydrating agent, a suitable acid catalyst,
- a suitable reducing agent such as sodium borohydride
- a suitable dehydrating agent such as sodium borohydride
- a suitable acid catalyst such as sodium borohydride
- the compound (XXII-17) which is a compound of the general formula (1) is obtained by reacting with acetic acid in a suitable solvent such as methanol. Manufacturing method example 23
- FIG. 23 shows a reaction process chart of Production Method Example 23.
- the compound (XXIII-2) is obtained by reacting a commercially available compound (XXIII-1) with 1-iodpropane in a suitable solvent such as DMF with a suitable base such as sodium hydride.
- a suitable solvent such as DMF
- a suitable base such as sodium hydride.
- the compound (XXIII-2) is reacted with a suitable reducing agent such as stannous chloride and sodium borohydride in a suitable solvent such as ethanol to obtain a compound (III-3).
- a suitable reducing agent such as stannous chloride and sodium borohydride in a suitable solvent such as ethanol
- the compound (XXIII-4) is reacted with a suitable solvent such as methanol in the presence of a suitable acid such as hydrochloric acid, followed by propionaldehyde and a suitable reducing agent such as sodium cyanoborohydride and a suitable acid. Reaction with a catalyst such as acetic acid in a suitable solvent such as methanol gives compound (XXIII-5).
- Compound (XXIII-5) is reacted with a suitable reducing agent, for example, lithium aluminum hydride, in a suitable solvent, for example, THF, followed by commercially available 2-imidazole carboxyaldehyde and a suitable reducing agent, for example, Reaction with sodium borohydride and a suitable dehydrating agent, such as trimethyl orthoformate, in a suitable solvent, such as methanol, followed by a commercially available tomethyl-2-imidazolecarboxaldehyde and a suitable reducing agent, such as Sodium borohydride and a suitable dehydrating agent such as onoleto Reaction with trimethyl formate or a suitable acid catalyst such as acetic acid in a suitable solvent such as methanol gives compound (XXIII-6) which is a compound of general formula (1).
- a suitable reducing agent for example, lithium aluminum hydride
- a suitable solvent for example, THF
- 2-imidazole carboxyaldehyde and a suitable reducing agent for
- FIG. 24 shows a reaction process chart of Production Method Example 2.
- a commercially available compound (XXIV-1) is reacted with a suitable condensing agent and a catalyst such as WSCI and HOBt in methanol to obtain a compound (XXIV-2).
- NBS N-bromosuccinimide
- a suitable radical generator such as azobisisobutyronitrile
- a suitable solvent such as tetrasulfonated carbon
- the compound (XXIV-4) is reacted with a suitable base, for example, hydrazine monohydrate in a suitable solvent, for example, methanol, followed by reaction with di-1-butyl dicarbonate and a suitable base, for example, triethylamine. To give compound (XXIV-5).
- a suitable base for example, hydrazine monohydrate in a suitable solvent, for example, methanol
- the compound (XXIV-5) is reacted with a suitable base such as sodium hydroxide and water in a suitable solvent such as methanol to obtain a compound (XXIV-6).
- the compound (XXIV-7) is reacted with a suitable solvent, for example, methanol in the presence of a suitable acid, for example, hydrochloric acid, followed by commercially available 2-imidazolecarboxaldehyde.
- a suitable reducing agent such as sodium borohydride
- a suitable dehydrating agent such as trimethylonoleformate
- Compound (XXIV-8) can be obtained by combining commercially available 1-methyl-2-imidazolecarboxaldehyde with a suitable reducing agent such as sodium borohydride and a suitable dehydrating agent, a suitable acid catalyst such as acetic acid and a suitable solvent such as acetic acid. The reaction is performed in methanol to obtain a compound (XXIV-9) which is a compound of the general formula (1).
- a suitable reducing agent such as sodium borohydride
- a suitable dehydrating agent e.g., sodium borohydride
- a suitable dehydrating agent e.g., sodium borohydride
- a suitable dehydrating agent e.g., sodium borohydride
- a suitable acid catalyst such as acetic acid
- a suitable solvent such as acetic acid.
- the reaction is performed in methanol to obtain a compound (XXIV-9) which is a compound of the general formula (1).
- the following compounds can be exemplified as
- the present invention relates to a C X C R 4 antagonist comprising the compound or a pharmaceutically acceptable salt thereof as an active ingredient.
- the CXCR4 antagonist or a salt thereof according to the present invention is used for the treatment or prevention of viral diseases such as AIDS, or for the treatment of cancer or rheumatism or the prevention thereof.
- the pharmacologically acceptable salt may be any pharmacologically acceptable salt which can form a salt with the amine compound represented by the above formula (1).
- trifluoroacetate, hydrochloride, acetate, sulfate, nitrate, lactate, maleate, methanesulfonate, toluenesulfonate, tartrate, citrate, oxalate, malonate, Conodate, fumarate, propionate, butyrate, Glucuronic acid, terephthalic acid, phosphoric acid and the like can be mentioned.
- these compounds may optionally form a hydrate or a solvate.
- one or two or more asymmetric carbons that may be present in the compound represented by the general formula (1), in the case of one, a pure optically active substance represented by the absolute configuration R or S, A mixture, racemate, or, in the case of two or more, an optically pure diastereomer, a racemate thereof, or a combination thereof in any ratio in any ratio, whichever is present.
- Pharmaceutical preparations containing the compound of the present invention represented by the general formula (1) or a pharmacologically acceptable salt thereof as an active ingredient usually include pharmacologically acceptable carriers, excipients, and the like known per se.
- the dosage varies depending on the type and severity of the disease, the compound to be administered and the route of administration, the age, sex, and weight of the patient.
- oral administration the usual dosage is 0.1 to 5000 mg, and especially 1 to 3000 mg per adult. Is preferred.
- a prodrug it is particularly preferable to administer 1 to 5000 mg.
- Example 1 Synthesis of 4-[ ⁇ bis (1H-imidazole-2-ylmethyl) amino] methyl ⁇ -N- (4-dipyraminobutyl) benzamide [Compound No. 1]
- Example 1-1 4- [ Synthesis of N-Boc-N- (1H-imidazole-2-ylmethyl) aminomethyl] benzoic acid
- the solvent was distilled off, and 43 ml of THF, 43 ml of methanol and 3 ml of an aqueous lm 0 l / l sodium hydroxide solution were added, followed by stirring at room temperature for 14 hours. After completion of the reaction, the solvent was distilled off, 5 ml of water was added, lmol / 1 hydrochloric acid was carefully added, and the acid precipitate was collected by filtration and dried to obtain 487 g of the title compound as a white solid.
- Example 2 203 mg of the compound obtained in Example 2 was dissolved in 5.0 ml of DMF and 5.0 ml of black form, and 0.337 ml of triethylamine, 382 mg of WSCI hydrochloride, 200 mg of HOBt and 463 mg of the compound obtained in Example 1-1 were dissolved. Was added and stirred at room temperature for 23 hours. After the completion of the reaction, the solvent was distilled off, and chloroform was added. The mixture was washed with water and saturated saline.
- the extract was dried over anhydrous sodium sulfate, the solvent was distilled off, and the residue was purified by silica gel column chromatography (formanol methanol / water) to obtain 168 mg of the title compound as a colorless foam.
- Example 1-3 117 mg of the compound obtained in Example 1-3 was dissolved in 1.2 ml of methanol, and 1.2 ml of a mol / l nodoxane hydrochloride solution was added, followed by stirring at room temperature for 5 hours. After completion of the reaction, the solvent was distilled off, and the residue was dissolved in water and purified by a solid phase extraction column (Seppack®, tcis, Waters) to obtain 118 mg of the hydrochloride of the title compound as a white solid.
- MS (FAB, Pos.): M / z 386 [M + H] +
- Example 1-1 2.01 g of the compound obtained in Example 1-1 was dissolved in 20 ml of 10% hydrochloric acid / methanol and stirred at room temperature for 23 hours. After the reaction is completed, concentrate and suspend in form An aqueous solution of lmol / 1 sodium hydroxide was added, and the mixture was separated. The organic layer was dried over anhydrous sodium sulfate, the solvent was distilled off, and the residue was dried under reduced pressure to obtain 0.80 g of the title compound as a white solid.
- Example 2-1 800 mg of the compound synthesized in Example 2-1 was dissolved in 32 ml of methanol, and 345 mg of 2-imidazole carboxyaldehyde and 307 mg of sodium cyanoborohydride were added. For 16 hours. After completion of the reaction, the solvent was distilled off, the residue was suspended in chloroform, and washed with lmol / 1 aqueous sodium hydroxide solution and saturated saline. After drying over anhydrous sodium sulfate, the solvent was distilled off. This was dissolved in 10 ml of methanol and 10 ml of a 1 mol / l aqueous sodium hydroxide solution, and stirred at room temperature for 2.5 hours.
- Example 2 The compound 125mg obtained in 3 was dissolved in Etanoru 7. 5 ml, 10% Palladium ⁇ beam - was stirred at room temperature for 1 hour a hydrogen atmosphere by adding carbon 63. 0 m g. After completion of the reaction, the catalyst was removed by celite filtration, the solvent was distilled off, and azeotropic distillation with dichloromethane was performed to obtain a deprotected product. This was dissolved in DMF (3.5 ml), DCC (84.9 mg, about 55.6 mg) and 128 mg of the compound obtained in Example 2-2 were added, and the mixture was stirred at room temperature for 17 hours. After completion of the reaction, insolubles were removed by decantation, and the solvent was distilled off.
- Example 3-1 22 mg of the compound obtained in Example 3-1 was dissolved in 0.2 ml of methanol, and 0.22 ml of a 4 mol / l dioxane hydrochloride solution was added, followed by stirring at room temperature for 30 minutes. After completion of the reaction, the solvent was distilled off, and the residue was dried under reduced pressure and suspended in chloroform. This was washed with an lmol / 1 sodium hydroxide aqueous solution and saturated saline, dried over anhydrous sodium sulfate, the solvent was distilled off, and the residue was dried under reduced pressure to obtain 32.5 mg of the title compound.
- Example 3-2 63.9 mg of the compound obtained in Example 3-2 was dissolved in 1.3 ml of anhydrous methanol, and 2-methoxybenzaldehyde (manufactured by Tokyo Chemical Industry) 0.0350 ml, trimethyl orthoformate (manufactured by Tokyo Chemical Industry) 0.0560 ml was added and stirred at room temperature for 30 minutes. Thereto was added 19.3 mg of sodium borohydride, and the mixture was stirred at room temperature for 15 minutes. After the reaction, the solvent was distilled off. Water was added and the mixture was extracted with black-mouthed form. Washed with saturated saline. It was dried over anhydrous magnesium sulfate. The solvent was distilled off and treated with hydrochloric acid. The residue was purified by a solid phase extraction column (Seppack®, tC18, manufactured by Otters Corporation) to obtain 6.80 mg of the hydrochloride of the title compound as a white solid.
- 2-methoxybenzaldehyde manufactured by Tokyo Chemical Industry
- Example 7-3 4- ⁇ [bis (1H-imidazole-2-ylmethyl) Amino] methyl ⁇ -Synthesis of N- (2-dipropylaminoethyl) benzamide [Compound No. 7]
- Example 7-2 165 mg of the compound obtained in Example 7-2 was dissolved in 1.7 ml of methanol, and 0.83 ml of a 4 mol / l hydrogen chloride / dioxane solution was added thereto, followed by stirring at room temperature for 1 hour. After completion of the reaction, the solvent was distilled off under reduced pressure, and the residue was dried under vacuum. This was dissolved in methanol (4.0 ml), and thereto were added trimethyl onoletoformate 1651, acetic acid 2001, propionaldehyde 78.01, sodium cyanoborohydride 68.6 mg, and the mixture was stirred at room temperature for 23 hours.
- the solvent was distilled off under reduced pressure, and the residue was dissolved in chloroform.
- the solution was washed with a 1 mol / ⁇ aqueous sodium hydroxide solution, and lmol / 1 hydrochloric acid was added to transfer the desired product to the aqueous layer. Mouth washes were performed. After adding 1 niol / 1 sodium hydroxide aqueous solution again to make the solution more viscous, the solution was extracted with chloroform, washed with brine and dried over anhydrous sodium sulfate. After filtration, the solvent was distilled off under reduced pressure, dried in vacuo and treated with hydrochloric acid to obtain the hydrochloride of the title compound (llOmg) as a white solid.
- Example 8 4- ⁇ [bis (1H-imidazole-2-ylmethyl) amino] methyl ⁇ -N- (2-cyclohexylaminoethyl) benzamide [Compound No. 8]
- Example 8-1 Synthesis of 4- ⁇ [bis (1H-imidazole-2-ylmethyl) amino] methyl ⁇ -N- (2-cyclohexylaminoethyl) benzamide [Compound No. 8]
- Example 7-2 165 mg of the compound obtained in Example 7-2 was dissolved in 1.7 ml of methanol, and 0.83 ml of a 4 mol / l hydrogen chloride / dioxane solution was added thereto, followed by stirring at room temperature for 1 hour. After completion of the reaction, the solvent was distilled off under reduced pressure, and the residue was dried under vacuum to obtain a crude product. This is methanol
- the solution was made alkaline by addition of 1 niol / 1 sodium hydroxide aqueous solution, extracted with chloroform, washed with brine, and dried over anhydrous sodium sulfate. After filtration, the solvent was distilled off under reduced pressure, dried in vacuo and treated with hydrochloric acid to obtain 116.Omg of the hydrochloride of the title compound as a white solid.
- Example 3-2 50.6 mg of the compound obtained in Example 3-2 was dissolved in 2.0 ml of anhydrous methanol, and 0.0240 ml of cyclohexancarpoxyaldehyde (manufactured by Tokyo Chemical Industry). 0.0430 ml of trimethyl orthoformate was added. Stirred at room temperature for 30 minutes. Thereto, 14.8 mg of sodium borohydride was added, and the mixture was stirred at room temperature for 15 minutes. After the reaction, the solvent was distilled off. It was dissolved in a black hole form and washed with 1 mol / 1 sodium hydroxide aqueous sodium hydroxide solution and saturated saline. It was dried over anhydrous magnesium sulfate.
- Example 3-2 50.6 mg of the compound obtained in Example 3-2 was dissolved in anhydrous methanol (2.0 ml), and 4-1-1-butylbenzaldehyde (manufactured by Tokyo Chemical Industry Co., Ltd.) 0.0330 ml, trimethyl orthoformate
- Example 11 4- ⁇ [bis (1H-imidazole-2-ylmethyl) amino] methyl ⁇ -N- [4- Synthesis of (2-trifluoromethylbenzylamino) butyl] benzamide [Compound No. 11]
- Example 11-1 4- ⁇ [bis (1H-imidazole-2-ylmethyl) amino] methyl ⁇ -N- [ Synthesis of 4- (2-trifluoromethylbenzylamino) butyl] benzamide [Compound No. 11]
- Example 3-2 50.6 mg of the compound obtained in Example 3-2 was dissolved in 2.0 ml of anhydrous methanol, and 0.0260 ml of 2-trifluoromethylbenzaldehyde (manufactured by Tokyo Danisei Co., Ltd.) and 0.0430 ml of trimethyl orthoformate were dissolved. Was added and stirred at room temperature for 30 minutes. Thereto, 14.8 mg of sodium borohydride was added, and the mixture was stirred at room temperature for 15 minutes. After the reaction, the solvent was distilled off. The residue was dissolved in a black hole form, and washed with lmol / 1 aqueous sodium hydroxide solution and saturated saline. It was dried over anhydrous magnesium sulfate.
- 2-trifluoromethylbenzaldehyde manufactured by Tokyo Danisei Co., Ltd.
- trimethyl orthoformate trimethyl orthoformate
- Example 12-1 4- ⁇ [bis (1H-imidazole-2-ylmethyl) amino] methyl ⁇ -N- [4- (2-trifluoromethoxypentinoleamino) butyl] benzamide [Compound No. 12] Synthesis
- Example 3-2 50.6 mg of the compound obtained in Example 3-2 was dissolved in 2.0 ml of anhydrous methanol, and 0.0290 ml of 2-trifluoromethoxybenzaldehyde (manufactured by ApoDone Earth) and 0.0430 ml of trimethyl orthoformate were added. In addition, the mixture was stirred at room temperature for 30 minutes. 14.8 mg of sodium borohydride was added thereto, and the mixture was stirred at room temperature for 15 minutes. After the reaction, the solvent was distilled off. It was dissolved in chloroform and washed with lmol / 1 sodium hydroxide aqueous solution and saturated saline. It was dried over anhydrous magnesium sulfate.
- Example 3- 50.6 mg of the compound obtained in 2 was dissolved in 2.0 ml of anhydrous methanol, and 4-methylthiobenzaldehyde (manufactured by Tokyo Chemical Industry Co., Ltd.) 0.0270 ml, trimethyl orthoformate 0.0430 ml was added and the mixture was stirred at room temperature for 30 minutes. Thereto, 14.8 mg of sodium borohydride was added, and the mixture was stirred at room temperature for 15 minutes. After the reaction, the solvent was distilled off. The residue was dissolved in a black hole form, and washed with lniol / 1 aqueous sodium hydroxide solution and saturated saline. It was dried over anhydrous magnesium sulfate.
- Example 3-2 50.6 mg of the compound obtained in Example 3-2 was dissolved in 2.0 ml of anhydrous methanol, and 24.2 mg of 3-methylpyridine-2-potassyl aldehyde and 0.0430 ml of trimethyl orthoformate were added, and the mixture was added at room temperature for 30 minutes. Stirred. Thereto, 14.8 mg of sodium borohydride was added, and the mixture was stirred at room temperature for 15 minutes. After the reaction, the solvent was distilled off. The residue was dissolved in black-mouthed form and washed with lniol / 1 aqueous sodium hydroxide solution and saturated saline. It was dried with anhydrous magnesium sulfate. The solvent was distilled off and treated with hydrochloric acid. The residue was purified by silica gel column chromatography (chloroform / methanol Z7J) to give 59.3 mg of the hydrochloride of the title compound as a white solid.
- Example 15 4- ⁇ [bis (1H-imidazole-2-ylmethyl) amino] methyl ⁇
- Example 15-1 Synthesis of N, N-dipropyl-N'-Boc-1,4-phenylenediamine -N- (4-dipyrupyraminophen-yl) benzamide [Compound No. 15]
- Example 2-2 300 mg of the compound obtained in Example 2-2 was dissolved in 10 ml of DMF, and 298 mg of DCC, 195 mg of HOBt and 185 m of the compound obtained in Example 15-1 were added, and the mixture was stirred at room temperature for one hour. After the completion of the reaction, the solvent was distilled off, the residue was dissolved in chloroform, and lmol / 1 hydrochloric acid was added to separate the solution. The aqueous layer was basified by the addition of lmol / 1 aqueous sodium hydroxide solution, extracted with chloroform, washed with brine, and the organic layer was dried over anhydrous sodium sulfate. Distill solvent The residue was removed, treated with hydrochloric acid, and purified by silica gel gel column chromatography (Formula Methanol Z water) to obtain 96.4 mg of the hydrochloride of the title compound as a white solid.
- Example 16 4-[[bis (1H-imidazole-2-ylmethyl) amino] methyl ⁇ -N- ⁇ 4- [bis (3-methylbutyl) aminobutyl] ⁇ benzamide [Synthesis of Compound No. 16]
- Example 16-1 4-([Bis (1H-imidazole-2-ylmethyl) amino] methyl ⁇ _N_ ⁇ 4- [Bis (3-methylbutyl) aminobutyl] ⁇ Synthesis of benzamide [Compound No. 16]
- Example 3-2 30 mg of the compound obtained in Example 3-2 was dissolved in 0.6 ml of methanol, and 30.0 t1, 3-methyl orthoformate, 30.0 acetic acid, and isovalerate aldehyde (manufactured by Tokyo Chemical Industry Co., Ltd.) were added thereto. 25.3 ⁇ l and 14.9 mg of sodium cyanoborohydride were added, and the mixture was stirred at room temperature for 3 hours.
- Example 17 Synthesis of 4- ⁇ [bis (1H-imidazole-2-ylmethyl) amino] methyl ⁇ -N- (4-dimethylaminobutyl) benzamide [Compound No. 17]
- Example 17-1 4 - ⁇ [Bis (1H-imidazole-2-ylmethyl) amino] methyl ⁇ -Synthesis of N- (4-dimethylaminobutyl) benzamide [Compound No. 17]
- Example 19-1 492 mg of the compound obtained in Example 19-1 was dissolved in 5.0 ml of methanol and 2.5 ml of THF, and 49.0 mg of activated carbon and 4.90 mg of iron trichloride hexahydrate (manufactured by Kanto Kagaku) were added. Heated and refluxed for minutes. After returning to room temperature, 0.35 ml of hydrazine monohydrate was added, and the mixture was heated under reflux for 3 hours. After the reaction, the mixture was filtered through celite, and the solvent was distilled off. Water was added to the mixture to extract the form of black mouth. It was dried over anhydrous magnesium sulfate. The solvent was distilled off, thereby obtaining the subject compound (437 mg) as a yellow oily substance.
- Example 20 N- (4-dipropylaminobutyl) -4- 4- [[(1H-imidazole-2-ylmethyl) pyridine-2-ylmethylamino] methyl ⁇ benzamide Synthesis of [Compound No. 20]
- Example 20-1 N- (4-dipropylaminobutyl) -4-[ ⁇ [(1H-imidazol-2-ylmethyl) pyridine-2-ylmethylamino] methyl ⁇ benzamide Synthesis of [Compound No.
- Example 21 N- Synthesis of (4-dipropylaminobutyl) -4- ⁇ [(1H-imidazole-2-ylmethyl) thiazole-2-ylmethylamino] methyl ⁇ benzamide [Compound No. 21]
- Example 21-1 N-( 4-Dipropylaminobutyl)-4- ⁇ [(1H-imidazole-2-ylmethyl) thiazole-2-ylmethylamino] methyl ⁇ benzamide [Compound No. 21]
- Example 22-2 2.67 g of the compound obtained in Example 22-2 was dissolved in 2.0 ml of anhydrous methanol, 20.0 ml of a 1 ⁇ 2ol / l hydrogen chloride Z dioxane solution was added, and the mixture was stirred at room temperature for 1.5 hours. After the completion of the reaction, the solvent was distilled off, and an lmol / laqueous sodium hydroxide aqueous solution was added thereto, followed by extraction with dichloromethane. The extract was washed with distilled water and saturated saline, and the organic layer was dried over anhydrous sodium sulfate. The solvent was distilled off to obtain 726 mg of the title compound as a pale yellow liquid.
- Example 22-4 4- ⁇ [bis (1H-imidazole-2-ylmethyl) amino] methylto N- (3-dipropyla) Synthesis of minopropyl) benzamide [Compound No. 22] 190 mg of the compound obtained in Example 2-2 was dissolved in 3.0 ml of DMF, and 189 mg of DCC was dissolved.
- the residue was purified by silica gel gel column chromatography (chloroform / methanol / water) to obtain 84.8 mg of the hydrochloride of the title compound as a white solid.
- Example 23-1 501 mg of the compound obtained in Example 23-1 was dissolved in 50 ml of anhydrous methanol, and Sodium borohydride (467 mg), trimethyl orthoformate (6771), and propionaldehyde (447 ⁇ l) were added, and the mixture was stirred at room temperature under a nitrogen atmosphere for 3 days. After the completion of the reaction, the solvent was distilled off, the residue was dissolved in chloroform, a saturated aqueous sodium hydrogen carbonate solution was added, and the mixture was stirred. This was extracted with chloroform, washed with saturated aqueous sodium hydrogen carbonate solution and saturated saline, and the organic layer was dried over anhydrous sodium sulfate. The solvent was distilled off to obtain 740 mg of the title compound as a pale yellow liquid.
- Example 23-2 740 mg of the compound obtained in Example 23-2 was dissolved in 3.0 ml of anhydrous methanol, and 15.0 ml of a mol / l hydrogen chloride Z-dioxane solution was added, followed by stirring at room temperature for 1 hour. After completion of the reaction, the solvent was distilled off, and an aqueous solution of lmol / 1 sodium hydroxide was added thereto, followed by extraction with dichloromethane. The extract was washed with distilled water and saturated saline, and the organic layer was dried over anhydrous sodium sulfate. The solvent was distilled off to obtain 351 mg of the title compound as a colorless liquid.
- Example 23-4 4- ⁇ [bis (1H-imidazole-2-ylmethyl) amino] methyl ⁇ -N- (3-di Synthesis of propylamino-2,2-dimethylpropyl) benzamide [Compound No. 23] Compound lOOmg obtained in Example 2-2 was dissolved in 2.0 ml of DMF, and DCC 55.4 mg, HOBt 36.3 mg and Examples 50. Omg of the compound obtained in 23-3 was added, and the mixture was stirred at room temperature. After completion of the reaction, the solvent was distilled off, the residue was dissolved in chloroform, and lBiol / 1 hydrochloric acid was added to carry out liquid separation.
- the aqueous layer was basified by the addition of lmol / 1 aqueous sodium hydroxide solution, extracted with chloroform, washed with brine, and the organic layer was dried over anhydrous sodium sulfate. After evaporating the solvent and treating the residue with hydrochloric acid, the residue was purified by silica gel gel column chromatography (chloroform / methanol Z water) to obtain 17.5 mg of the hydrochloride of the title compound as a white solid.
- Benzylamine (manufactured by Tokyo Chemical Industry Co., Ltd.) (1.00 g) was dissolved in purified water (20 ml), N-carboxy phthalimide (manufactured by Tokyo Chemical Industry Co., Ltd.) (3.06 g ) and sodium carbonate (2.47 g) were added, and the mixture was stirred at room temperature for 3 hours. After completion of the reaction, the mixture was filtered and the residue was washed with purified water. This was vacuum dried at 60 ° C. to obtain 1.82 g of the title compound as a white solid.
- Example 24-1 330 mg of the compound obtained in Example 24-1 was dissolved in black hole form, and 0.177 ml of chlorosulfuric acid (manufactured by Kishida Chemical Co., Ltd.) was added under ice-cooling. The mixture was stirred at room temperature for 2 days, concentrated and dried. 300 mg of phosphorus pentachloride was gradually added thereto. This was heated to 80 ° C and stirred for 4 'hours.
- chlorosulfuric acid manufactured by Kishida Chemical Co., Ltd.
- Example 24-3 4- (l, 3-dioxo-1,3-dihydroisoindole-2-ylmethyl) Synthesis of) -N- (4-dipropylaminobutyl) benzenesulfonamide
- 150 mg of the compound obtained in Example 24-2 was dissolved in 10 ml of chloroform, 131 mg of the compound obtained in Example 1-2 and 0.224 ml of triethylamine were added, and the mixture was stirred at room temperature for 15 minutes. Water was added for extraction, and the organic layer was washed with saturated saline. This was dried over anhydrous sodium sulfate and concentrated to give the title compound (160 mg) as a colorless viscous liquid.
- MS (FAB, Pos.): M / z 472 [M + H] +
- Example 24-4 Synthesis of 4-aminoamino-N- (4-dipropylaminobutyl) pentene sulfonamide
- Example 24-3 To 160 mg of the compound obtained in Example 24-3, 2.0 ml of a 40% methylamine / methanol solution (manufactured by Tokyo Kasei) was added, and the mixture was stirred at room temperature for 40 hours. After completion of the reaction, the solvent was distilled off, and an extraction was performed by adding an aqueous solution of lmol / 1 sodium hydroxide and chloroform. The organic layer was dried over anhydrous sodium sulfate and the solvent was distilled off to obtain the title compound as a colorless viscous liquid.
- a 40% methylamine / methanol solution manufactured by Tokyo Kasei
- Example 24-4 The compound ll1 ⁇ 2g obtained in Example 24-4 was dissolved in anhydrous methanol 7. 0 ml, 2-I Mi indazole Cal Po carboxaldehyde 73. 0 m g, Shiano hydride Hou sodium hydrogen
- Example 25-1 103 mg of the compound obtained in Example 25-1 was dissolved in 10 ml of anhydrous methanol, and llg of the hydrochloride of the compound obtained in Example 1-2 was added. 0.18 ml of triethylamine and 3 g of anhydrous magnesium sulfate were added thereto, and the mixture was stirred at room temperature for 1 hour. The anhydrous magnesium sulfate was removed by filtration through celite, methanol was distilled off, and the residue was dried with a vacuum pump. This was dissolved in 10 ml of anhydrous methanol, and 22.Omg of sodium borohydride was gradually added under ice-cooling. This was returned to room temperature and stirred for 1 hour.
- Example 25-3 [4- (1,3-Dioxo-1,3-dihydroisoindole 2-ylmethyl) benzyl]- Synthesis of t-butyl (4-dipropylaminobutyl) rubbamate 60.3 mg of the compound obtained in Example 25-2 was dissolved in chloroform, and di-t-butoxydicarbonate 47.Omg was added thereto. added. After stirring at room temperature for 30 minutes, the mixture was concentrated, and purified by silica gel column chromatography (form: form / methanol) to obtain 70.Omg of the title compound as a colorless viscous liquid.
- Example 25-5 N- (4- ⁇ [bis (1H-imidazole-2-ylmethyl) amino] methyl ⁇ benzyl) -N ', N'-pybutan-1,4-diamine at dibu-mouth [Compound No. 25]
- Example 25-4 45.5 mg of the compound obtained in Example 25-4 was dissolved in anhydrous methanol (3.0 ml), and 2-imidazolecarboxyaldehyde (25.0 ing), sodium cyanoborohydride (15.0 mg), and acetic acid (0.1 ml) were dissolved. Added in order. The mixture was stirred at room temperature for 15 hours, methanol was distilled off, and then 1 mol / 1 sodium hydroxide aqueous solution was added to the mixture. Extract with chloroform, dry over anhydrous sodium sulfate, evaporate the solvent, and perform silica gel column chromatography. The residue was purified by chromatography (form-form / methanol / water) and treated with hydrochloric acid to give the hydrochloride of the title compound (28.Omg) as a white solid.
- Example 27-1 N- (4-dipropylaminobutyl) -4-( ⁇ (1H-imidazole-2-ylmethyl)-(1H-pyrazol-3-ylmethyl) amino] methyl ⁇ benzamide [ Synthesis of Compound No. 27]
- Example 28 N- (4-dipropylaminobutyl)-4- ⁇ [(1H-imidazole-2-ylmethyl)-(2R) -pyrrolidine- Synthesis of 2-ylmethylamino] methyl ⁇ benzamide [Compound No. 28]
- Example 28-1 N- (4-dipropylaminobutyl) -4- ⁇ [(1H-imidazole-2-ylmethyl)-( Synthesis of 2R) -Pyrrolidine-2-ylmethylamino] methyl ⁇ benzamide [Compound No. 28]
- Example 1-4 53.8 mg of the compound obtained in Example 1-4 was dissolved in 0.8 ml of methanol, and 50 ⁇ l of trimethyl orthoformate, 50 ⁇ l of acetic acid, 25.7 mg of N-Boc-L-prolinal (manufactured by Aldrich) were added. After stirring at room temperature for 10 minutes, 24.4 mg of sodium cyanoborohydride was added, and the mixture was stirred at room temperature for 1 B. The solvent was distilled off under reduced pressure, the residue was dissolved in chloroform, washed with lmol / 1 sodium hydroxide and saturated brine, and dried over anhydrous sodium sulfate.
- Example 31 (4- ⁇ [bis (IH-imidazo-1- / re-2-ylmethyl) amino] methyl ⁇ phenyl)-(4-dipropylaminopiperidine- Synthesis of 1-yl) methanone [Compound No. 31]
- Example 31-1 Synthesis of 4-N, N-dipropylaminopiperidine
- Example 31-2 (4- ⁇ [bis (1H-imidazole-2-ylmethyl) amino] methyl ⁇ phenyl)-(4 Synthesis of -Zip mouth pyraminopiperidine-1-yl) methanone [Compound o. 31] Compound 31.2 mg, DCC 30.0 mg, HOBt 20.5 mg obtained in Example 2-2 were added to DMF 0.5 ml. After dissolving and stirring for 15 minutes, 25.6 m of the compound obtained in Example 3 was added, and the mixture was stirred at room temperature for 5 hours.
- Example 32 1- (4- ⁇ [bis (1H-imidazole-2- Synthesis of (methyl) amino] methyl ⁇ phenyl) -4-propylpiperazineamide [Compound No. 32]
- Example 32-1 1- (4- ⁇ [N, N-bis (1H-imidazole-2-) Synthesis of (Methylmethylamino) methyl ⁇ phenyl) -4-Bocpiperazinamide
- Example 2-2 500 mg of the compound obtained in Example 2-2 was dissolved in 10 ml of DMF, 257 mg of WSCI hydrochloride, 81 mg of H0Btl and 249 mg of 1-Boc piperazine (manufactured by Aldrich) were added, and the mixture was stirred at room temperature for 3 days. After completion of the reaction, the solvent was distilled off, and the residue was dissolved in chloroform and extracted. The organic layer was washed with distilled water, lmol / 1 aqueous sodium hydroxide solution and saturated saline, and dried over anhydrous sodium sulfate. The solvent was distilled off, and the residue was purified by silica gel column chromatography (form-form methanol / water Z) to obtain the title compound (llmg) as a yellow oil.
- Example 32-2 8.8 mg of the compound obtained in Example 32-2 was dissolved in 1.0 ml of anhydrous methanol, and sodium borohydride 16.2 mg, trimethyl orthoformate 21.1 ⁇ l, propion aldehyde 13.9 / l was added and stirred at room temperature under a nitrogen atmosphere. After completion of the reaction, the solvent was distilled off, the residue was dissolved in chloroform, a saturated aqueous solution of sodium hydrogen carbonate was added, and the mixture was stirred. This was extracted with chloroform, washed with saturated aqueous sodium hydrogen carbonate solution and saturated saline, and the organic layer was dried over anhydrous sodium sulfate.
- Example 33-1 595 mg of the compound obtained in Example 33-1 was dissolved in 6.0 ml of methanol and 3.0 ml of THF, and 59.0 mg of activated carbon and 5.90 mg of iron trichloride hexahydrate (manufactured by Kanto Chemical Co.) were added. Heated and refluxed for minutes. After returning to room temperature, 0.43 ml of hydrazine monohydrate was added, and the mixture was heated under reflux for 24 hours. After the reaction, the mixture was filtered through celite, and the solvent was distilled off. Water was added to extract with chloroform. It was dried with anhydrous magnesium sulfate. The solvent was distilled off, and the residue was purified by silica gel gel chromatography (chloroform / methanol) to obtain 343.9 mg of the title compound as a yellow oil.
- activated carbon and 5.90 mg of iron trichloride hexahydrate manufactured by Kanto Chemical Co.
- Example 34 Synthesis of 4- ⁇ [bis (1H-imidazole-2-ylmethyl) amino] methyl-N- (4- ⁇ [(1H-imidazole-2-ylmethyl) aminomethyl] methyl ⁇ phenyl) benzamide [Compound No. 34]
- Example 34-1 Synthesis of (1H-imidazole-2-ylmethyl)-(4-ditobenzyl) amine
- Example 34-2 (1H-imidazole-2-ylmethyl)-(4-dimethoxybenzyl) canolebamic acid t-butyl ester Synthesis of 733 mg of the compound obtained in Example 34-1 was dissolved in 15 ml of chloroform, and 1.51 of di-1-butyldicarbonate was added thereto. After stirring at room temperature for 1 hour, the mixture was concentrated and purified by silica gel column chromatography (form: methanol in methanol) to obtain 993 mg of the title compound as a pale yellow viscous liquid.
- Example 34-2 325 mg of the compound obtained in Example 34-2 was dissolved in 15 ml of ethanol, cooled with ice, and carefully added with 300 mg of 10% palladium-carbon (Mitsuwa Chemical Co., Ltd.), followed by stirring under a hydrogen atmosphere for 30 minutes. did. The mixture was filtered through celite, and the filtrate was concentrated to obtain 233 mg of the title compound as a pale red-white solid.
- Example 34-3 150 mg of the compound obtained in Example 34-3 was dissolved in 3.0 ml of DMF, and 140 mg of the compound synthesized in Example 2-2 was added thereto.
- 79.0 mg of H0Bt and 681 mg of PS-carboimide (Argonaut) were added, and the mixture was stirred at room temperature for 18 hours.
- PS-carboimide was filtered, DMF of the filtrate was distilled off, and then chloroform was added.
- the mixture was washed with 1 mol / 1 sodium hydroxide aqueous solution and saturated saline. It was dried over anhydrous sodium sulfate, concentrated, and purified by column chromatography (chloroform / methanol) to obtain 105 mg of the title compound as a white solid.
- Example 34-5 4- ⁇ [bis (1H-imidazole-2-ylmethyl) amino] methyl ⁇ -N- (4- ⁇ Synthesis of [(1H-imidazole-2-ylmethyl) aminomethyl] methyl ⁇ phenyl) benzamide
- Compound No. 34 105 mg of the compound obtained in Example 34-4 was dissolved in 10 ml of methanol, and 2.0 ml of 1 mol / 1 hydrochloric acid was added thereto, followed by stirring at room temperature for 5 minutes. It was concentrated, dried and purified by column chromatography (form-form / methanol) to give 6 mg of the hydrochloride of the title compound as a white solid.
- Example 2.00 g of the compound obtained in Example 1-1 was dissolved in 40 ml of methanol, to which 1.74 g of WSCI hydrochloride and 1.22 g of HOBt were added, followed by stirring at room temperature overnight. After completion of the reaction, the solvent was distilled off, the residue was dissolved in chloroform, a saturated aqueous sodium hydrogen carbonate solution was added, and the mixture was stirred. This was extracted with a filter form, washed with a saturated aqueous solution of sodium hydrogencarbonate, a saturated aqueous solution of ammonium chloride, and saturated saline, and the organic layer was dried over anhydrous sodium sulfate. The solvent was distilled off, thereby obtaining the subject compound (2.42 g) as a colorless solid.
- Example 35-1 2.42 g of the compound obtained in Example 35-1 was dissolved in 5.0 ml of anhydrous THF, 799 mg of lithium aluminum hydride was added in an ice bath, and the mixture was stirred at room temperature for 2 hours. After completion of the reaction, methanol and then an aqueous solution of sodium potassium tartrate were added and stirred. This was extracted with Kuguchiguchi form, washed with saturated saline, and the organic layer was dried over anhydrous sodium sulfate. The solvent was distilled off, and the residue was purified by silica gel gel column chromatography (form-form Z methanol) to obtain 1.76 g of the title compound as a colorless solid.
- Example 35-2 107 mg of the compound obtained in Example 35-2 was dissolved in 2.0 ml of THF, and 76.8 mg of the compound obtained in Example 35-3, 177 mg of triphenylphosphine, and getylazodicarboxylate (Tokyo Chemical Industry Co., Ltd.) 305 ⁇ l was added and the mixture was stirred at room temperature overnight. After completion of the reaction, the solvent was distilled off, and the residue was dissolved in chloroform and extracted. The extract was washed with a saturated saline solution, and the organic layer was dried over anhydrous sodium sulfate. The solvent was distilled off, and the residue was purified by silica gel gel chromatography (chloroform / methanol) to obtain 28.4 g of the title compound as a yellow oil.
- silica gel gel chromatography chloroform / methanol
- Example 35-5 [4- (4- ⁇ [N- (1H-imidazole-2-ylmethyl) amino] methyl ⁇ benzyl ⁇ benzyloxy ) Synthesis of benzyl] dipropylamine 28.4 mg of the compound obtained in Example 35-4 was dissolved in 1.0 ml of anhydrous methanol, 1.00 ml of a 4 mol / l hydrogen chloride nodoxane solution was added, and the mixture was stirred at room temperature for 2 hours. After the completion of the reaction, the solvent was distilled off, and an aqueous solution of lmol / 1 sodium hydroxide was added thereto, followed by extraction with chloroform. The extract was washed with distilled water and saturated saline, and the organic layer was dried over anhydrous sodium sulfate. The solvent was distilled off, thereby obtaining the subject compound (20. mg) as a yellow oily substance.
- Example 36 4- ⁇ [4-bis (1H-imidazole-2-ylmethyl) amino] methyl ⁇ naphthalene, 1-carboxylic acid
- Example 36-1 Synthesis of methyl 4-bromomethyl-1-naphthalenecarboxylate (4-dipropylaminomethylphenyl) amide [Compound No. 36]
- Example 4 Synthesis of commercially available 4-methyl 251 mg of 1-naphthalenecarboxylic acid (manufactured by Tokyo Chemical Industry Co., Ltd.) was dissolved in 7.5 ml of methanol, and hydrogen chloride gas was bubbled under ice cooling for 5 minutes.
- Example 36-1 328 mg of the compound obtained in Example 36-1 was dissolved in 7.2 ml of DMF, 359 mg of phthalimidocharium was added, and the mixture was stirred at room temperature for 12 hours. After completion of the reaction, the solvent was distilled off, and the residue was dissolved in chloroform, and washed with distilled water, lmol / 1 sodium hydroxide aqueous solution, and saturated saline. After drying over anhydrous sodium sulfate and evaporating the solvent, the residue was purified by silica gel column chromatography (hexane / ethyl acetate) to obtain 281 mg of a white solid.
- Example 36-3 To 675 mg of the compound obtained in Example 36-3, 7.0 ml of methanol and 7.0 ml of lmol / sodium hydroxide were added, and the mixture was stirred for 1 hour. After the reaction, 8.0 ml of 1 mol / 1 hydrochloric acid was added to adjust the pH of the solution to 4, and the solvent was distilled off. The residue was washed with methanol. Drying afforded 677 mg of the title compound as a white solid.
- Example 36-4 The compound 130mg obtained in Example 36-4 was dissolved in DMF 3. 0ml, DCC 60. 0m g , a HOBt 40. Omg, and the mixture was stirred for 2 hours at room temperature. 50. Omg of the compound obtained in Example 19-2 was added at room temperature, followed by stirring under reduced pressure. After the completion of the reaction, insolubles were removed with a G4 glass filter, and the solvent was distilled off. It was dissolved in black-mouthed form and washed with lmol / 1 hydrochloric acid. Hydrochloric acid was added to the organic layer to separate the layers, and an aqueous sodium hydroxide solution was added to the aqueous layer to adjust the pH to 12.
- Example 32-2 57.7 mg of the compound obtained in Example 32-2 was dissolved in 1.73 ml of methanol, and 30.7 ⁇ l of 4-heptanone (manufactured by Tokyo Chemical Industry Co., Ltd.), 13.8 mg of sodium cyanoborohydride, 76.5 ml of triethylamine 1 was added, the pH was adjusted to 5 with acetic acid, and the mixture was stirred at room temperature for 7 days. An aqueous solution of lmol / 1 sodium hydroxide was added to the reaction solution, and the mixture was separated and extracted with chloroform.
- 4-heptanone manufactured by Tokyo Chemical Industry Co., Ltd.
- Example 38-1 1- (4- ⁇ [bis (1H-imidazole-2-ylmethyl) amino] methyl ⁇ phenyl) -4-cyclohexylpiperazine Synthesis of mid 57.7 mg of the compound obtained in Example 32-3 was dissolved in 1.73 ml of methanol, 21.6 mg of cyclohexanone, 13.8 mg of sodium cyanoborohydride and 76.5 ⁇ l of triethylamine were added, and acetic acid was added. Was adjusted to 5 and stirred at room temperature for 7 days. An aqueous solution of lmol / sodium hydroxide was added to the reaction solution, and the mixture was separated and extracted with chloroform.
- Example 25-1 17.6 mg of the compound obtained in Example 25-1, 13.2 mg of the compound obtained in Example 19-2, and 8.7 mg of sodium cyanoborohydride were dissolved in 1.0 ml of anhydrous methanol. Subsequently, acetic acid was added to adjust the pH to 5, followed by stirring at room temperature for 4 hours. Distilled water was added to the reaction solution, and the mixture was extracted with chloroform. The organic layer was washed with saturated saline and dried over anhydrous sodium sulfate. After evaporating the solvent, the obtained residue was purified by silica gel preparative thin-layer chromatography (formula methanol) to obtain 72.9 mg of the title compound as a yellow solid.
- Example 39-1 521.6 mg of the compound obtained in Example 39-1 was dissolved in 15 ml of methanol, 0.11 ml of hydrazine monohydrate was added, and the mixture was stirred at 60 ° C for 1.5 hours. To the reaction solution was added a 1 mol / 1 aqueous sodium hydroxide solution, and the mixture was extracted with chloroform. The organic layer was washed with saturated saline and dried over anhydrous sodium sulfate. After evaporating the solvent, 372 mg of the title compound was obtained as a yellow solid.
- Example 39-2 57.3 mg of the compound obtained in Example 39-2 was dissolved in 2.5 ml of methanol, 1-methyl-2-imidazolecarboxyaldehyde (158 rag) was added, and 68.1 ⁇ 2 g of sodium cyanoborohydride was added. added. Acetic acid was added to the reaction solution to adjust the pH to 5, followed by stirring at room temperature for 17 hours. An aqueous solution of lmol / 1 sodium hydroxide was added to the reaction solution, and the mixture was extracted with porcine. Then, the organic layer was washed with saturated saline and dried over anhydrous sodium sulfate. After the solvent was distilled off, a 10% hydrochloric acid / methanol solution was added, and the solvent was distilled off. The obtained residue was purified by silica gel gel chromatography (black-mouthed form Z methanol / water) to obtain 55.2 mg of the title compound as a yellow solid.
- Production example 40 4- ⁇ [Bis (1-methyl-1H-imidazole-2-ylmethyl) amino] methyl ⁇ -Synthesis of N- (4-dipropylaminobutyl) benzamide [Compound No. 40]
- Example 40-1 Synthesis of 4- ⁇ [bis (1-methyl-1H-imidazole-2-ylmethyl) amino] methyl ⁇ benzoic acid
- Example 2-2 The compound lOOmg obtained in Example 2-2 was dissolved in DMF (2.0 ml), DCC (73.0 mg) and HOBt (36. Omg) were added, and the mixture was stirred for 15 hours. 1.0 ml of a solution of the compound 73.Omg obtained in Example 19-2 in DMF was added to the reaction system, and the mixture was stirred for 24 hours. After the completion of the reaction, DMF was distilled off, the residue was dissolved in porcine form, and extracted with lmol / 1 hydrochloric acid. The aqueous layer was added with an aqueous solution of lmol / 1 sodium hydroxide, and extracted with chloroform.
- Example 42-1 ⁇ 4- [4- (1,3-dioxo-1,3-dihydro) Synthesis of Benzyl Esters of Isoindole-2-ylmethyl) benzylamino] butyl
- Example 42-1 153 rag of the compound obtained in Example 42-1 was dissolved in 15 ml of chloroform, and 106 mg of di-1-butyldicarbonate was added thereto. After stirring at room temperature for 1 hour, the mixture was concentrated, and purified by silica gel column chromatography (form: form / methanol) to obtain 173 mg of the title compound as a colorless viscous liquid.
- Example 43-1 199 mg of the compound obtained in Example 43-1 was dissolved in 6 ml of methanol, and 57.lmg of 2-imidazolecarboxaldehyde and 65.g of sodium cyanoborohydride were added. Acetic acid was added to the reaction solution to adjust the pH to 5, followed by stirring at room temperature for 14 hours. A 1 mol / 1 aqueous sodium hydroxide solution was added to the reaction solution, and the mixture was extracted with chloroform. The organic layer was washed with saturated saline and dried over anhydrous sodium sulfate. After the solvent was distilled off, the obtained residue was purified by silica gel gel column chromatography (form: form / methanol). This was treated with hydrochloric acid to give the hydrochloride of the title compound (231 mg) as a yellow solid.
- Example 44 (4-Dipropylaminomethylphenyl)-(4- ⁇ [(1H-imidazole-2-ylmethyl)-(1-methyl-1H-imidazoyl / le-2-) Synthesis of [ylmethyl) amino] methyl ⁇ benzyl) amine [Compound No. 44]
- Example 44-1 (4-Dipropylaminomethylphenyl)-(4- ⁇ [(1H-imidazole-2-ylmethyl)-( Synthesis of 1-methyl-1H-imidazole-2-ylmethyl) amino] methyl ⁇ benzyl) amine [Compound No. 44]
- Example 43-1 72.7 mg of the compound obtained in Example 43-1 was dissolved in 3.5 ml of methanol, and 28.6 mg of 1-methyl-2-imidazolecarboxyaldehyde and 22.8 mg of sodium cyanoborohydride were added.
- Acetic acid was added to the reaction solution to adjust the pH to 5, followed by stirring at room temperature for 14 hours.
- a 1 mol / 1 aqueous sodium hydroxide solution was added to the reaction solution, and the mixture was extracted with chloroform. The organic layer was washed with brine and dried over anhydrous sodium sulfate. After distilling off the solvent, the obtained residue was subjected to silica gel gel column chromatography (Chromatography (Formyl acetate). This was treated with hydrochloric acid to give 71.3 mg of the hydrochloride of the title compound as a yellow solid.
- Example 45-1 (4-dipropylaminomethylphenyl)-(4- ⁇ [(1H-imidazole-2-ylmethyl)-(2H-pyrazol-3-ylmethyl) amino] methyl ⁇ benzyl) amine Synthesis of [I-Danigo Compound No. 45]
- Example 43-1 72 mg of the compound obtained in Example 43-1 was dissolved in 3.5 ml of methanol, and 24.5 mg of pyrazole-3-carboxaldehyde and 35.9 mg of sodium cyanoborohydride were added. Acetic acid was added to the reaction solution to adjust the pH to 5, followed by stirring at room temperature for 14 hours. To the reaction solution was added a 1 mol / ⁇ aqueous solution of sodium hydroxide, and the mixture was extracted with chloroform. The organic layer was washed with saturated saline and dried over anhydrous sodium sulfate. After evaporating the solvent, the obtained residue was purified by silica gel column chromatography (form / formyl acetate). This was treated with hydrochloric acid to give 52.3 mg of the hydrochloride of the title compound as a yellow solid.
- Example 46-1 N- (4-dipropylaminobutyl) -4- ⁇ [(1H-imidazole-2-ylmethyl)-(6-methylpyridine-2-ylmethyl) amino] methyl ⁇ Synthesis of benzamide compound No. 46]
- Example 44.3 mg of the compound obtained in Example 1-4 was dissolved in 1.0 ml of methanol, and 20.7 mg of 6-methylpyridine-2-carboxaldehyde and 10.7 mg of sodium cyanoborohydride were added. The pH was adjusted to around 5 with acetic acid, and the mixture was stirred at room temperature for 15 hours. After completion of the reaction, the solvent was distilled off, and the residue was dissolved in chloroform. The extract was washed with lmol / 1 aqueous sodium hydroxide solution and saturated saline, and dried over anhydrous sodium sulfate. The solvent was distilled off, and the residue was purified by silica gel column chromatography (chloroform / methanol / water) to obtain 9.9 mg of the title compound as a white solid.
- the alcohol compound was dissolved in 16.5 ml of solvent-containing form, 2.33 g of manganese dioxide (chemically treated product, manufactured by Wako Pure Chemical Industries, Ltd., same hereafter) was added, and the mixture was stirred at room temperature for 0.5 hours.
- the reaction solution was filtered using celite, the solvent was distilled off, and the residue was purified by silica gel gel chromatography (hexane Z ethyl acetate) to obtain 20.2 mg of the title compound as an orange solid.
- silica gel gel chromatography hexane Z ethyl acetate
- Example 47-2 N_ (4-dipropylaminomethylphenyl) )-Synthesis of 4- ⁇ [N-Boc-N- (1H-imidazole-2-ylmethyl) amino] methyl ⁇ benzamide
- Example 47-4 N- (4-dipropylaminomethylphenyl) -4- ⁇ ((1H-imidazole-2-ylmethyl) isoquinoline-3-ylmethylamino) methyl ⁇ benzamide [Compound No. 47]
- Example 47-3 53.9 mg of the compound obtained in Example 47-3 was dissolved in 2.0 ml of methanol, and 20.2 mg of the compound obtained in Example 47-1 and 12.8 mg of sodium cyanoborohydride were added, followed by addition of acetic acid. The pH was adjusted to 5, and the mixture was stirred at room temperature for 14 hours. After completion of the reaction, lmol / 1 sodium hydroxide aqueous solution was added to the reaction solution, and the mixture was separated and extracted with chloroform.
- Example 48 N- (4-dipropylaminomethylphenyl)- Synthesis of 4- ⁇ [(1H-imidazole-2-ylmethyl) pyridine-2-ylmethylamino] methyl ⁇ benzamide [Compound No. 48]
- Example 48-1 N- (4-dipropylaminomethylphenyl) )-4- ⁇ Synthesis of [(1H-imidazole-2-ylmethyl) pyridine-2-ylmethylamino] methyl ⁇ benzamide [Compound No. 48]
- Example 25-5 150.7 mg of the compound obtained in Example 25-5 was dissolved in 3.0 ml of methanol, and a 50% aqueous solution of 36% formaldehyde (Kanto Chemical; fcM) was added. 2 mg was added. Acetic acid was added to the reaction solution to adjust the pH to 5, followed by stirring at room temperature for 17 hours. To the reaction solution was added lmol / 1 aqueous sodium hydroxide solution, and the mixture was extracted with a column. The organic layer was washed with saturated saline and dried over anhydrous sodium sulfate.
- Example 47-3 104.9 mg of the compound obtained in Example 47-3 was dissolved in 3.2 ml of methanol, and 36.3 mg of the compound obtained in Example 51-1 and 31.1 ⁇ 2 g of sodium cyanoborohydride were added, followed by addition of acetic acid. The pH was adjusted to 5, and the mixture was stirred at room temperature for 14 hours. After the reaction is complete, add An aqueous solution of lmol / 1 sodium hydroxide was added, and the mixture was separated and extracted with a black hole form.
- Example 47-3 104.9 mg of the compound obtained in Example 47-3 was dissolved in 3.2 ml of methanol, and 55.8 mg of 6-butanemopyridine-2-aldehyde, 31.10 g of sodium cyanoborohydride were added, and the mixture was added with acetic acid. The pH was adjusted to 5, and the mixture was stirred at room temperature for 14 hours. After completion of the reaction, lmol / 1 aqueous sodium hydroxide solution was added to the reaction solution, and the mixture was separated and extracted with a chloroform-form.
- Example 47-3 104.9 mg of the compound obtained in Example 47-3 was dissolved in 3.2 ml of methanol, and 36.3 mg of the compound obtained in Example 53-1 and 31.1 ⁇ 2 g of sodium cyanoborohydride were added. The pH was adjusted to 5 with an acid, and the mixture was stirred at room temperature for 14 hours. After completion of the reaction, lmol / 1 aqueous sodium hydroxide solution was added to the reaction solution, and the mixture was separated and extracted with a chloroform-form.
Description
Claims
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2004535901A JP3714948B2 (ja) | 2002-09-11 | 2003-09-05 | アミン化合物及びその用途 |
US10/516,158 US7176227B2 (en) | 2002-09-11 | 2003-09-05 | Amine compounds and use thereof |
AU2003261974A AU2003261974A1 (en) | 2002-09-11 | 2003-09-05 | Amine compounds and use thereof |
EP03795301A EP1550657A4 (en) | 2002-09-11 | 2003-09-05 | AMINO COMPOUNDS AND THEIR USE |
CA2488785A CA2488785C (en) | 2002-09-11 | 2003-09-05 | Amine compound and use thereof |
US11/704,860 US7833991B2 (en) | 2002-09-11 | 2007-02-09 | Amine compound and use thereof |
US12/902,918 US20110046113A1 (en) | 2002-09-11 | 2010-10-12 | Amine compound and use thereof |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2002-265247 | 2002-09-11 | ||
JP2002265247 | 2002-09-11 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10516158 A-371-Of-International | 2003-09-05 | ||
US11/704,860 Continuation-In-Part US7833991B2 (en) | 2002-09-11 | 2007-02-09 | Amine compound and use thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2004024697A1 true WO2004024697A1 (ja) | 2004-03-25 |
Family
ID=31986566
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2003/011381 WO2004024697A1 (ja) | 2002-09-11 | 2003-09-05 | アミン化合物及びその用途 |
Country Status (8)
Country | Link |
---|---|
US (3) | US7176227B2 (ja) |
EP (1) | EP1550657A4 (ja) |
JP (1) | JP3714948B2 (ja) |
KR (1) | KR100863667B1 (ja) |
CN (1) | CN100528846C (ja) |
AU (1) | AU2003261974A1 (ja) |
CA (1) | CA2488785C (ja) |
WO (1) | WO2004024697A1 (ja) |
Cited By (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005085209A1 (ja) * | 2004-03-10 | 2005-09-15 | Kureha Corporation | アミン系塩基性化合物とその用途 |
WO2006022454A1 (ja) * | 2004-08-27 | 2006-03-02 | Ono Pharmaceutical Co., Ltd | 塩基性基を含有する化合物およびその用途 |
WO2006095542A1 (ja) * | 2005-03-04 | 2006-09-14 | Kureha Corporation | アミン系化合物を含む医薬組成物 |
WO2006129679A1 (ja) | 2005-05-31 | 2006-12-07 | Ono Pharmaceutical Co., Ltd. | スピロピペリジン化合物およびその医薬用途 |
WO2007023788A1 (ja) * | 2005-08-22 | 2007-03-01 | Kureha Corporation | アミン誘導体、その製造方法及び用途 |
WO2007049771A1 (ja) | 2005-10-28 | 2007-05-03 | Ono Pharmaceutical Co., Ltd. | 塩基性基を含有する化合物およびその用途 |
WO2007058322A1 (ja) | 2005-11-18 | 2007-05-24 | Ono Pharmaceutical Co., Ltd. | 塩基性基を含有する化合物およびその用途 |
WO2007132846A1 (ja) | 2006-05-16 | 2007-11-22 | Ono Pharmaceutical Co., Ltd. | 保護されていてもよい酸性基を含有する化合物およびその用途 |
WO2008016006A1 (en) | 2006-07-31 | 2008-02-07 | Ono Pharmaceutical Co., Ltd. | Compound having cyclic group bound thereto through spiro binding and use thereof |
WO2010119741A1 (ja) * | 2009-04-17 | 2010-10-21 | 株式会社クレハ | 外用剤 |
US7833991B2 (en) | 2002-09-11 | 2010-11-16 | Kureha Corporation | Amine compound and use thereof |
WO2012046653A1 (ja) | 2010-10-06 | 2012-04-12 | 株式会社クレハ | アミン系化合物とその用途 |
EP1613613B1 (en) * | 2003-04-11 | 2021-06-02 | Genzyme Corporation | Cxcr4 chemokine receptor binding compounds |
Families Citing this family (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP3949708B2 (ja) * | 2003-04-02 | 2007-07-25 | タイゲン・バイオテクノロジー | ケモカイン受容体介在疾患を治療するためのポリアミン化合物 |
US7504422B2 (en) * | 2003-04-02 | 2009-03-17 | Taigen Biotechnology Co. Ltd. | Polyamine compounds |
US7498323B2 (en) * | 2003-04-18 | 2009-03-03 | Ono Pharmaceuticals Co., Ltd. | Spiro-piperidine compounds and medicinal use thereof |
JP4953298B2 (ja) * | 2004-03-10 | 2012-06-13 | 株式会社クレハ | アミン系塩基性化合物とその用途 |
US7501526B2 (en) | 2005-01-20 | 2009-03-10 | Taigen Biotechnology | Synthesis of polyamine compounds |
US20080293711A1 (en) * | 2007-03-08 | 2008-11-27 | Clark Michael P | Chemokine receptor modulators |
CN102083427B (zh) | 2008-01-09 | 2014-12-10 | 分子洞察制药公司 | 碳酸酐酶ix的抑制剂 |
WO2010065899A2 (en) * | 2008-12-05 | 2010-06-10 | Molecular Insight Pharmaceuticals, Inc. | Technetium-and rhenium-bis(heteroaryl)complexes and methods of use thereof |
US8211402B2 (en) | 2008-12-05 | 2012-07-03 | Molecular Insight Pharmaceuticals, Inc. | CA-IX specific radiopharmaceuticals for the treatment and imaging of cancer |
WO2010065902A2 (en) * | 2008-12-05 | 2010-06-10 | Molecular Insight Pharmaceuticals, Inc. | Technetium- and rhenium-bis(heteroaryl) complexes and methods of use thereof for inhibiting psma |
US8465725B2 (en) | 2009-06-15 | 2013-06-18 | Molecular Insight Pharmaceuticlas, Inc. | Process for production of heterodimers of glutamic acid |
PL3412676T3 (pl) | 2010-08-10 | 2021-04-06 | Melinta Therapeutics, Inc. | Cykliczne pochodne estrowe kwasu boronowego, sposób otrzymywania oraz ich zastosowania terapeutyczne |
WO2013033461A1 (en) | 2011-08-31 | 2013-03-07 | Rempex Pharmaceuticals, Inc. | Heterocyclic boronic acid ester derivatives and therapeutic uses thereof |
EA029984B1 (ru) | 2011-12-30 | 2018-06-29 | ПиТиСи ТЕРАПЬЮТИКС, ИНК. | Соединения для лечения спинальной мышечной атрофии |
AU2013207486A1 (en) | 2012-01-06 | 2014-08-21 | Molecular Insight Pharmaceuticals | Metal complexes of poly(carboxyl)amine-containing ligands having an affinity for carbonic anhydrase IX |
US9156858B2 (en) | 2012-05-23 | 2015-10-13 | Rempex Pharmaceuticals, Inc. | Boronic acid derivatives and therapeutic uses thereof |
US10561675B2 (en) | 2012-06-06 | 2020-02-18 | Rempex Pharmaceuticals, Inc. | Cyclic boronic acid ester derivatives and therapeutic uses thereof |
MX2014016054A (es) | 2012-06-26 | 2015-04-10 | Bayer Pharma AG | N-[4-(quinolin-4-iloxi)ciclohexil(metil)](hetero)arilcarboxamidas como antagonistas del receptor de androgenos, su produccion y usos como productos medicinales. |
WO2014089296A2 (en) * | 2012-12-06 | 2014-06-12 | Institute For Hepatitis And Virus Research | Functionalized benzamide derivatives as antiviral agents against hbv infection |
EA201591004A1 (ru) | 2013-01-04 | 2016-02-29 | Ремпекс Фармасьютикалз, Инк. | Производные бороновой кислоты и их терапевтическое применение |
US9241947B2 (en) | 2013-01-04 | 2016-01-26 | Rempex Pharmaceuticals, Inc. | Boronic acid derivatives and therapeutic uses thereof |
US9101638B2 (en) | 2013-01-04 | 2015-08-11 | Rempex Pharmaceuticals, Inc. | Boronic acid derivatives and therapeutic uses thereof |
AU2014204045B2 (en) | 2013-01-04 | 2018-10-18 | Rempex Pharmaceuticals, Inc. | Boronic acid derivatives and therapeutic uses thereof |
CN105025933B (zh) | 2013-01-14 | 2019-03-26 | 分子制药洞察公司 | 三嗪类放射性药物和放射性显影剂 |
LT3140310T (lt) | 2014-05-05 | 2019-11-25 | Rempex Pharmaceuticals Inc | Boronato druskų sintezė ir jų panaudojimas |
US9687497B1 (en) | 2014-05-05 | 2017-06-27 | Rempex Pharmaceuticals, Inc. | Salts and polymorphs of cyclic boronic acid ester derivatives and therapeutic uses thereof |
MX2016015093A (es) | 2014-05-19 | 2017-03-27 | Rempex Pharmaceuticals Inc | Derivados de acido boronico y sus usos terapeuticos. |
EP3164406A4 (en) | 2014-07-01 | 2018-04-04 | Rempex Pharmaceuticals, Inc. | Boronic acid derivatives and therapeutic uses thereof |
US10662205B2 (en) | 2014-11-18 | 2020-05-26 | Qpex Biopharma, Inc. | Cyclic boronic acid ester derivatives and therapeutic uses thereof |
WO2016149393A1 (en) | 2015-03-17 | 2016-09-22 | Rempex Pharmaceuticals, Inc. | Boronic acid derivatives and therapeutic uses thereof |
DK3478693T3 (da) | 2016-06-30 | 2021-09-20 | Qpex Biopharma Inc | Boronsyrederivater og terapeutiske anvendelser deraf |
JP7061394B2 (ja) * | 2017-03-31 | 2022-04-28 | 国立大学法人 長崎大学 | キノリノン化合物および抗rnaウイルス薬 |
JP7377545B2 (ja) | 2017-10-11 | 2023-11-10 | キューペックス バイオファーマ, インコーポレイテッド | ボロン酸誘導体およびその合成 |
CN109134354B (zh) * | 2018-09-19 | 2022-03-25 | 天津科技大学 | 2-吡啶甲基硫醚的合成方法及相关药物的合成工艺 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0628551A1 (en) * | 1993-06-14 | 1994-12-14 | Shionogi & Co., Ltd. | Semicyclic urea derivatives as antihistaminic agents |
US6096773A (en) * | 1998-04-16 | 2000-08-01 | Texas Biotechnology Corporation, Inc. | Compounds that inhibit the binding of integrins to their receptors |
WO2001010842A2 (en) * | 1999-08-04 | 2001-02-15 | Millennium Pharmaceuticals, Inc. | Melanocortin-4 receptor binding compounds and methods of use thereof |
Family Cites Families (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3634316A (en) | 1968-08-23 | 1972-01-11 | Showa Denko Kk | Sulfur-vulcanizable natural and synthetic rubbery polymers containing xylylene diamines as antiozonants |
JPS599664B2 (ja) * | 1975-11-08 | 1984-03-03 | 旭化成株式会社 | タンソセンイヨウヒヨウメンシアゲザイ |
EP0183271B1 (en) | 1984-11-30 | 1990-05-16 | Shosuke Okamoto | Lysin derivative and proteinase inhibitor |
US5086069A (en) * | 1990-02-05 | 1992-02-04 | Rorer Pharmaceutical Corporation | Anti-thrombotic peptide and pseudopeptide derivatives |
DE4331135A1 (de) | 1993-09-14 | 1995-03-16 | Bayer Ag | Neue antiviral wirksame valinhaltige Pseudopeptide |
EP0809492A4 (en) * | 1995-02-17 | 2007-01-24 | Smithkline Beecham Corp | IL-8 RECEPTOR ANTAGONISTS |
US6077954A (en) | 1996-08-01 | 2000-06-20 | Isis Pharmaceuticals, Inc. | Substituted heterocyclic compounds |
AR008290A1 (es) | 1996-08-15 | 1999-12-29 | Smithkline Beecham Corp | Nuevos compuestos que contienen guanidina utiles como antagonistas de los receptores de il-8, composiciones farmaceuticas que los contienenprocedimiento para la preparacion de dichos compuestos y procedimiento para la preparacion de intermediarios. |
AU1684099A (en) | 1997-12-26 | 1999-07-19 | Kureha Chemical Industry Co., Ltd. | Amino acid derivatives |
JPH11269146A (ja) * | 1998-03-24 | 1999-10-05 | Mitsui Chem Inc | 分化誘導剤 |
AU5241099A (en) | 1998-07-31 | 2000-02-21 | Trustees Of Columbia University In The City Of New York, The | Use of inhibitors of the activation of cxcr4 receptor by sdf-1 in treating rheumatoid arthritis |
CA2368047A1 (en) | 1999-03-24 | 2000-09-28 | Anormed Inc. | Chemokine receptor binding heterocyclic compounds |
US6750348B1 (en) | 1999-03-24 | 2004-06-15 | Anormed, Inc. | Chemokine receptor binding heterocyclic compounds |
AU4875301A (en) * | 2000-04-14 | 2001-10-30 | Kureha Chemical Ind Co Ltd | Nitrogenous compounds and antiviral drugs containing the same |
BR0113930A (pt) | 2000-09-15 | 2003-06-24 | Anormed Inc | Compostos heterocìclicos de ligação aos receptores de quimiocina |
IL154229A0 (en) | 2000-09-15 | 2003-07-31 | Anormed Inc | Chemokine receptor binding heterocyclic compounds |
MXPA03002788A (es) * | 2000-09-29 | 2004-12-13 | Neurogen Corp | Moduladores de receptor c5a de molecula pequena de alta afinidad. |
WO2002062766A2 (en) * | 2001-02-07 | 2002-08-15 | Millennium Pharmaceuticals, Inc. | Melanocortin-4 receptor binding compounds and methods of use thereof |
EP1389460A1 (en) | 2001-05-24 | 2004-02-18 | Kureha Chemical Industry Co., Ltd. | Cxcr4-antagonistic drugs comprising nitrogen-containing compound |
EP1431290A4 (en) | 2001-09-28 | 2004-12-15 | Kureha Chemical Ind Co Ltd | NITROGEN COMPOUND AND CORRESPONDING USE |
EP1550657A4 (en) * | 2002-09-11 | 2009-12-30 | Kureha Corp | AMINO COMPOUNDS AND THEIR USE |
WO2005085209A1 (ja) | 2004-03-10 | 2005-09-15 | Kureha Corporation | アミン系塩基性化合物とその用途 |
-
2003
- 2003-09-05 EP EP03795301A patent/EP1550657A4/en not_active Withdrawn
- 2003-09-05 AU AU2003261974A patent/AU2003261974A1/en not_active Abandoned
- 2003-09-05 CA CA2488785A patent/CA2488785C/en not_active Expired - Fee Related
- 2003-09-05 CN CNB038082985A patent/CN100528846C/zh not_active Expired - Fee Related
- 2003-09-05 WO PCT/JP2003/011381 patent/WO2004024697A1/ja active Application Filing
- 2003-09-05 KR KR1020057001832A patent/KR100863667B1/ko not_active IP Right Cessation
- 2003-09-05 JP JP2004535901A patent/JP3714948B2/ja not_active Expired - Fee Related
- 2003-09-05 US US10/516,158 patent/US7176227B2/en not_active Expired - Fee Related
-
2007
- 2007-02-09 US US11/704,860 patent/US7833991B2/en not_active Expired - Fee Related
-
2010
- 2010-10-12 US US12/902,918 patent/US20110046113A1/en not_active Abandoned
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0628551A1 (en) * | 1993-06-14 | 1994-12-14 | Shionogi & Co., Ltd. | Semicyclic urea derivatives as antihistaminic agents |
US6096773A (en) * | 1998-04-16 | 2000-08-01 | Texas Biotechnology Corporation, Inc. | Compounds that inhibit the binding of integrins to their receptors |
WO2001010842A2 (en) * | 1999-08-04 | 2001-02-15 | Millennium Pharmaceuticals, Inc. | Melanocortin-4 receptor binding compounds and methods of use thereof |
Cited By (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7833991B2 (en) | 2002-09-11 | 2010-11-16 | Kureha Corporation | Amine compound and use thereof |
EP1613613B1 (en) * | 2003-04-11 | 2021-06-02 | Genzyme Corporation | Cxcr4 chemokine receptor binding compounds |
WO2005085209A1 (ja) * | 2004-03-10 | 2005-09-15 | Kureha Corporation | アミン系塩基性化合物とその用途 |
US7932281B2 (en) | 2004-03-10 | 2011-04-26 | Kureha Corporation | Amine-based compound and use thereof |
JPWO2006022454A1 (ja) * | 2004-08-27 | 2008-05-08 | 小野薬品工業株式会社 | 塩基性基を含有する化合物およびその用途 |
JP5135795B2 (ja) * | 2004-08-27 | 2013-02-06 | 小野薬品工業株式会社 | 塩基性基を含有する化合物およびその用途 |
JP2012131820A (ja) * | 2004-08-27 | 2012-07-12 | Ono Pharmaceut Co Ltd | 塩基性基を含有する化合物およびその用途 |
US8822459B2 (en) | 2004-08-27 | 2014-09-02 | Ono Pharmaceutical Co., Ltd. | Compound containing basic group and use thereof |
WO2006022454A1 (ja) * | 2004-08-27 | 2006-03-02 | Ono Pharmaceutical Co., Ltd | 塩基性基を含有する化合物およびその用途 |
US7951816B2 (en) | 2004-08-27 | 2011-05-31 | Ono Pharmaceutical Co., Ltd. | Compound containing basic group and use thereof |
WO2006095542A1 (ja) * | 2005-03-04 | 2006-09-14 | Kureha Corporation | アミン系化合物を含む医薬組成物 |
WO2006129679A1 (ja) | 2005-05-31 | 2006-12-07 | Ono Pharmaceutical Co., Ltd. | スピロピペリジン化合物およびその医薬用途 |
WO2007023788A1 (ja) * | 2005-08-22 | 2007-03-01 | Kureha Corporation | アミン誘導体、その製造方法及び用途 |
JP4945448B2 (ja) * | 2005-08-22 | 2012-06-06 | 株式会社クレハ | アミン誘導体、その製造方法及び用途 |
US7977512B2 (en) | 2005-08-22 | 2011-07-12 | Kureha Corporation | Amine derivative, and production method and use thereof |
WO2007049771A1 (ja) | 2005-10-28 | 2007-05-03 | Ono Pharmaceutical Co., Ltd. | 塩基性基を含有する化合物およびその用途 |
EP2657235A1 (en) | 2005-10-28 | 2013-10-30 | Ono Pharmaceutical Co., Ltd. | Compound containing basic group and use thereof |
US8168783B2 (en) | 2005-11-18 | 2012-05-01 | Ono Pharmaceutical Co., Ltd. | Chemokine receptor antagonists and use thereof |
WO2007058322A1 (ja) | 2005-11-18 | 2007-05-24 | Ono Pharmaceutical Co., Ltd. | 塩基性基を含有する化合物およびその用途 |
US8519124B2 (en) | 2005-11-18 | 2013-08-27 | Ono Pharmaceutical Co., Ltd. | Chemokine receptor antagonists and use thereof |
JP5217438B2 (ja) * | 2005-11-18 | 2013-06-19 | 小野薬品工業株式会社 | 塩基性基を含有する化合物およびその用途 |
WO2007132846A1 (ja) | 2006-05-16 | 2007-11-22 | Ono Pharmaceutical Co., Ltd. | 保護されていてもよい酸性基を含有する化合物およびその用途 |
JP5257068B2 (ja) * | 2006-05-16 | 2013-08-07 | 小野薬品工業株式会社 | 保護されていてもよい酸性基を含有する化合物およびその用途 |
US8618122B2 (en) | 2006-05-16 | 2013-12-31 | Ono Pharmaceutical Co., Ltd. | Compound having acidic group which may be protected, and use thereof |
WO2008016006A1 (en) | 2006-07-31 | 2008-02-07 | Ono Pharmaceutical Co., Ltd. | Compound having cyclic group bound thereto through spiro binding and use thereof |
WO2010119741A1 (ja) * | 2009-04-17 | 2010-10-21 | 株式会社クレハ | 外用剤 |
WO2012046653A1 (ja) | 2010-10-06 | 2012-04-12 | 株式会社クレハ | アミン系化合物とその用途 |
US8722719B2 (en) | 2010-10-06 | 2014-05-13 | Kureha Corporation | Amine compound and use for same |
Also Published As
Publication number | Publication date |
---|---|
EP1550657A1 (en) | 2005-07-06 |
US20050165063A1 (en) | 2005-07-28 |
JPWO2004024697A1 (ja) | 2006-01-05 |
EP1550657A4 (en) | 2009-12-30 |
KR20050035873A (ko) | 2005-04-19 |
CN1646495A (zh) | 2005-07-27 |
US7833991B2 (en) | 2010-11-16 |
CA2488785C (en) | 2012-07-03 |
JP3714948B2 (ja) | 2005-11-09 |
KR100863667B1 (ko) | 2008-10-15 |
US7176227B2 (en) | 2007-02-13 |
CN100528846C (zh) | 2009-08-19 |
AU2003261974A1 (en) | 2004-04-30 |
US20110046113A1 (en) | 2011-02-24 |
US20070208033A1 (en) | 2007-09-06 |
CA2488785A1 (en) | 2004-03-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP3714948B2 (ja) | アミン化合物及びその用途 | |
US11390616B2 (en) | Apelin receptor agonists and methods of use | |
US10508104B2 (en) | 6-hydroxy-5-(phenyl/heteroarylsulfonyl)pyrimidin-4(1H)-one as APJ agonists | |
CN105814019B (zh) | 脲衍生物、或其药理学上所容许的盐 | |
JP5315254B2 (ja) | 溶媒和物化されたイラプラゾールの結晶形 | |
US11174228B2 (en) | Antagonists of human integrin (α4)(β7) | |
JP6609065B2 (ja) | 1−(5−(2,4−ジフルオロフェニル)−1−((3−フルオロフェニル)スルホニル)−4−メトキシ−1h−ピロール−3−イル)−n−メチルメタンアミンの新規な酸付加塩 | |
EP1389460A1 (en) | Cxcr4-antagonistic drugs comprising nitrogen-containing compound | |
WO2005085209A1 (ja) | アミン系塩基性化合物とその用途 | |
KR100632882B1 (ko) | 4, 4-디플루오로-1, 2, 3,4-테트라하이드로-5h-1-벤즈아제핀 유도체 또는 그 염 | |
TW201444798A (zh) | 作爲強效rock1及rock2抑制劑之苯基吡唑衍生物 | |
WO2005034870A2 (en) | Amide compounds and ion channel ligands and uses thereof | |
JPWO2003029218A1 (ja) | 新規含窒素化合物及びその用途 | |
AU2001248753B2 (en) | Nitrogenous compounds and antiviral drugs containing the same | |
CN112920133B (zh) | (e)-4-甲基-2-(4-(三氟甲基)苯乙烯基)噁唑类化合物及其制备方法与用途 | |
CN115260194B (zh) | 新型egfr降解剂 | |
TW202115023A (zh) | 新型細胞凋亡訊號調節激酶1抑制劑 | |
WO2012130159A1 (zh) | 氨基吡啶类衍生物及其用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2004535901 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 20038082985 Country of ref document: CN |
|
REEP | Request for entry into the european phase |
Ref document number: 2003795301 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2003795301 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2488785 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020057001832 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10516158 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 1020057001832 Country of ref document: KR |
|
WWP | Wipo information: published in national office |
Ref document number: 2003795301 Country of ref document: EP |